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- ABSTRACT -
x 
A new prostaglandin - prostaglandin X (later renamed prostacyclin or 
prostaglandin 12 (PGI 2)), was discovered by Moncada, Gryglewski, 
Bunting and Vane in 1976. This unstable substance was shown to be 
produced by vascular tissue and to be a vasodilator and the most 
potent endogenous inhibitor of platelet aggregation known. Because .of 
its properties, it appeared that a lack of it may be related to the 
deve 1 opment and! or ma i ntenance of hypertens i on, a di sorder featuri ng 
vasoconstriction and an increased tendency to arterial thrombosis. 
The present studies aimed to investigate this possibility using a rat 
mode 1. 
A bioassay for prostacyclin was first perfected. This consisted of a 
modification of the method used by Moncada, Higgs and Vane (1977): 
PGI 2 released by rat aortic strips, during incubation in tris 
buffer, was measured by assessing the abil ity of the incubate to 
inhibit adenosine diphosphate induced aggregation of human platelets, 
as compared to the inhibitory effect of standard prostacyclin sodium 
salt. The specificity of the assay for the detection of PGI 2 was 
tested. 
The abil ity of hypertensive rat aorta to release prostacycl in was 
investigated in two studies. The first compared aortas of Wistar rats 
of the New Zealand genetically hypertensive strain (GH) with those of 
matched normotensive Wistar controls. In the second study, 
hypertens ion was induced by wrappi ng the ri ght kidney wi th surgi ca 1 
silk and removing the contralateral kidney. Ten weeks later, aortic 
generation of prostacyclin by these animals was compared with that of 
matched sham controls which had received identical surgical 
manipulation but for the application of silk to the right kidney. 
Contrary to expectation, in both forms of hypertension, aortas of the 
xi 
rats with elevated pressure produced consistently more prostacyclin 
than those of matched controls. 
In order to discover more about the relationship between elevated 
pressure and elevated PGI 2 production, the effect of pressure 
reduction with hypotensive agents on the ability of GH rat aortas to 
produce prostacyclin, was investigated. After pressure had been 
controlled within normal range for one week (achieved by oral 
administration of furosemide, dihydralazine and reserpine for one 
month), aortic PGI 2 was reduced in comparison with matched GH 
controls. However, the reduction was not consistent and statistical 
significance was not reached. Because it was subsequently reported by 
other workers, that some of the hypotensive agents which had been 
employed may effect prostaglandin levels per se, no conclusions could 
be drawn from this study as to any possible direct relationships 
between pressure and aortic prostacyclin generating capacity. A 
further means of reducing elevated pressure (which had no inherent 
effect on prostaglandin levels) was thus sought. 
A mechanical method was eventually selected, application of a silver 
clip to the aortas of GH rats, just below the diaphragm, producing an 
immediate reduction in pressure distal to the constriction. Eighteen 
hours 
with 
later, PGI 2 production by these distal aortas 
those of matched sham GH controls and was 
was compared 
found to be 
consistently reduced. These results indicate that the ability to 
produce PGI 2 may be influenced by prior local pressure changes and 
that the increased capacity of hypertensive rat aortas to generate 
prostacyclin may be related to the increased mechanical transmural 
stress consequent on elevated pressure. 
Since haemostatic balance must be influenced not on ly by vascular 
xii 
PGI 2 generation but also by platelet sensitivity to PGI 2, the 
response of GH platelets to the anti-aggregatory effect of 
prostacyc1in was also investigated. As it had been shown by 
Sinzinger, Si1berbauer, Horsch and Gall (1981) that intra-arterial 
infusion of PGI 2 in humans decreased platelet sensitivity to the 
substance, the possibility existed that platelet sensitivity in 
hypertens i on mi ght be reduced. Th i s hypothes i s was, however, 
invalidated as the sensitivity of GH platelets to the anti-aggregatory 
effect of PGI 2 was almost identical to that of normotensive 
controls. 
The shortcomi ngs of the methodo logy and the poss i b 1 e importance of 
these findings in the hypertensive animal are discussed. The idea 
that elevated PGI 2 in hypertension may playa protective role both 
with respect to platelet aggregation and in attenuating further 
pressure rises is considered. It is finally suggested that it will be 
possible to draw more accurate conclusions as to the meaning of the 
increased PGI 2 generation in hypertension (both in relation to 
vascular tone and platelet function) only when details of production 
of, and sensitivity to, thromboxane A2 are known. Thromboxane A2 
(TXA2) is a vasoconstrictor and promotor of aggregation (Hamberg, 
Svensson and Samuelson, 1975) and it may be that, despite elevated 
vascular PGI 2 generation, the TXA2'PGI 2 balance is still tipped 
in favour of vasoconstriction and platelet aggregation in hypertension. 
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Recognition of the fact that compl ications attending an 
elevated blood pressure constitute one of the most frequent 
causes of a decreased life expectancy (Grollman, 1980) has 
inspired a tremendous interest in hypertension. The scientific 
medical 1 iterature is replete with confl icting elaborate 
theories as to its pathogenesis. 
In 1976 Moncada, Gryglewski, Bunting and Vane discovered a new 
derivative of arachidonic acid - prostaglandin X, later renamed 
prostacyclin or prostaglandin 12 (Johnson, Morton, Kinner, 
Gorman, McGuire, Sun, Whittaker, Bunting, Salmon, Moncada and 
Vane, 1976 and Nomenclature Announcement, 1977). 
The site of production and the properties of this prostaglandin 
immediately stimulated interest in its possible involvement in 
hypertension. 
Prostacyclin was found to be locally generated in blood vessel 
walls and was able to relax vascular smooth muscle (Bunting, 
Gryglewski, Moncada and Vane, 1976) suggesting that it might 
play a part in the contro 1 of vascu 1 ar tone. Th ismay be of 
particular relevance in situations of sustained elevation of 
arterial pressure which are associated in most cases with 
increased peripheral vascular resistance due to decreased 
diameter i.e. vasoconstriction of resistance vessels. Cardiac 
output is generally normal (Pickering, 1974). 
While the many vasoregulatory mechanisms which might be 
deranged in hypertension have received much attention, reports 
of their involvement are conflicting. 
Prostacyclin has a second notable property - it is a potent 
2 
inhibitor of platelet aggregation (Moncada, Gryglewski, Bunting 
and Vane, 1976a). This too may have a bearing on hypertension, 
since it has been suggested that a major determinant of the 
thrombotic and atherosclerot i c complications of hypertensive 
vascu 1 ar disease, may be the increased tendency to adhere and 
aggregate which has been reported for platelets of hypertensive 
patients (Lentini and Bologna, 1974). 
The discovery of this exciting new vasodilatory, 
anti-aggregatory prostaglandin created a new dimension in the 
knowledge of cardiovascular function and pathology. An 
investigation into the role of prostacyclin in hypertension, 
using a rat model, is the subject of this study. 
CHAPTER 2 
LITERATURE REVIEW 
3 
2.1. PROSTAGLANDINS - AN INTRODUCTION 
In 1930, two American gynaecologists noted that strips of human 
uterus relaxed or contracted when exposed to human semen 
(Kurzrok and L ieb , 1930). A few years later, Goldblatt in 
England and von Euler in Sweden independently reported 
vasodepressor and smooth muscle contracting activity in seminal 
fluid and accessory reproductive glands. Von Euler identified 
the active material as a 1 ipid soluble acid which he named 
"prostaglandin" (Goldblatt, 1935 and von Euler, 1936). More 
than 20 years passed before technical advances allowed the 
isolation, in pure form, of some prostaglandins and the 
elucidation of their structure (Figure 1) as 20-carbon 
unsaturated carboxylic acids with a cyc10pentane ring 
(Bergstrom and Sjovall, 1960, and Samuelsson, 1963) . Now, in 
1981, few substances command more widespread interest in 
biological circles than the prostaglandins and related 
compounds. They are among the most prevalent of autocoids, 
being widely distributed throughout the animal kingdom in 
tissues and body fluids, and are being seen to be involved in 
an ever increasing number of fundamental responses of cells and 
organs. 
Two independent groups (Bergstrom, Danie1sson, and Samue1sson, 
1964 and va n Dorp, Beerthuis, Nugteren and Vonkeman, 1964) 
demonstrated that prostaglandins are biosynthesised from 
polyunsaturated fatty acids. 
These acids include (Figure 2) eicosatrienoic acid 
(dihomo-gamma- 1ino1enic acid), eicosatetraenoic acid (arachi-
4 
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donic acid) and eicosapentaenoic acid, which give rise to the 
mono - (1 series), bis - (2 series) and trienoic - (3 series) 
prostaglandins respectively. Each series carries the relevant 
subscript 1, 2 or 3 after the abreviation of prostaglandin PG, 
e.g. PG2 series. The number indicates the number of double 
bonds in the side chain. Prostaglandins are further 
distinguished by substitutions on the cyc10pentane ring and are 
designated accordingly by capital letters, e.g. see Figure 1. 
Members of the F series are further designated a or S depending 
upon the spatial arrangement of the OH group at position 9. 
The unsaturated fatty acid precursors are normally not found 
free in any important quantity but are esterified as a 
component of phospholipids or other complex lipids. The first 
step in prostaglandin synthesis is therefore the release of the 
precursors from the bound esterified form in tissue stores by 
acy1hydro1ases such as phospholipase A2. 
Arachidonic acid, which can be obtained directly from the diet 
or by anabolic desaturation and chain elongation from dietry 
linoleic acid, is the most common fatty acid precursor of 
prostaglandins in membrane phospholipids (Moncada and Vane, 
1979a). 
After release from phospho1.ipids, it is metabolised by two 
types of enzymes: 
The 1ipoxygenases peroxidize arachidonic acid at different 
carbon atoms 5 and 12 to form unstable hydroperoxides (e.g. 
5-HPETE and 12-HPETE) which then break down to stable 
hydroxyacids, e.g. 12-hydroxyarachidonic acid (HETE) or are 
further transformed to other products such as the recently 
[ C;(XX)COOH 6cosalrienoic acid 1 
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FIG . 2: DIAGRAM SHOWING THE PROSTAGLANDIN PRECURSORS AND SOME 
IMPORTANT METABOLITES OF ARACHIDONIC ACID . 
(Adapted from McGlff 1979) 
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described leukotrienes. (This pathway is reviewed by Moncada, 
Flower and Vane, 1980). 
The second group of enzymes, the cyclo-oxygenase system, 
metabolises arachidonic acid to another range of products some 
of which are shown in Figure 2. The first step consists of an 
oxygenation and a cyclisation to form the cyclic endoperoxide 
derivatives PGG2 and H2• These unstable substances break 
down enzymatically or nonenzymatically to the more stable 
substances PGE2, PGF2a and PGD2 and l2-hydroxY-5,8,lO-
heptadecatrienoic acid (HHT) as well as to malondialdehyde 
(MDA). The prostaglandin endoperoxides are also transformed 
enzymatically into two other products, namely prostacyclin 
(PGI 2) and the chemically distinct thromboxane A2(TXA2). 
These two unstable substances break down nonenzymatically to 
the more stable 6-keto-PGF la and TXB 2 respectively. 
The final product formed from arachidonic acid varies with the 
type of tissue, the physical state of the animal and the 
presence of injury and disease. 
Unt il recent ly it was be 1 i eved that PGE2 and PGF 2a were the 
most important prostaglandins. However, the discoveries of the 
last decade have caused a radical shift in emphasis towards the 
newer prostaglandins and the thromboxanes. 
2.2. ISOLATION OF THE ENDOPEROXIDES AND DISCOVERY OF THROMBOXANES. 
Although an endoperoxide was proposed as an intermediate in the 
biosynthesis of prostaglandins by Samuelsson in 1965, it was 
only during the early 1970's that the unstable endoperoxides 
8 
were i so 1 ated (Hamberg and Samue 1 sson, 1973, Nugteren and 
Hazelhof, 1973 and Hamberg, Svensson, Wakabayashi and 
Samuelsson, 1974). The endoperoxides had some effects that 
could not be attributed to conversion into the known stable 
prostagl and i ns: they induced rapi d aggregat ion when added to a 
suspens i on of washed human plate 1 ets (Hamberg, Svensson, 
Wakabayashi and Samuelsson, 1974) and were potent stimulators 
of the isolated rabbit aortic strip (Hamberg and Samuelsson, 
1973 and Hamberg, Svensson, Wakabayashi and Samuelsson, 1974). 
This latter property led Samuelsson's group to compare the 
endoperoxides with the so-called rabbit aorta contracting 
substance (ReS) discovered by Piper and Vane in 1969. However, 
such factors as the difference in half lives between the 
endoperoxides and ReS, led them to look for additional 
substances. They reported (Hamberg, Svensson and Samuel sson, 
1975) that PGG2 was converted by platelets to an unstable, 
non-prostaglandin substance which they named thromboxane A2 
(TXA2). TXA2 degraded to the relatively inert substance, 
thromboxane B2 (TXB2) . Thromboxane A2 was more potent 
than the parent endoperox ide in i nduc i ng platelet aggregat i on 
(Hamberg, Svensson and Samuelsson, 1975) and in constricting 
rabbit aorta (Needleman, Moncada, Bunting, Vane, Hamberg and 
Samuelsson, 1976 and Bunting, Moncada and Vane, 1976). In 
fact, it has been concluded that the activity of ReS is mainly 
due to thromboxane A2 (Hamberg, Svensson and Samuel sson, 1975 
and Bunting, Moncada and Vane, 1976). 
9 
2.3. DISCOVERY OF PROSTACYClIN. 
Moncada, Gryg1ewski, Bunting and Vane were interested in the 
possibil ity that thromboxane synthesised in the 
vasculature might explain the vasoconstriction which 
immediately follows the cutting of a small vessel. They 
accordingly searched the vessel wall for the thromboxane 
synthetase which had been recently identified in platelets 
(Needleman, Moncada, Bunting, Vane, Hamberg and Samue1sson, 
1976) . 
Thi s work 1 ed to the discovery of one of the most exc i t i ng 
substances in the prostaglandin family. In 1976 they reported 
that microsomes prepared from rabbit and pig aortas transformed 
endoperox ides, not to thromboxanes, but to an un stab 1 e, 
hitherto unknown substance not recogni sab 1 e by their standard 
bioassay tissues. They called the substance protag1andin X 
(Moncada, Gryg1ewski, Bunting and Vane, 1976a and band 
Gryg1ewski, Bunting, Moncada, Flower and Vane, 1976). 
Invest i gators of the Up john and Wellcome groups 1 ater 
identified the chemical structure of prostaglandin X as 
5 9-deoxY-6,9a-epoxY-1I -PGF 1a and proposed the trivial name 
prostacyc1in for the substance (Johnson, Morton, Kinner, 
Gorman, McGuire, Sun, Whittaker, Bunting, Salmon, Moncada and 
Vane, 1976). Finally, in acknowledgement of the alphabetical 
progression of its predecessors, it was rechristened 
prostaglandin 12 (Nomenclature Announcement, 1977). 
10 
2.4. STABILITY OF PROSTACYCLIN. 
Prostacyclin is unstable in aqueous solutions, at neutral pH. 
Gryglewski, Bunting, Moncada, Flower and Vane (1976) reported 
the disappearance of its activity within 15 seconds on boiling 
or within 10 minutes at 37·C. Alkaline pH increases the 
stability (Cho and Allen, 1978 and Johnson, Morton, Kinner, 
Gorman, McGuire, Sun, Whittaker, Bunting, Salmon, Moncada and 
Vane, 1976), and recent ev i dence suggests an extended stab il ity 
in plasma or blood, possibly associated with binding to albumin 
(Vane, 19B1). 
Prostacyclin hydrolyses in aqueous solutions (Cho and Allen, 
1978) to 6-keto-PGF la which was first described by 
Pace-Asciak in 1976. In fact, Pace-Asciak and co-author Wolfe 
postu 1 ated the structure of prostacyc 1 in as a met abo 1 ite of 
arachidonic acid in rat stomach as early as 1971. 
2.5. BIOSYNTHESIS AND METABOLISM OF PROSTACYCLIN. 
In addition to microsomes of rabbit aorta, pig aorta and 
mesenter i c arteri es, and rat stomach fundus all of wh ich were 
shown to transform endoperoxides predominantly to prostacyclin, 
microsomal fractions from other tissues, e.g. rat stomach 
corpus and liver, rabbit lung, spleen, kidney and heart and ram 
seminal vesicles, . generated much smaller amounts of 
prostacyclin together with other prostaglandin products 
(Moncada, Gryglewski, Bunting and Vane, 1976b and Gryglewski, 
Bunting, Moncada, Flower and Vane, 1976). Bunting, 
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Gryglewski, Moncada and Vane (1976) also reported that 
prostacyc 1 in was produced by fresh chopped arteri a 1 tissue, 
either from exogenous arachidonic acid or endoperoxides, or 
from endogenous substrate. Early in 1977, Moncada, Higgs and 
Vane reported the generat i on of prostacyc 1 in by human arteri a 1 
and venous tissue. Thus, besides the fact that prostacycl in 
has been demonstrated to be the main prostaglandin generated by 
vascular tissue (Gryglewski, Bunting, Moncada, Flower and Vane, 
1976, Moncada, Gryglewski, Bunting and Vane, 1976b and Johnson 
et al. 1976), it has also been shown to be formed by many 
vascular tissues from several species. Further examp 1 es 
include:- bovine coronary arteries (Raz, Isakson, Minkes and 
Needleman, 1977), foetal arteries (Powel and Solomon, 1977), 
the ductus arteriosus of the lamb (Pace-Asciak and Rangaraj, 
1977) and bovine ductus arteriosus (Terragno, Terragno, McGiff 
and Rodriguez, 1977). 
Prostacyclin is also the major prostaglandin released from 
isolated perfused rabbit and rat hearts (Isakson, Raz, Denny, 
Pure and Needleman, 1977 and de Deckere, Nugteren and ten Hoor, 
1977) • 
The lung is of particular interest in relation to prostacyclin 
biosynthesis and metabol ism. Unl ike other prostaglandins such 
as E2 and F2a , prostacyclin is not inactivated in vivo by 
passage through the pulmonary circulation (Armstrong, Lattimer, 
Moncada and Vane, 1978, Dusting, Moncada and Vane, 1978a and b, 
Pace-Asciak, Carrara and Nicolaou, 1978, Pace-Asciak, Rosenthal 
and Domazet, 1979 and Wa 1 dman, Alter, Kot, Rose and Ramwe 11, 
1978). On the contrary the pulmonary circulation constantly 
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releases small amounts of prostacyclin into passing blood 
(Gryglewski, Korbut and Ocetkiewiez, 1978). Dusting, Moncada 
and Vane (1978b) have reported that, though the activity of 
prostacyclin does not disappear after passage through the 
lungs, it is inactivated in the hind quarters and the liver. 
The concentration of prostacyclin is thus higher in arterial 
than in venous blood (Moncada, Korbet, Bunting and Vane, 1978 
and Hensby, Barnes, Dollery and Dargie, 1979). The lack of 
uptake of prostacyclin by the pulmonary vascular bed has 
prompted the suggestion that it may function as a circulating 
hormone (Gryglewski, Korbut and Ocetkiewicz, 1978, Moncada, 
Korb~t, Bunting and Vane, 1978, Pace-Asciak and Carrara, 1978 
and Gryglewski, 1979). Other work has, however, provided 
evidence against this possibility (Smith, Ogletree, Lefer and 
Nicolaou, 1978, Christ-Hazelhof and Nugteren, 1980, Steer, 
MacIntyre, Levine and Salzman, 1980, Haslam and McClenaghan, 
1981 and Pace-Asciak, Carrara, Levine and Nicolaou, 1981). 
Quilley, McGiff, Lee, Sun and Wong (1980) suggest that 
6-keto-PGE l may be one of the products of either prostacycl in 
or 6-keto-PGF la metabolism in the liver and that, since it is 
not inactive, it may account for some of the prolonged effects 
occasionally seen with prostacyclin. Though it contracts 
bovine coronary arterial strips, it i s equipotent to PGI 2 i n 
its ability to decrease mesenteric, renal and systemic vascu l ar 
resistance and inhibit responses to pressor stimuli 
(Pontecorvo, Myers, Lippton and Kadowitz, 1981). However, it s 
exact potency as an anti-aggregant is debated (Miller, Aiken, 
Shebus ki and Gorman, 1980) and further research will be 
required to determine its relative i mportance as a potentiall y 
naturally occurring antithrombotic and vasodepressive molec ule . 
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2.6. BIOLOGICAL PROPERTIES OF PROSTACYCLIN. 
2.6.1. 
Prostacycl in has two main properties:- (il it is a potent 
inhibitor of platelet aggregation and (ii) it relaxes vascular 
smooth muscle. In terms of both activities it is opposite to 
thromboxane A2. 
INHIBITION OF PLATELET AGGREGATION. 
The potent inhibitory effect of prostacyclin on in vitro 
platelet aggregation was soon noted and it was shown to be some 
30 times more potent in this respect than PGE l (Moncada, 
Gryglewski, Bunting and Vane, 1976a and Gryglewski, Bunting, 
Moncada, Flower and Vane, 1976). It inhibited in vitro 
aggregation induced by a number of aggregants, e.g. arachidonic 
acid, adenosine diphosphate (ADP), adrenaline, S-hydroxy-
tryptami ne (SHT) , PGG2, PGH2 and collagen (Moncada, 
Gryglewski, Bunting and Vane, 1976b). PGI 2 also inhibited 
platelet aggregation in vivo: applied locally it inhibited 
thrombus formation due to ADP in the microcirculation of the 
hamster cheek pouch (Higgs, Higgs, Moncada and Vane, 1978) and 
when given systemically, prevented electrically induced 
thrombus formation in the carotid artery of the rabbit 
(Ubatuba, Moncada and Vane, 1979). Prostacyclin was also able 
to disaggregate platelets in vitro (Moncada, Gryglewski, 
Bunting and Vane, 1976b) and in vivo (Ubatuba, Moncada and 
Vane, 1979 ). 
The ability of the vascular wall to actively prevent aggrega-
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tion has been postulated before (Saba and Mason, 1974). For 
example, the presence of an ADP-ase in the vessel wall has led 
to the suggestion that this enzyme, by breaking down ADP, 
limits platelet aggregation (Heyns, van den Berg, Potgieter and 
Retief, 1974 and Lieberman, Lewis and Peters, 1977). While the 
Wellcome team have confirmed the presence of an ADP-ase 
(Bunting, Moncada and Vane, 1977), there is now much evidence 
that the anti-aggregatory activity of the wall is related 
mainly to the release of prostacyclin (Bunting, Moncada and 
Vane, 1977 and Bunting, Moncada, Reed, Salmon and Vane, 1978). 
Though vascular tissue utilises both arachidonic acid and 
endoperox i des as precursors in prostacyc 1 in metabo 1 ism, it is 
far more effective in using endoperoxides (Bunting, Gryglewski, 
Moncada and Vane, 1976). Though disputed by some authors, 
there is considerable ev idence (Moncada and Vane, 1979b) that 
the vessel wall can form prostacycl in not only from its own 
endogenous precursors, but also from endoperoxides released by 
platelets. Accordingly, a biological relationship between 
platelet and vessel has been suggested, such that platelets 
adher i ng to the vesse 1 wa 11 re 1 ease endoperox ides wh i ch are 
then utilised by the vessel to produce prostacyclin which, in 
turn, prevents formation of platelet aggregates. 
It is apparent that the prostaglandin endoperoxides are pivotal 
in arachidonic acid metabolism as they are precursors of 
substances with opposed biological properties . Prostacyclin 
inhibits platelet aggregation by stimulating adenyl cyclase 
thus leading to an increas e in cyclic adenosine 3,5-mono-
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phosphate (cAMP) levels in platelets (Gorman, Bunting and 
Miller, 1977 and Tateson, Moncada and Vane, 1977), and 
thromboxane AZ reduces cAMP formation in platelets (Miller, 
Johnson and Gorman, 1977) and produces platelet aggregat i on. 
Owing to these opposite effects, it has been proposed (Moncada, 
Gryglewski, Bunting and Vane, 1976a) that a balance between the 
thromboxane generating system in platelets and the prostacyclin 
generating system in the vascular endothelium, regulates 
platelet aggregation. This proposal has been supported by 
Gorman, Bunt i ng and Mill er (1977) who constructed the 
postulated mechanism of platelet homeostasis illustrated in 
Figure 3. A further relationship between the two subtances is 
the ability of PGI Z to prevent platelet TXAZ production 
(Lefer, Ogletree, Smith, Silver, Nicoloau, Barnette and Gasic, 
1978 and Dembinska-Kiec, RUcker and Schonhoffer, 1979). 
Whi le prostacycl in may provide an expl anation for the 
resistance of the healthy vessel wall to the deposition of 
platelet aggregates, whether or not injury to the wall leads to 
thrombus formation, depends to a considerable extent on the 
amount of vascular damage. Prostacyclin inhibits platelet 
aggregation (platelet-platelet interaction) at lower 
concentrations than those needed to inhibit adhesion 
(platelet-collagen interaction) (Higgs, Moncada, Vane, Caen, 
Michel and Tobelem, 1978), suggesting that prostacyclin allows 
platelets to stick to vascular tissue and interact with it, 
while at the same time limiting thrombus formation (Higgs, 
Higgs, Moncada and Vane, 1978). Vascular damage leads to 
adhesion but not necessarily to thrombus formation. When the 
injury is minor, platelet thrombi are formed which break away 
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from the vessel wall and are washed away by the circulation. 
For the development of thrombosis severe damage or physical 
detachment of the endothel ium must occur (Moncada and Vane, 
1979a). These observations are consistent with the 
distribution of prostacycl in synthetase, the concentration of 
which progressively decreases from the intima to the 
adventitia. These two opposing factors result in an 
anti-aggregatory endothelial lining and thrombogenic outer 
layer of the vascular wall (Moncada, Herman, Higgs and Vane, 
1977) • 
RELAXATION OF VASCULAR SMOOTH MUSCLE. 
There are a few vascular strips, e.g. porcine coronary arteries 
(Dusting, Moncada and Vane, 1977a) and some strips of rat 
venous tissue (Levy, 1978) which are weakly contracted by 
prostacyclin in vitro. In human umbilical artery, prostacyclin 
has been shown to induce re 1 ax at i on at low concentrations and 
contraction at higher concentrations (Pomerantz, Sintos and 
Ramwell, 1978). However, it relaxes most vascular tissues in 
vitro e.g. rabbit coeliac and mesenteric arteries (Bunting, 
Gryglewski, Moncada and Vane, 1976), bovine coronary arteries 
(Dusting, Moncada and Vane, 1977b and Needleman, Bronson, 
Wyche, Sivakoff and Nicolaou, 1978), cat coronary arteries 
(Lefer, Ogletree, Smith, Silver, Nicolaou, Barnette and Gasic, 
1978 and Ogletree, Smith and Lefer, 1978), human and baboon 
cerebral arteries (Boullin, Bunting, Blaso, Hunt and Moncada, 
1979), and lamb ductus arteriosus (Coceani, Bishai, Bodach, 
Wh ite and all ey, 1979). S i ntetos, Bolger and Ramwe 11 (1979) 
have reported that while prostacyclin did not relax canine 
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renal artery or vein strips with basal resting tone, it induced 
relaxation in contracted preparations . 
In vivo, it causes vasodilation and hypotension. 
arachidonic acid across various circulations 
Passage of 
of the 
anaesthetised dog, e.g. hind quarter and pulmonary circulations, 
results in the production of prostacyclin-like material and a 
concomitant vasodilatation (Mullane, Moncada and Vane, 1979). 
Langendorff perfused hearts of rabbits, rats and guinea pigs 
convert arachidonic acid principally to prostacyclin and the 
dilation of coronary arteries observed is due to this 
metabolite (de Deckere, Nugteren and ten Hoor, 1977, Needleman, 
Bronson, Wyche, Sivakoff and Nicolaou, 1978 and Schr6r, 
Moncada, Ubatuba and Vane, 1978). 
Direct application of prostacyclin produces vasodilation in 
several vascular beds for example, local injection into the 
coronary circulation increased coronary blood flow in 
anaesthetised open-chested dogs (Armstrong, Chapple, Dusting, 
Hughes, Moncada and Vane, 1977 and Dusting, Chapple, Hughes, 
Moncada and Vane, 1978). In the same model prostacyclin 
applied epicardially to the left ventricle also caused marked 
and prolonged coronary vasodilation (Dusting, Chapple, Hughes, 
Moncada and Vane, 1978). Prostacyclin also causes vasodilation 
in the mesenteric and hind limb circulation in the dog 
(Dusting, Moncada and Vane, 1978c), on the precapillary side of 
the microcirculation of the hamster cheek pouch (Higgs, 
Cardinal, Moncada and Vane, 1979), in the pulmonary vascular 
bed of the foetal lamb (Leffler and Hessler 1979) and locally, 
in a portion of the epicerebral network when applied topically 
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to the cerebral cortex of the dog (Branan, Pou 1 sen, Wo 1 fe, 
Dila, Hodge and Feindel, 1979). 
In the dog, prostacyclin infused intrarenally increased renal 
blood flow and urinary excretion of sodium and potassium 
(Bolger, Eisner, Ramwell, Slotkoff and Corey, 197B and Hill and 
Moncada, 1979). Bolger et al. gathered data to suggest that 
the net effect of prostacyclin on renin release, is the 
summation of its stimulatory action by means of haemodynamic 
changes and/or direct stimulation of the juxtaglomerular 
apparatus, versus a dampening effect produced by altered sodium 
transport at the macula densa. There is increasing evidence, 
revi ewed by Moncada and Vane (1980a), that prostacyc 1 in 
mediates the release of renin from the renal cortex. 
The vasodepressor effect of prostacycl in produces hypotens i on 
when administered to anaesthetised rats and rabbits (Armstrong, 
Lattimer, Moncada and Vane, 1978), the anaesthetised cat 
(Lefer, Ogletree, Smith, Silver, Nicolaou, Barnette and Gasic, 
1978), the anaesthetised dog (Armstrong, Chapple, Dusting, 
Hughes, Moncada and Vane, 1977 and Fitzpatrick, Alter, Corey, 
Ramwell, Rose and Kot, 1978) and anaesthetised rhesus monkeys 
(Fletcher and Ramwell, 1979). 
The vasodilator effects of prostacyclin caused a lowering of 
diastolic blood pressure when infused in conscious man. The 
heart rate was also increased (O'Grady, Warrington, Moti, 
Bunting, Flower, Fowle, Higgs and Moncada, 1979 and Szczeklik 
and Gryglewski, 1979). At doses higher than those required to 
produce tachycardia and change in diastolic pressure, 
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prostacyclin produced bradycardia and a distinct fall in both 
systolic and diastolic pressure (Szczeklik, Gryglewski, 
Nizankowski, Musial, Pieton and Mruk, 1978). This effect is 
probably mediated by a vagal reflex, for in dogs, prostacyclin 
produces a bradycardia which is abolished by vagotomy or 
reversed by atropine (Chapple, Dusting, Hughes and Vane, 1978 
and 1980). These authors also report that the hypotensive 
effects of prostacyclin were reduced by the vagotomy to a 
greater extent than by atropine, suggesting that the 
hypotension has at least two components: direct relaxion of 
vascular smooth muscle and reflex non-cholinergic vasodilation. 
2.7. POSSIBLE IMPORTANCE OF PROSTACYCLIN AND A PROSTACYCLI N 
THROMBOXANE BALANCE. 
2.7.1. THERAPEUTIC POTENTIAL OF PROSTACYCLIN. 
Because of its biological properties, there has been 
considerable interest in the possible usefulness of 
prostacyclin or chemical analogues as "hormone replacement 
therapy" in various pathological conditions. It has been 
suggested that these properties may be potentially useful in 
such situations as : unstable angina (Borer, 1980), acute 
myocardial ischaemia (Lefer, Ogletree, Smith, Silver, Nicolaou, 
Barnette and Gasic, 1978), deep vein thrombosis, different 
types of shock, disseminated intravascular coagulation and 
organ transplantation (Moncada and Vane, 1980b). 
2.7.2. 
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Infusions of prostacyclin have been used with a degree of 
success in pati ents with advanced peri ph era 1 arteri al disease 
of the lower extremities (Szczeklik, Nizankowski, Skawinski, 
Szczeklik, G~uszko and Gryglewski, 1979 and Szczeklik, 
Gryglewski, Nizankowski, Skawinski, G~uszko and Korbut, 1980) 
and have been shown to have beneficial effect when used in 
several extracorporea1 systems in experimental animals. 
Preliminary indications are that in patients receiving 
prostacyclin during cardiopulmonary bypass, platelet number and 
function is better preserved and blood loss decreased in the 
post-operative period (O'Grady, 1980). 
Obviously, the most direct approach to antithrombotic therapy 
in general wi 11 be a method directed at i ncreas i ng plate 1 et 
cAMP, i.e. prostacyclin or an analogue (with or without a 
phosphodiesterase inhibitor), or a substance which stimulates 
endogenous prostacycl in production. Th i sis so because 
increasing platelet cAMP inhibits most forms of aggregation, 
whether or not they are dependent on arachidonic acid metabolic 
products (Moncada and Vane, 1980a). However, other attempts at 
thrombosis prevention, which relate to manipulation of the 
proposed thromboxane/prostacyc1in haemostatic mechanism, have 
received widespread attention. 
THROMBOXANE SYNTHETASE INHIBITION. 
Selective inhibition of thromboxane synthetase is one approach 
to the development of antithrombotic agents. Such inhibition 
2.7.3. 
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might result, not only in preventing formation of the 
pro-aggregatory thromboxane A2, but also in endoperoxide 
metabolism being directed towards prostacyclin production when 
the alternative thromboxane pathway is blocked. Nijkamp, 
Moncada, White and Vane (1977) have shown that during selective 
inhibition of thromboxane A2 synthesis with imidazole, 
formation of other products of endoperoxide metabolism is 
enhanced. 
ASPIRIN. 
A further consequence of the discovery of prostacyclin has been 
the need to re-examine the use of aspirin as an antithrombotic 
compound. 
Aspirin and other aspirin-like drugs inhibit generation of 
thromboxane A2 in platelets, and that is why, prior to the 
discovery of prostacycl in, aspirin was widely promoted as an 
anti thrombotic drug (Moncada and Vane, 1980b). However, since 
these agents exert their inhibitory effect by acetylation (Roth 
and Majerus, 1975) of cyclo-oxygenase, it is now clear that 
they also inhibit prostacyclin formation by the vessel wall. 
Many workers have investigated the possibility of adjusting the 
aspirin dosage schedule so as to produce a greater inhibitory 
effect on thromboxane A2 than on prostacyclin production. 
This work is reviewed by Moncada and Vane (1980a). While it 
appears that the effect of asp i ri n on thromboxane A2 
synthesis by platelets is of longer duration than its inhibitory 
2.7.4. 
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effect on prostacyclin synthesis by the vessel wall, further 
studies are required to determine the dose regimen of aspirin 
which will inhibit thromboxane A2 production, wh i 1 e 
permitting continuing prostacyclin synthesis (Preston, Whipps, 
Jackson, French, Wyld and Stoddard, 1981). 
POSSIBLE DIETARY MANIPULATION. 
Dyerberg and Bang (1978) have suggested that the low incidence 
of acute myocardial infarction in Greenland Eskimos could be 
due not only to their plasma lipid profile but also to the 
relative lack of substrate required for the formation of 
proaggregatory prostaglandins by platelets. O'Grady (1980) has 
reviewed evidence that the plasma lipids of these Eskimos 
contain only small amounts of arachidonic acid and relatively 
high amounts of eicosapentaenoic acid, the latter being 
transformed in plate 1 ets to thromboxane A3, wh i ch in contrast 
to thromboxane A2 derived from arachidonic acid, is not 
pro-aggregatory. However, the vesse 1 wa 11 can ut i 1 i se 
eicosapentaenoic acid to synthesise an anti-aggregatory 
substance, probably prostaglandin (Dyerberg, Bang, 
Stoffersen, Moncada and Vane, 1978). The possibility that 
dietary supplementation, or medication with eicosapentaenoic 
acid would provide prophylaxis against arterial thromboembolic 
disease remains to be explored. 
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2.8. CHANGES IN PROSTACYCLIN AND/OR THROMBOXANE A2 IN PATHOLOGICAL 
S ITUA TI ONS. 
2.8.1. 
The discovery of prostacyclin opened a new field of 
investigation into whether or not prostacyclin and/or 
thromboxane levels may be altered in various pathological 
conditions. 
One disorder which has received much attention is 
atherosclerosis 
ATHEROSCLEROSIS. 
Lipid peroxidation, induced by free radical formation, is known 
to occur in certain pathological conditions (Slater, 1972). 
The role of lipid peroxides in the development of 
atherosclerosis has been debated since Glavind, Hartmann, 
Clemmesen, Jessen and Dam (1952) described the presence of 
1 ipid peroxides in human atherosclerotic aortas and reported 
the peroxide content to be directly proportional to the 
severity of the atherosclerosis. Though thi s work was 
subsequently disputed, Moncada and Vane (1979a) in their review 
ment io n a number of authors whose work has supported the 
findings of Glavind et a1. Recently it has been shown that a 
1 i P i d perox i de 15-hydroperoxy arach i don i c ac i d (Bunt i ng, 
Gryglewski, Moncada and Vane, 1976, Gryglewski, Bunting, 
Moncada, Flower and Vane, 1976 and Moncada, Gryglewski, Bunting 
and Vane, 1976b) inhibits prostacyclin formation. Other fatty 
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acid peroxides and their methyl esters behave similarly 
(Salmon, Smith, Flower, Moncada and Vane, 1978) as do other 
substances related to atherosclerosis such as low density 
lipoproteins (Nord~y, Svensson, Wiebe and Hoak, 1978). 
Accumulation of 1 ipid peroxides in atheromatous plaques could 
predispose to thrombus formation by inhibiting prostacyclin 
formation by the vascular wall without impairing thromboxane 
A2 generation by platelets (see Figure 4 proposed by 
Gryglewski, 1980). Indeed, Dembinska-Kiec, Gryglewska, Zmuda 
and Gryglewski (1977) have found that there is a reduction in 
prostacyclin formation by vessels of rabbits made 
atherosclerotic by diet. (Though after 5 months there is a 
tendency for synthesising capacity to recover 
(Gryglewski, Dembinska-Kiec, Zmuda and Gryglewska, 1978).) 
Similarly, it has been reported that human atherosclerotic 
tissue does not produce prostacyclin though normal vessel does 
(D'Angelo, Villa, Mysl iewiec, Donati and de Gaetano, 1978). In 
addition, arteries of species susceptible to the development of 
atherosclerotic lesions have a lower capacity for the synthesis 
of PGI 2 (Sinzinger, Silberbauer, Winter and Clopath, 1979). 
Since cell proliferation in vitro is inhibited by substances 
which stimulate cAMP formation, it has been suggested that 
prostacyclin may playa role in regulation of cell growth in 
the vascu 1 ar wa 11, and that smooth musc 1 e pro 1 iferat i on in 
atherosclerotic plaques (Bendit, 1977) might be a consequence 
of inhibition of prostacyclin generation by lipid peroxides 
(O'Grady, 1980). 
It is interesting to note, that in addition to decreased 
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prostacyclin generation by the vasculature in rabbits made 
atherosclerotic by diet, at certain stages (Gryglewski, 
Dembinska-Kiec, Zmuda and Gryglewska, 1978) their platelets 
generate increased amounts of thromboxane A2 and are more 
sensitive than controls to the actions of arachidonic acid, 
thromboxane A2 and prostacyclin (Zmuda, Dembinska-Kiec, 
Chyckowski and Gryglewski, 1977). 
DIABETES. 
The incidence of atherosclerosis and thrombosis is increased in 
patients with diabetes mellitus (Keen, 1976 and Timperley, 
Ward, Preston, Duckworth and O'Malley, 1976) and abnormalities 
of platelet function have been described in diabetic patients 
(Breddin, Grun, Krzywanek and Schremmer, 1976 and Ferguson, 
Mackay, Philip and Sumner, 1975). The possibility that 
disturbance in prostacyclin and/or thromboxane A2 might be 
related to the development of diabetic angiopathy has been 
invest i gated. Reduced generat ion of prostacyc 1 in by vascu 1 ar 
tissue (Harrison, Reece and Johnson, 1978, Johnson, Harrison, 
Raferty and Elder, 1979, Silberbauer, Schernthaner, Sinzinger, 
Piza-Katzer and Winter, 1979 and Gerrard, Stuart, Rao, Steffes, 
Mauer, Brown and White, 1980), and elevated thromboxane 
generation by platelets (Butkus, Skrinska and Schumacher, 1980 
and Gerrard, Stuart, Rao, Steffes, Mauer, Brown and White, 
1980) have been reported for diabetic experimental animals and 
patients. 
2.8.3. 
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OTHER DISORDERS IN WHICH ABNORMAL LEVELS OF PROSTACYCLIN, 
THROMBOXANES OR ENDOPEROXIDES HAVE BEEN REPORTED. 
Platelets of patients with arterial thrombosis and post-
surgical deep vein thrombosis synthesise more prostagland in 
endoperoxides, one minute after being stimulated with collagen, 
than do those of controls (Lagarde and Dechavanne, 1977). 
Platelets from patients who have survived myocardial infarction 
produce more thromboxane A2 than those from contro 1 sand in 
addition, require significantly less thromboxane A2 to 
initiate their aggregation (Szczeklik, Gryglewski, Musial, 
Grodzinska, Serwonska and Marcinkiewicz, 1978). Lewy, Smith, 
Silver, Wiener and Walinsky (1979) have demonstrated elevated 
thromboxane B2 levels in the blood of patients with 
Prinzmetal's angina (Moncada and Vane, 1980a). Specimens of 
venous tissue from patients with renal failure have been shown 
to produce more prostacyc 1 in-l ike act i vity than contro 1 s 
(Remuzzi, Cavenaghi, Mecca, Donati and de Gaetano, 1977). 
Remuzzi, Misiani, Marchesi, Livio, Mecca, de Gaetano and Donati 
(1978) suggest that patients with haemolytic-uraemic syndrome 
or related conditions lack a plasma factor which stimulates 
vascular prostacyclin activity. Defect ive prostacyclin 
activity could favour the formation of platelet thrombi in the 
microcirculation which is typical in such disorders. Patients 
with Bartter's syndrome excrete in the urine about four times 
as much 6-oxo-PGF la as do controls (GUllner, Cer1etti, 
Bartter, Smith and Gill, 1979). 
2.8.4. 
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HYPERTENSION. 
Hypertension is characterised by an abnormal sustained 
elevation of the basal systemic arterial blood pressure and is 
associated with vascular complications accompanied by increased 
tendency of platelets to aggregate (Lentini and Bologna, 
1974). This is, therefore, a disorder in which prostacyclin 
would obviously be of interest in view of its properties as a 
vasodilator and potent anti-aggregant, and its predominant 
production in the blood vessel wall. 
In most forms of hypertens i on, card i ac output is normal, and 
the raised pressure is thus due to an increase in peripheral 
resistance (Pickering, 1974). The increase in peripheral 
res i stance may resu 1 t from morpho 1 og ica 1 or funct i ona 1 changes 
of the arteri 0 1 es, or from an a lterat i on in any of the many 
complex and integrated mechanisms which function to maintain 
arterial pressure. 
Morphological and Functional Changes in Arterioles. 
Several changes in the arteriolar smooth muscle in hypertension 
have been described including a reduction in cAMP and increase 
of the muscle's permeability to various cations (Fasciolo, 
1979). Folkow, Grimby and Thulesius (1958) list a number of 
authors who have suggested that a generalised hypertrophic 
thickening of the arteriolar wall takes place in chronic 
hypertension more or less independent of its original 
background. These authors point out that the existence of an 
increased wall mass causes a proportionally bigger lumen 
2.8.4.2. 
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decrease and hence resistance to flow for a given smooth muscle 
shortening, i.e. a structurally based "potent iation" of a 
vasoconstrictor response is obtained by virtue of an anatomical 
change in the vessel. 
Blood Pressure Control Systems - Alteration of which may be 
Involved in Hypertension. 
In certain types of secondary hypertension, that is 
hypertension which is secondary to some identif iable cause, 
e.g. phaeochromocytoma, involvement of one of these systems is 
clearly implicated. However, for the most part,particularly in 
primary or essential hypertension (which is the largest single 
form of hypertension), no cause has been clearly defined. 
2.8.4.2.1. Sympathetic Nervous System, Sympathomimetics and Adreno-
receptors. 
Alpha and beta adrenoreceptors part ic i pate in blood pressure 
regulation (especially in the short term) and pharmacological 
manipulation of adrenergic mechanisms, both peripherally and 
centrally, lowers blood pressure in the long term. This 
manipulation is the basis of much successful antihypertensive 
therapy today. 
Neura l mechanisms in hypertension have recently been reviewed 
by Brody, Haywood and Touw (1980). Some data, such as direct 
record i ng of increased peri phera 1 sympathet i c nerve act i v ity, 
supports the contribution of increased sympathetic activity to 
hypertension in Okamoto spontaneously hypertensive rats (SHR). 
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However, other data suggests that in conscious SHR, removal by 
ganglion blockade of sympathetic activity does not produce a 
greater fall in vascular resistance than that observed in 
normotensive, age matched controls. Certain studies suggest a 
central impairment of brain catecholamine function in SHR, 
characterised by a decrease in hypothalamic catecholamines and 
an increase in brain stem adrenal ine and noradrenal ine. 
However, the critical site(s) of central catecholamines in 
hypertension remain unclear. 
In man, increased adrenal secretion of adrenaline and 
noradrenal ine is responsible for the raised arterial pressure 
of phaeochromocytoma. However the role of the sympathetic 
nervous system and of adrenal medullary hormones in essential 
hypertension is debatable. Excessive vessel constriction is 
not due to overaction of sympathetic nerves, for it persists in 
hand, brain and kidney when sympathetic action is eliminated 
(Pickering, 1974). Estimations of plasma or urinary 
catecholamines give, at best, a shadowy indication of activity 
of the sympathetic system, and while some claims have been made 
that patients with essential hypertension have a greater output 
of catecholamines than age matched, normotensive patients 
(reviewed by Sleight, 1980), other authors (e.g. Reid, Jones 
and Hamilton, 1978) are not able to confirm this. Reid et al. 
also report that any increased pressor responsiveness to 
infused noradrenal ine appears to be shared with other pressor 
agents and is probably secondary to hypertrophy of vascular 
smooth muscle. 
It appears that there is, to date, no unequivocal evidence that 
increased activity of the sympathetic nervous system, increased 
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catecholamine levels or increased specific sensitivity of 
adrenoreceptors to catecho1amines underlie the raised blood 
pressure of human essential hypertension. 
2.8.4.2.2. Baroreceptor Reflexes 
The ex i stence of along term i nf1 uence by baroreceptors on 
blood pressure has been questioned, but some regard it as 
important. Their views are supported by the observations that 
in experimental animals interference with the baroreceptor 
reflex pathway centrally, or in the peripheral afferent arc, 
not only increases 1abil ity of arterial pressure but produces 
elevated arterial pressure in several species (Brody, Haywood 
and Touw, 1980). In addition, when the baroreceptors are 
exposed to a high arterial pressure, they are gradually 
"reset", so that eventually their output is similar to normal 
although the pressure stimulating them is abnormally high 
(Zanchetti, 1979). Thus sensitivity of the reflex varies 
inversely with arterial pressure (Pickering, 1974). 
It is also unknown whether loss of reflex sensitivity is cause 
or effect, i.e. is hypertension caused by loss of reflex 
control or does hypertension damage the receptors by, for 
example, increasing the rigidity of the artery and thus the 
pressure increment required to produce a given stretch of the 
receptor? Both mechanisms may possibly be operative, producing 
a vicious cycle. 
case, pressure 
Whatever the cause of hypertension in a given 
could not be corrected efficiently if 
baroreceptor function were compromised. 
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2.8.4.2.3. Renin, Angiotensin and Aldosterone 
Few would disagree that the kidney is of importance in the 
determination of arterial pressure. For example, it has been 
shown that the high blood pressure of selectively bred, 
spontaneously hypertensive rats can be lowered by transplanting 
the kidneys of normotensive rats and vice versa (Bianchi, Fox, 
di Francesco, Giovanetti and Pagetti, 1974). Since Goldblatt, 
Lynch, Hanzel and Summerville (1934) produced hypertension in 
dogs by constricting the renal arteries with clamps, it has 
become clear that many different renal lesions could lead to 
hypertension. The role of the renin-angiotensin system has 
received much attention. From its strategic origin in the 
kidney it serves a vital function in the homeostatic mechanisms 
of the body. It is a servomechanism regulating sodium exchange 
and blood volume through its action on receptor sites in the 
adrena 1 cortex, re leas i ng aldosterone, an important regu 1 ator 
of water and electrolyte metabolism and the volume of the fluid 
compartments of the body. Ang iotens ina 1 so acts on receptor 
sites of vascular smooth muscle, on the kidney and on the 
central nervous system; thus it may participate in the 
regulation of blood flow through the kidney, the tone of 
vascular smooth muscle, the production of renal prostaglandins 
and possibly, to a small degree, controls the modulation of 
arterial blood pressure by the central nervous system 
(Grollman, 1980). 
As regards the importance of the ren i n-ang i otens i n system in 
hypertension, some authors, e.g. Page (1980) feel nit is highly 
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probable that the core of the mechanism of essential, 
renovascular and mal ignant hypertension is angiotensin." On 
the other hand, Grollman, in his recent survey of hypertension 
(1980), cites the mass of incontrovertible data available, 
proving that angiotensin II, or its active des-aspartic acid 
derivative angiotensin III, is not concerned in the 
pathogenesis of clinical or experimental hypertension and he 
points out that there is no correlation between the severity of 
hypertension and peripheral renin activity. 
2.8.4.2.4. Kinins and Prostaglandins 
While development of hypertension may reflect changes in one or 
more of several pressor hormones, e.g. overactivity of the 
renin-angiotensin system or a mineralocorticoid excess, a 
failure of opposing forces that normally act to lower blood 
pressure, may be of no less importance. 
It is now believed that defects of vasodilatory systems, such 
as the prostaglandins and the kallikrein-kinin systems 
operating to offset vasoconstrictor influences, may be 
important in the aetiology of hypertension. 
Renal prostaglandins are theoretically integrated with the 
kal1 ikrein-kinin and renin-angiotensin systems in a vasoactive 
hormone complex summarised in Figure 5. 
The role of prostaglandins and kinins in the regulation of 
blood pressure has recently been reviewed by McGiff and Quilley 
(1980). The kinins (such as bradykinin), released by the 
action of the enzyme kallikrein, are polypeptides having 
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Klnlns directly stimulate prostaglandin release which 
In turn stimulates renin release. Angiotensin II stimulates 
aldosterone, prostaglandin and kallikrein release. 
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vasodilator and diuretic properties; it has been suggested that 
they participate in the regulation of blood pressure. A defect 
of kall ikrein release and subsequent deficient generation of 
kinins could contribute to the pathogenesis of some forms of 
hypertension. Excretion of kallikrein has been reported to be 
decreased in human and experimental forms of hypertension. A 
component of this poss ible role in blood pressure regulation is 
the ability of kinins to release prostaglandins. The released 
prostaglandins usual ly augment the action of kinins. 
Local prostagl and ins may be an important determinant of 
vascular reactivity. For example, prostaglandin E2 released 
in response to a pressor stimulus (angiotensin II, 
noradrena 1 i ne or adrenergic nerve exc i tat i on), has been shown 
to attenuate the Jasoconstrictor action of that stimulus 
(McGiff and Quilley, 1980). On the other hand, PGF2a may 
enhance the pressor response of the vasculature (Hedqvist, 
1976). These observations have suggested that an alteration in 
production or activity of various prostaglandins could be 
involved in hypertension. 
Though Hornych (1978) has generally found PGE2 to be 
significantly elevated in the peripheral and renal venous blood 
of hypertensive patients, basal urinary excretion of PGE2 
(which also usually has a direct vasodilator action on 
resistance vessels (Nowak, 1979)), has been shown to be low in 
an appreciable number of patients with essential hypertension 
(Weber, Siess and Scherer, 1980) . Weber et al. have also 
reported a reduced capacity of the essential hypertensive 
kidney to produce vasodilating compounds and 
kallikrein) upon challenge with furosemide. 
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The possible significance of renal prostaglandins in essential 
hypertension has been discussed recently by Weber, Siess and 
Scherer (1980): 
In vivo and in vitro studies show that renal formation of 
prostaglandins, possibly in the vasculature of the cortex, 
represents an essential step in the mechanisms regulating the 
secretion of renin. Many of the experimental conditions known 
to be associated with alterations of renin secretion, renal 
blood flow or glomerular filtration rate have also been shown 
to lead to changes in renal prostaglandin formation. However, 
because of the complex interrelation it is difficult to 
de 1 i neate the re 1 at i ve importance of PGs and reni n and the 
sequence of events operating in different functional states of 
the kidney. 
It is suggested that an impairment in renal production of 
vasodilating and renin-stimulating PGs e.g. PGEZ (which could 
also lead to unbuffered response to pressor substance) could be 
the common denominator for both the reduced renin secretion and 
increased vascul ar res i stance, wh i ch have been reported to be 
associated in essential hypertension. 
McGiff and Quilley, (1981) have highlighted the importance of 
species difference when . using the rat as a model for human 
hypertension, particularly when studying renal prostaglandins. 
In the rat, unlike the human, . prostaglandins of the E series 
constrict renal blood vessels and enhance the vasoconstrictor 
response to sympathetic nerve stimulation. Thus, they could 
actually contribute to elevation of blood pressure. This 
anomalous constrictor response of the renal vasculature of the 
rat to PGEZ' is exaggerated in the New Zealand strain of 
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genetically hypertensive rat (GH), where an abnormal ity of PG 
metabolism has been found which could account for the elevation 
in pressure. There is evidence for a vasodilator mechanism in 
the rat kidney, probably subserved by PGI 2 or its active 
metabolite 6-keto-PGE l which, unlike PGE 2, can dilate the 
renal vasculature in this species. 
2.9. AIMS OF THE STUDY. 
There is clearly a mosaic of interrelated, vasoregulatory 
mechanisms, derangement of any of which may be related to the 
increased peripheral vascu 1 ar resistance, which is 
characteristic of elevated arterial pressure. 
The fact that prostacyclin is locally generated in the arterial 
wall and can relax arterial smooth muscle, suggests that it may 
playa part in the control of vascular tone. It is therefore a 
substance of obvious interest in hypertension. In fact, 
Moncada, Gryglewski, Bunting and Vane (1976a) suggested in 
their paper reporting the discovery of prostacyclin, that a 
deficiency could perhaps underlie some forms of hypertension. 
The anti-aggregatory properties of prostacyclin are also of 
interest : platelet adhesiveness and ADP-induced aggregation in 
vitro have been reported to be increased in patients with 
hypertension (Coccheri and Fiorentini, 1971, Bologna, 1974 and 
Lentini and Bologna, 1974). It has been suggested (Lentini and 
Bologna, 1974) that this may be a major determinant of the 
thrombotic and atherosclerotic complications of hypertensive 
vascular disease. 
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The aims of this study were accordingly to investigate, using a 
rat model: 
a) Whether there was any alteration in vascular (aortic) 
prostacyclin production in animals with elevated blood pressure. 
b) Whether subsequent manoeuvres designed to lower elevated 
pressure affected aortic prostacyclin production. 
c) The in vitro sensitivity of platelets of hypertensive 
animals to the effect of ADP and prostacyclin. 
In the text, after consideration of general materials and 
methods, each study is presented individuallY together with the 
immediately obvious conclusions. All the findings and their 
implications are discussed in the final chapter of this thesis. 
CHAPTER 3 
GENERAL MATERIALS AND METHODS 
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3.1. EXPERIMENTAL ANIMALS. 
The entire study involved the use of albino rats. These were 
all housed under the same conditions, received a standard diet 
of Un ited Oil Epo 1 rat cubes and were a 11 owed unrestri cted 
access to tap water. 
3.2. MEASUREMENT OF RAT BLOOD PRESSURE 
Arterial systol ic blood pressures were measured in conscious 
animals by a modification of the tail cuff method developed in 
this laboratory by Lockett, Leary and Asmal (1979). Briefly, 
the procedure is as follows: After spending approximately 
20 minutes in a warming box at 39'C the rat is placed in a 
small, cylindrical, wire, restraining cage. Its tail, after 
being passed through a small pressure cuff, has a Whitney 
mercury silastic strain gauge wound around it. Output from the 
strain gauge and from a pressure transducer (connected to the 
tail cuff sphygmanometer) are recorded simultaneously on a 
potentiometric recorder (Figure 6). Cuff pressure is raised to 
a point above the expected systolic pressure and slowly 
released. The strain gauge registers pulsations once caudal 
arterial pressure exceeds cuff pressure. Joining this point to 
the pressure curve gives the value of the systolic arterial 
pressure which is measured against 100 mm Hg standard. 
An average of three readings was recorded as the blood pressure 
of the animal. 
o 
FIG.6: DIAGRAM OF RECORDER TRACING OF BLOOD PRESSURE 
MEASUREMENT. 
Strain gauge output (tail pulsations) is shown In the middle 
of the trace. The sloping line running top to bottom indicates 
pressure in mmHg. 100mm Hg standard is shown on the left. 
The two measurements shown indicate a rat with systolic 
arterial pressure of 120mmHg 
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3.3. ASSAY OF PROSTACYCLIN 
3.3.1. 
The ability of prostacyclin to inhibit the in vitro aggregation 
of blood platelets, provides a useful method for direct assay 
of the substance. Human blood plate 1 ets were used to detect 
prostacyclin in these studies. 
PREPARATION AND STORAGE OF PLATELET RICH AND PLATELET POOR 
PLASMA. 
Human venous blood was obtained from healthy, male, adult 
Indian volunteers who had taken no drugs during the preceeding 
2 weeks. On each occasion blood was collected from the 
antecubital vein and immediately added to 3,8", trisodium 
citrate (9 parts blood part citrate) as anticoagulant 
(Biggs, 1976). 
After careful mixing, the sample was centrifuged at room 
temperature at 160g for 10 minutes (Rubin, Weston, Bullock, 
Roberts, Langley, White and Williams, 1977). Only the top two 
thirds of the generated platelet rich plasma (prp) was utilised 
in the study as 1eucocytes, present in the lower third, are a 
rich source of prostacyc1in synthesising enzymes (Blackwell, 
Flower, Russel-Smith, Salmon, Thorogood and Vane, 1978). 
A small portion of the prp was centrifuged for 15 minutes at 
2000g (Sagel, Colwell, Crook and Laimins, 1975) at 4'C to yield 
a supernatant of platelet poor plasma (ppp). This low 
temperature causes better sedimentation of fibrinogen and cells 
(Marcus, 1978). 
3.3.2. 
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The rema i nder of the prp was di spensed in 450 ~ 1 Quant i ties 
into siliconised glass cuvettes. These were kept at room 
temperature until used. Cooling of platelets below this 
temperature was considered inadvisable as considerable 
variation occurs in platelet shape during cooling (Zucker and 
Borrelli, 1954). 
During this period, prp was kept under 5',. carbon 
dioxide 95',. oxygen (Carbogen, Afrox) (Weksler, Ley and 
Jaffe, 1978). This procedure ensured that loss of carbon 
dioxide, and an associated rise in pH of the prp did not 
occur. Han and Ardlie (1974) have reported that the pH of prp 
increases during storage at room temperature and that this 
change is associated with increased response to ADP. 
Care was taken that the assay was completed and platelets were 
used within 120 minutes of drawing blood because Cronberg 
(1971) has shown that when plasma is stored for this period, 
though the number of aggregat ing plate 1 ets remains the same, 
'stickiness' decreases. 
It has been known since the observations of Ranvier and Vulpian 
in 1873 that platelets adhere to glass surfaces (Ulutin, 1976), 
therefore blood and plasma were handled exclusively with 
plastic and siliconised glass apparatus throughout these 
studies. 
PLATELET COUNTS. 
Platelet counts were carried out on both prp and ppp. Plasma 
was diluted 1 in 20 with trisodium citrate 3,2". in a plastic 
3.3.3. 
3.3.3.1. 
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tube and, after mixing, a sample was transfered to a Newbauer 
counting chamber using a capillary tube. The chamber was 
placed in a petri dish containing damp filter paper (to provide 
a moist atmosphere to prevent drying) and left for 40 minutes. 
Ashman (1976) has shown that at least 40 minutes is required 
for all platelets to settle. After this time platelets were 
counted, in duplicate, under x40 magnification. 
On ly prp with counts between 300 000 and 500 000 Imm3 (i. e. 
withi n norma 1 range) were used in these stud ies. Ppp never 
contained more than 2000 platelets/mm3 • 
AGGREGATION OF PLATELETS. 
Aggregant. 
A number of substances, including epinephrine, serotonin 
(Mitchell and Sharp, 1964), collagen (Wilner, Nossel and Le 
Roy, 1968) and arachidonic acid (Moncada, Gryglewski, Bunting 
and Vane, 1976a) can be used to aggregate platelets in vitro. 
Adenosine 5'-diphosphate (ADP) (Gaarder, Jonsen, Laland, Hellem 
and Owren, 1961) was used as aggregant in these studies. 
Adenosine 5'-diphosphate grade I sodium salt was obtained from 
Sigma Ltd., St. Louis, U.S.A. Sigma reports that decomposition 
can be reduced by adjusting the pH to 6,8 and storing the 
solution at -20·C. A stock solution of ADP (1 mg/ml) was 
therefore prepared in tris acid maleate buffered sal ine (Sano, 
Boxer, Boxer and Yokoyama 1971) at pH 6,8 and 0,5 ml al iquots 
were stored at -20·C. Immediately before use, aliquots were 
diluted with the same buffered saline to produce the required 
concentrations of ADP. 
3.3.3.2 
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Photometric Measurement of Aggregation. 
The photometric method first described by Born (1962), is 
valuable for investigating platelet aggregation in vitro and 
for the Quantitative study of substances influencing this 
process. The method depends on the continuous measurement of 
changes in transmission of light of constant wave length, 
through a suspension of platelets. When platelets aggregate, 
the optical density decreases because the light scattering 
power of the comparatively few coarse particles present at the 
end of the experiment, is less than that of the many small 
part ic 1 es (free platelets) whose diameter approaches the 
wavelength of light (O'Brien, 1962). 
Born first measured changes in transmission in an 
absorptiometer, but subsequently platelet aggro-meters have 
been designed to regulate the many factors that must be kept 
constant during aggregation tests. 
Chrono 1 og Aggro-meter was used 
A dual channel model 340 
in these studies. This 
instrument was thermostatically controlled so that all tests 
were carried out at a constant temperature (37·C). In 
addition, each cuvette of prp was allowed to equilibrate in a 
water bath at 37'C for 4 minutes before insertion into the 
instrument. Temperature control is important as speed of 
aggregat i on is inf1 uenced by temperature (Born, 1962 and 
0' Bri en, 1962). 
Stirring (collision) of platelets is required for aggregation 
to occur on the addition of ADP (O'Brien, 1962 and Born and 
Cross, 1963) and different stirring rates result in different 
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rates of aggregation (Born, 1962 and O'Brien, 1962). In these 
studies with the Chronolog model 340 Aggro-meter, a constant 
st i r rate of 1000 rpm was prov i ded in each channe 1 by the 
addition of a small teflon covered magnetic stirrer bar to the 
prp sample. 
The extent of aggregation induced by ADP is dependant upon the 
concentration of platelets (Born and Cross, 1963 and Rossi and 
Louis, 1977). Concentration was kept constant from sample to 
samp 1 e by ali Quot i ng exactl y 450 ~ 1 of prp into each cuvette 
from a well mixed prp pool (as already described). 
Changes in light transmission were monitored on a two pen 
recorder coupled with the aggro-meter. A device on the 
instrument allowed for zeroing of each channel on the recorder 
prior to each study. The recorder scale of both channels was 
cal ibrated at the beginning of every study by adjusting the 
sensitivity to give a standard, nearly full scale deflection, 
between prp and ppp. (i.e. to allow 5% light transmission 
with prp and 95 % transmission with ppp). 
Plate 1 ets were aggregated by add it ion of 20 ~ 1 Quant it i es of 
ADP. This produced characteristic curves on the chart 
recorder:- first a rapid small decrease in light transmission, 
caused by a change in shape of the platelets (Born, 1970 and 
Michal and Born, 1971), overtaken within a few seconds by the 
much larger increase in light transmission associated with the 
formation of aggregates (Figure 7 ). 
Calculations were made by assuming that the ppp blank 
represents 100° / ° aggregation and that the percentage change 
in absorbance was equivalent to the percentage aggregation. 
PPP-
x 
PRP ...... tN 
ADP 
Time (min) 
% Aggregation calculated as: 
..Lx 100 at O,5min 
x 
+x 100 at 4min 
z 
• 4 
(PRP and PPP represent 0 and 100 % aggregation 
respectively) 
FIG.7: DIAGRAM OF CHARACTERISTIC RECORDER TRACING SHOWING 
THE CHANGE IN LIGHT TRANSMISSION WITH TIME ON THE 
ADDITION OF ADP TO HUMAN PRP . 
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Th is was based on the fact that the absorbance of many prp 
suspensions will approach zero if treated with adequate 
aggregating agent (Sagel, Colwell, Crook and Laimins, 1975). 
Two parameters of the curve were used for quantitation and 
comparison: 
a) the initial rate of aggregation as indicated by the extent 
of aggregation 0,5 minutes after the addition of ADP (Born and 
Cross, 1963) and 
b) the extent of permanent aggregation 4 minutes after the 
addition of ADP (Sagel, Colwell, Crook and Laimins, 1975) 
(Figure 7). 
Comparison of the Two Channels of the Aggro-meter. 
A dual channel instrument was chosen for these studies since it 
a 11 owed compari son of prostacyc 1 in product i on by aortas from a 
control and a test animal in parallel. 
Three prel iminary experiments were conducted to confirm that 
results from the two channels did not differ appreciably. Each 
of these involved one volunteer's platelets which were 
aggregated by varying concentrations of ADP, in duplicate, in 
the two channels. 
The mean values of percentage aggregation for the two Channels 
were 40,95 and 39,99 respectively, the mean difference being 
0,96. The mean percentage var i at i on between channe 1 s was thus 
2,40,0. This was felt to be within the 1 imits of experi-
mental error; in addition, when estimating PGI 2 production, 
test and control animals were deliberately randomised by 
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alternating between the two channels from experiment to 
experiment. 
3.3.3.4. Choice of ADP Concentration. 
3.3.4. 
The result of the study comparing the two channels of the 
aggro-meter also confirmed the finding of Born and Cross (1963) 
that, up to a point, as the concentration of added ADP in the 
plasma increases the rate at which, and the extent to which, 
platelets aggregate also increases. Figure 8 shows the 
concentrat ion of ADP plotted aga ins t percentage aggregat i on as 
measured at 0,5 and 4 minutes respectively (results for one 
vo 1 unteer) • 
The 'plateau' nature of both these concentration effect curves 
indicates the importance of chosing a submaximal dose of ADP if 
the effects of an inhibitor of aggregation are to be 
investigated. Maximal concentrations with responses on the 
plateau portion of the curve, may give the same response (i.e. 
slightly further to the left on the plateau) in the presence of 
an inhibitor and therefore inhibitory activity would not be 
detected. Thus, in all studies, platelets were aggregated with 
a submaximal dose of ADP. 
IHIBITION OF AGGREGATION BY AORTIC INCUBATE. 
Moncada, Higgs and Vane reported in 1977 that an inhibitor of 
platelet aggregation (prostacyclin) was generated by incubation 
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of fresh rings of human artery in tris buffer. The method used 
in these studies was based on this work. 
3.3.4.1. Collection and Storage of Vessels. 
3.3.4.2. 
After an overn i ght fast, pa i red test and control anima 1 s were 
sacrificed by a blow to the neck. The abdominal aortas, from 
the right renal artery to the bifurcation into the common iliac 
arteries, were removed, cleared, and rinsed with ice cold tris 
buffer (0,5 mmol/l, pH 7,5). Each aorta was adjusted to a wet 
weight of 10-20 mg. (Weight adjustments were made by trimming 
the aorta at the proximal end to ensure that a comparative 
portion as well as weight of aorta was always used. It has 
been suggested that there may be a segmental distribution of 
enzyme activity in blood vessels (Skidgel and Printz, 1978).) 
Aortas were then stored in 1,5 ml tris buffer on ice until 
tested (within 30 minutes). 
Production of Inhibitory Incubate. 
Each aorta was cut once 
approximately equal strips 
longitudinally to 
(in some studies 
produce two 
3 additional 
transverse cuts were made to produce 8 strips). Strips were 
used in preference to the rings of Moncada, Higgs, and Vane 
(1977) since they could be produced more reproducibly. If, as 
has been suggested (Moncada and Vane, 1977), prostacyclin is 
produced by vesse 1 sin response to damage, then the number of 
cuts and surface area exposed per vessel would be important in 
3.3.4.3. 
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determining the amount of prostacyclin released. As these 
studies required quantitative comparison the use of strips 
aimed to keep such variation to a minimum. 
Strips of aorta were incubated in 700 III tris buffer at room 
temperature. Use of amb i ent temperature meant that no 
comparison of results from day to day was possible and 
emphas i ses the necess ity of us i ng a dual channe 1 aggro-meter 
for assay of a control and test animal in parallel. 
Removal and assay of 20 III aliquots of incubate during 
preliminary experiments, indicated that prostacyclin was not 
distributed homogenously throughout the incubation mixture. 
This problem was overcome by the addit ion of a small, plastic 
covered magnetic stirrer bar, which also stimulated 
prostacyclin production mechanically. An identical stir rate 
in both test and control incubate was ensured by the use of a 
common magnetic stirrer plate. 
Measurement of the Inhibitory Activity of Aortic Incubate. 
At various times after incubation began (usually 2 , 8 and 14 
mi nutes) 20 III samp 1 es of the incubate were removed and added 
to prp 1 mi nute before the addit i on of ADP. The percentage 
inhibition of platelet aggregation produced by each sample 0,5 
and 4 minutes after the addition of ADP, was assessed by 
comparing the extent of aggregation at both times, with the 
corresponding control values. Control values were the 
percentage aggregation at 0,5 and 4 minutes for control curves, 
obtained by adding 20 III of tris at room temperature to prp 
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1 minute before the addition of ADP (Figure 9). A diagram of a 
typical recorder tracing is shown in Figure 10. As can be 
seen, a control curve was recorded before and after each 
assay. Control values (for each channel) were the means of the 
values for these 2 curves. 
The second rat in each experiment was always sacrificed 7,5 
minutes after the first, to allow time for the preparation of 
the first aorta before storage. There was thus a corresponding 
7,5 minute delay in the incubation of the second aorta, to 
ensure that both vesse 1 s were stored for the same 1 ength of 
time. Animals from each group, viz normotensive and 
hypertensive were sacrified first in alternate experiments. 
CONVERSION OF PERCENTAGE INHIBITION TO ABSOLUTE UNITS. 
The values of percentage inhibition, as measured at 0,5 and 4 
minutes for each sampling time 2, Band 14 minutes, were 
converted into absolute units (ng prostacyclin/ml). This was 
ach i eyed us i ng the concentrat ion effect curves obtained when 
synthetic prostacycl in sodium salt was used to inhibit 
aggregation in the same platelets. Use of the same platelets 
was obligatory, since platelets provide an assay material which 
varies considerably from batch to batch (Maguire and Michal, 
1968). Standard curves were therefore prepared with every 
exper iment. 
Storage and Stability of Prostacyclin Sodium Salt. 
Prostacyclin sodium salt was supplied by Upjohn (Kalamazoo). 
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Approximately 1 mg al iqouts of the sol id were dispensed into 
plastic tubes and stored under nitrogen at -20·C. Checking 
purity by techniques within the scope of this laboratory (viz 
TLC) proved impossible because of the rapid breakdown of 
prostacyclin. It was thus necessary to assume that purity 
prevailed under the storage conditions described. This 
assumption was confirmed with Dr.Pike of Upjohn (personal 
communication). 
Because of the instability of prostacyclin in solution, a 
1 mg/ml solution was only prepared immediately before use, by 
addition of the required volume of tris buffer (0,5 mmol/l, 
pH 9,9) to a previously weighed aliquot. Tris buffer (0,5 
mmolll, pH 8,6) was used to serially dilute this to give 
approximately 10 solutions, ranging in concentration from 1 to 
100 ng/ml. Solutions of prostacyclin were stored on ice 
throughout. Prostacyc 1 in has a half 1 ife of about 10 mi nutes 
in tris buffer at pH 7,5 at 24·C. It is considerably more 
stable at lower temperature and higher pH (Chapter 2.4.). 
Hence the use of low temperature and high pH in preparation of 
solutions. pH 8,6 was used in preference to pH 9,9 in 
preparation of the final dilutions for addition to platelets, 
in order not to overtax the buffering capacity fo the prp. 
Measurement of the Inhibitory Effect of Prostacycl in Sodium 
Salt. 
20 ul samples of each of the 10 solutions over the range 
1 - 100 ng/ml were added to prp 1 minute before the addition 
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of ADP. The inhibitory activity of each was assessed by 
comparing, with control values, the percentage aggregation 0,5 
and 4 minutes after the addition of ADP. 
Control values were obtained from calculation of the percentage 
aggregation at 0,5 and 4 minutes for control curves, obtained 
by adding 20 III tris buffer (pH 8,6 on ice) to prp 1 minute 
before the addition of ADP. The mean values from two control 
curves (one at the begi nn i ng and one at the end) were used to 
provide control values for each channel. 
Concentration Effect Curves. 
A concentration effect curve (ng prostacycl in/ml versus 
percentage i nhi b it i on of aggregat i on) was drawn dai ly for each 
of the parameters 0,5 and 4 minutes. From these curves values 
of percentage inhibition, at 0,5 and 4 minutes respectively, 
were converted into ng prostacyclin/ml. The mean of these two 
values gave the value of ng prostacyclin/ml for each sampl ing 
time, viz 2 , 8 and 14 minutes. After correction for volume 
and weight, the final results were quoted as ng prostacyclin/mg 
wet weight of aorta at each sampling time. 
SPECIFICITY OF THE ASSAY. 
Conversion of the inhibitory activity of the aortic incubate to 
abso 1 ute un its of prostacyc 1 in, presupposed that the incubate 
contained prostacyclin as the sole inhibitory substance. 
Obviously other substances may be present, and any which 
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inhibits ADP-induced aggregation of human prp in vitro, could 
interfere in the assay. This would be especially true if the 
substance were a potent inhibitor andlor were present in 
appreciable amounts. 
ADP-ase could be expected to affect the aggregation process (a) 
by decreasing the amount of ADP and (b) by increasing adenosine 
and AMP which are inhibitors of ADP induced aggregation. (Born 
and Cross, 1973). 
Apyrase was obtained from Sigma Ltd., St. Louis, USA. A 
1 mglml solution (containing 0,75 units of ADP-ase activity/ml) 
was prepared in tris buffer (0,5 mmol/l, pH 7,5). 20 \11 of 
this solution added to prp 1 minute before the addition of ADP 
had very 1 itt 1 e i nhi b i tory effect (70 10 ) on the percentage 
aggregation as measured at 0,5 minutes. However, it inhibited 
by 63010, aggregation as measured 4 minutes after the 
addition of ADP. It is therefore possible that if ADP-ase were 
present to any extent in the aortic incubate, it could be 
responsible for part of the inhibitory effect observed. 
PGE l has been shown to inhibit ADP-induced aggregation in 
human prp (Kloeze, 1967) and Smith, Silver, Ingerman and Kocsis 
(1974) and Nishizawa, Miller, Gorman, Bundy, Svensson and 
Hamberg (1975) have shown that PGD2 is even more potent than 
PGE1, in this regard. 
Miller, Aiken, Shebuski and Gorman (1980) have shown 
prostacyclin to be about 70 times and 48 times more potent than 
PGE l and D2 respectively in inhibiting human platelet 
aggregation induced by ADP. This means that either of these 
two substances would contribute to the inhibitory effect 
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observed, only if they were present in the incubate in higher 
concentrations than PGI 2• 
ADP-ase, PGE 1 and PGD2 therefore all have the capacity to 
interfere with the assay if present in the aortic incubate in 
appreciable amounts. 
While an ADP-ase is present in the blood vessel wall, it is 
un1 ike1y that it contributes significantly to the wall's 
ant i-aggregatory act ivity (Chapter 2.6.1) . 
do not arise in appreciable amounts from intrinsic 
endoperox ides (Need1 eman, Wh itaker, Wyche, Watters, Sprech 1 er 
and Raz, 1980). In addition, PGE 1 is probably not likely to 
be present to any extent, as rats have 1 arge amounts of the 
,,5-desaturase enzyme system. (Stone, Willis, Hart, Kirtland, 
Kernoff and McNicol, 1979). This means that dihomo gamma 
linolenic acid synthesis is probably directed largely to the 
formation of arachidonic acid rather than PGE 1. 
However, to confirm that the anti-aggregatory activity being 
detected in these studies was due to PGI 2, the incubate was 
tested to see if it possessed some of the other properties of 
prostacyc1in besides that of inhibition of platelet aggregation. 
As a further confirmation, when radio-immuno-assay reagents 
became available for measurement of the stable metabolite of 
prostacyc 1 in, 6-keto-PGF la' the incubate was assayed by th i s 
method in parallel with the usual assay in six experiments. 
Effect of Boiling on Inhibitory Activity of Incubate. 
Moncada, Gryg1ews ki, Bunting and Vane (1976 a and b) have 
reported that the anti-aggregatory activity of prostacyc1in 
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disappears on boiling for 15 seconds. Two experiments were 
conducted to determine whether the aortic incubate behaved 
similarly. Aortic strips were incubated in tris buffer as 
previously described. After 20 minutes, 600 ~l of incubate 
were transferred to a siliconised glass tube containing a few 
anti-bumping granules. 20 ~l samples of this were tested for 
anti-aggregatory activity and were found to cause total 
inhibition. The remainder was boiled for 15 seconds. After 
cooling to room temperature, addition of 20 ~l samples to prp 1 
minute before the addition of ADP showed the inhibitory 
activity to have been almost totally abolished (Figure 11). 
Stability of Inhibitory Incubate at Room Temperature(22'C) 
and on Ice (l·C). 
Moncada, Gryglewski, Bunting and Vane (1976a) showed that the 
anti-aggregatory activity of PGI 2 was preserved much longer 
in buffered solution when kept at l'C, than when allowed to 
stand at 22·C. 
In one experiment, a 5 minute aortic incubate was divided into 
two. One half was stored on ice and the other allowed to stand 
on the bench at room temperature. Each was tested for its 
inhibitory activity at 0 , 7 and 16 minutes after storage 
began. As shown in Figure 12, inhibitory activity (as measured 
both 0,5 and 4 minutes after addition of ADP) decayed at 22'C 
but not at O·C. 
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Comparison of the Decay Rate at Room Temperature, of the Aortic 
Incubate and Standard Prostacyclin . 
If the aortic incubate and a standard prostacyclin solution 
owed their inhibitory activity to the 
their anti-aggregatory potency should 
same substance, then 
decline in parallel, 
provided they were both held under identical conditions. 
In each of two experiments 500 ~l of a 14 minute aortic 
incubate and 500 ~l of a solution of prostacyclin sodium salt 
(100 ng/ml) prepared using the same tris buffer (pH 7,5), were 
allowed to stand side by side on the bench. Each was assayed 
for its ability to inhibit aggregation at intervals over the 
next hour. 
While decay rates varied from day to day, depending upon the 
ambient temperature, within each experiment decay rates for the 
incubate and standard substance were similar. 
Percentage inhibition was measured both 0,5 and 4 minutes after 
the addition of ADP. Figure 13 shows the decay curves for 
incubate and standard, obtained using each of these parameters 
respectively. (Results from one of the two experiments.) 
Compar i son of Concentrat i on Effect Curves of Aort i c Incubate 
and Standard Prostacyclin. 
If the anti-aggregatory activity of the incubate were due to 
prostacyclin, then the incubate and a solution of the standard 
substance shou 1 d have comparab 1 e concentrat i on effect and log 
concentration effect curves. 
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In one experiment a 14 minute aortic incubate and a standard 
prostacyclin sodium salt solution (lOOng/ml) were prepared 
using tris buffer pH 7,5. These solutions were both serially 
diluted with the same tris buffer. All solutions were kept on 
ice and were assayed in parallel for their inhibitory activity, 
as measured by their effect on percentage aggregation 0,5 and 4 
minutes after the addition of ADP. Hyperbolic dilution versus 
effect curves were obtained. The sigmoidal log dilution versus 
effect curves as obtained by 0,5 and 4 minute measurements, are 
shown in Figure 14. 
Compari son of curves for standard and incubate shows that both 
are capable of the same maximum effect and that the central 
nearly linear portions of the curves, are almost parallel. 
The similarity of these curves, supports the idea that 
inhibitory activity of the incubate may be due to prostacyclin. 
Effect of Indomethacin on the Inhibitory Activity of the Aortic 
Incubate. 
Aspirin-like drugs inhibit prostaglandin production by blocking 
the conversion of arachidonic acid to cyclic endoperoxides, 
PGG2 and H2 (Chapter 2) . Whi le it is uncertain how 
important this pathway is for aortic microsomes (Gryglewski, 
Bunting, Moncada, Flower and Vane; 1976), Bunting, Gryglewski, 
Moncada and Vane (1976) were able to show that rabbit arterial 
rings washed with a solution containing 1 ~g/ml indomethacin, 
did not generate PGI 2 either spontaneously or when incubated 
with arachidonic acid. Indomethacin would thus be expected to 
affect the inhibitory activity of the incubate used in the 
present studies. 
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An experiment was conducted in which a rat abdominal aorta, 
prepared as usual, was cut longitudinally into two 
approximately equal strips. Each was incubated for 20 minutes 
in 700 pl tris buffer, one buffer containing indomethacin in a 
concentration of 5 pg/ml. 20 pl samples of each were tested at 
intervals for their anti-aggregatory activity. 
Figure 15 shows the inhibitory abi 1 ity of both incubates after 
correction for tissue weight. With advancing time, while the 
inhibitory activity of the control incubate increased, that of 
the i ndomethac i n incubate decreased. As both these curves are 
a function of production and decay of inhibitory activity, the 
findings indicate that indomethacin had the ability to block 
product i on of the i nh i b itory act i v i ty, add i ng further ev i dence 
to the view that this activity was due to a prostaglandin. 
3.3.6.6. Effect of Tranylcypromine on the Inhibitory Activity of the 
Aortic Incubate. 
Grygl ewsk i , Bunting, Moncada, Flower and Vane (1976) 
preincubated aortic microsomes with various drugs for 3 minutes 
prior to the addition of PGG 2 or H2, to investigate the 
ability of these agents to inhibit the conversion of 
endoperoxides to PGI 2 . They found that tranylcypromine, but 
no other mono-ami ne-ox i dase i nh i b i tor, reduced convers i on by 
50°/. at a concentration of 160 pg/ml and prevented it 
totally at 500 pg/ml. 
To invest i gate the effect of tranyl cypromi ne in the present 
studies the following experiments were conducted:-
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In one experiment, a rat abdominal aorta was cut long itudina lly 
into two approximately equal strips. Each strip was incubated 
in 700 )J 1 of tri s buffer (pH 7,5), one buffer conta i n i ng 
tranylcypromine at a concentration of 160 )Jg/ml. During a 
16 minute incubation period, 20 )Jl 
i nterva 1 s from each incubate and 
samples were removed at 
assessed as usual for 
anti-aggregatory activity. Figure 16a illustrates the reduced 
ability of the incubate containing tranylcypromine, to inhibit 
plate 1 et aggregat i on as compared to the contro 1 (act i v i ties 
corrected to the same weight of vesse l). The experiment was 
repeated, thi s time us i ng a tranyl cypromi ne concentrat ion of 
500 )Jg/ml. The higher concentration had . an even greater 
inhibitory effect on the production of anti-aggregatory 
activity (Figure 16b - once again after being corrected for 
weight). 
Due to the difference in experimental design, a quantitative 
comparison of these results with those of Gryglewski, Bunting, 
Moncada, Flower and Vane (1976) was obviously not possible. 
However, the same qualitative effect of tranylcypromine, a 
specific inhibitor of prostacyclin synthetase, is a further 
indicator to the identity of the inhibitory activity of the 
aortic incubate. 
The Hypotensive Action of the Incubate. 
Pace-Asciak, 
prostacyclin 
Carrara and Nicolaou (1978) have shown that 
has a potent ability to lower arterial blood 
pressure and is of equal potency via the carotid artery or the 
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jugular vein, indicating a lack of pulmonary inactivation. 
The aortic incubate used in the present studies was tested for 
its hypotensive activity as follows:-
A hypertensive rat was anaesthetised with intraperitoneal 
pentobarbital 60 mg/kg. (Sagatal, May and Baker). 30-50 units 
of heparin (Pularin, Glaxo Allenbury) were administered 1.V. 
The throat was opened and a tracheostomy performed. A fi ne 
plastic cannula was introduced into the left carotid artery and 
the blood pressure was measured continuously by a Stratham 
strain-gauge tranducer and traced on a Unicorder U400 pen 
recorder. Another cannula was introduced into the right 
jugular vein for the purpose of administration of substances to 
be tested. 
When steady pressure was recorded, 0,1 ml of normal sal ine 
mixed with 0,1 ml of tris buffer (pH 7,5) was injected slowly 
into the jugular cannula. This procedure acted as a control 
for the second injection of 0,1 ml saline mixed with 0,1 ml of 
a 15 minute incubate prepared as usual in the same tris 
buffer. When pressure had returned to normal, the procedure 
was repeated with injections being administered in random 
order. Figure 17 shows the effect on the blood pressure of 
these injections. It is evident that even after passage 
through the lungs, the incubate has hypotensive activity. 
Comparative Assays of Prostacyclin and 6-ke to-PGF la in the 
Aortic Incubate. 
When reagents 
radio-immuno-assay 
became 
(R1A) 
commercially available for the 
of 6-keto-PGF la , the hydrolysis 
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product of prostacyclin (Chapter 2.4.), the aortic incubate was 
assayed in para 11 e 1 by th i s method and by the usual method in 
six experiments. 
Each abdominal aorta, prepared as usual, was incubated in 700~1 
tris buffer at room temperature. At each of the sampling times 
2, 8, 14, 20 and 38 minutes, two samples were withdrawn. One 
was assayed immediately for prostacyclin (by the usual method) 
and the other was reserved for R1A. Samples for R1A were 
allowed to stand on the bench for approximately 2 hours prior 
to assay. The study reported in Chapter 3.3.6.3 showed most of 
the anti-aggregatory activity of prostacyclin and of the aortic 
incubate to have disappeared with i n 2 hours at room 
temperature. This was considered as an indication of almost 
total conversion of any prostacyclin present, to 
6-keto-PGF lo.· (While their studies involved the use of 
arachidonate as aggregant, Pace Asciak and Nashat (1977) have 
shown that 6-ketoPGF lo. has only weak anti-aggregatory 
activity). 
Reagents for R1A were supplied by New England Nuclear, Boston, 
USA (kit number NEK - 008) and the assay was carried out 
according to the instruction manual. The antibody was stated 
to show cross reactivity of less than 3010 with PGs E2, 
F2o.' A2, Al and TxB2· 
The cross reactivity of the antibody with other substances of 
particular interest in this study was also checked. This was 
100/0 for PGE l and was insignificant for PGD2 and ADP-ase. 
Figure 18 shows the trend of prostacyclin and 6-keto-PGF lo. 
(measured as ng/mg wet weight of aorta) present at the various 
sampling times. 
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The increase in the 6-keto-PGF 1a as prostacyc1in increased 
over the first 20 minutes would be expected, as prostacyc1 in 
undergoes hydrolysis in aqueous solutions to 6-keto-PGF 1a 
(Chapter 2.4.). 
At the 2 minute samp1 ing time, amounts of 6-keto-PGF1a were 
already greater than prostacyc1in, probably due to 6-keto-
PGF1a present initially in the vessel, plus prostacyc1in 
converted to 6-keto-PGF 1a in the first two minutes. 
As expected the two curves are not para 11 e 1. The lower curve 
(prostacyc1in) is a function of production and rapid breakdown, 
whereas the upper curve (6-keto-PGF 1a ) is steeper as it is a 
function of production only (6-keto-PGF 1a being more stable). 
The curves therefore diverge further with time. By 38 minutes, 
values of prostacyc1in in the incubate have dropped, as the 
rate of breakdown has exceeded the rate of production. This is 
reflected in the plateau value of 6-keto-PGF1a at 38 
minutes. At this point, as there is little further 
prostacyc 1 in to convert to 6-keto-PGF 1 a' 1 eve 1 s of the 1 atter 
have become fairly constant. 
Features of the curves are thus consistent with the idea that 
prostacyc1in was present in the aortic incubate. 
Conclusion. 
None of the tests conducted in Sections 3.6.1 to 3.6.8 provide 
absolute proof that the sole anti-aggregatory substance in the 
aortic incubate is prostacyc1in. However, together they all 
provide circumstantial evidence that expression of 
anti-aggregatory activity in terms of absolute values of 
prostacyc1in is acceptable. 
CHAPTER 4 
AORTIC RELEASE OF PROSTACYCLIN 
IN GENETICALLY HYPERTENSIVE RATS 
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4.1. INTRODUCTION. 
There may be some hereditary predisposition to the development 
of hypertension in man, as reflected by its varying incidence 
in different races and high family i ncidence (Grollman, 1980). 
In the rat, genetically determined hypertension is well 
documented and by selective breeding, strains of hypertensive 
rats can be developed. The spontaneously hypertensive rat 
provides a convenient model for human essential hypertension 
(Grollman, 1972) with similar clinical course and pathological 
findings. This model was therefore chosen for the 
investigation of aortic prostacyclin production in animals with 
elevated blood pressure. 
4.2. MATERIALS AND METHODS. 
The systemic arterial blood pressures of eight, nine month old, 
Wi star rats of the New Zealand genetically hypertensive strain 
(GH) and eight, age and sex matched normotensive Wi star control 
rats (N), were measured on three successive occas ions at two 
day intervals, by the method described in Chapter 3.2. The 
last measurement (which followed an overnight fast) was 
recorded immediately prior to assay of prostacyclin production 
by aortas of pairs of rats (one GH and one N) - see Chapter 
3.3. 
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4.3. RESULTS. 
The results of the eight experiments in this study can be found 
in Appendix I. They are summarised in Tables 1 and 2. 
The weight variation between the two groups (Table 1) was 
considered acceptable in view of the fact that animals were 
strictly age matched (Pace-Asciak, 1979 and Panganamala, 
Hanumaiah and Merola, 1981 have shown that there is a clear, 
direct relationship between aortic prostacyclin production and 
rat age). Of the three blood pressure measurements, only the 
last, immediately prior to the assay of aortic prostacyclin, is 
recorded (Table 1). The first two, while similar to the third, 
were performed mainly to familiarise the animals with the 
procedure. 
Whi le for both Nand GH rats more prostacycl in was detected 
with increasing incubation time (Table 2), at all three 
sampl ing times aortas of GH rats released more prostacycl in 
than those of their matched normotensive controls. This 
response was fairly consistent and when analysed by the 
Wi lcoxon matched-pairs signed-ranks test, reached a level of 
significance of p < 0,05 at the 2 minute sampling time and 
p < 0,02 at the 8 and 14 minute sampling time. 
4.4. CONCLUSION. 
Contrary to expectat i on, the aortas of GH rats were shown to 
consistently release greater amounts of prostacyclin than those 
of matched normotensive controls. 
MEAN DIFFERENCE WITHIN PAIRS 
N GH MINIMUM MAXIMUM 
WEIGHT (g) 350 304 22 60 
BLOOD PRESSURE (mmHg) 121 199 55 100 
TABLE 1 WEIGHTS AND BLOOD PRESSURES OF NORMOTENSIVE (N) 
AND GENETICALLY HYPERTENSIVE (GH) RATS RECORDED 
IMMEDIATELY BEFORE ASSAY OF AORTIC PROSTACYCLIN. 
ng PGI2 PRODUCTION/mg WET WT. AORTA 
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INCUBATION MEAN MEAN DIFFERENCE WITHIN PAIRS 
TIME 
(m; n) 
2* 
8** 
14** 
TABLE 2 
(NUMBER OF PAIRS IN BRACKETS) 
N GH N > GH GH > N 
1,66 2,31 0,30(2) 0,97(6) 
3,17 3,94 0,20(1 ) 0,91(7) 
3,80 4,37 0,03(1) 0,66(7) 
PROSTACYCLIN PRODUCTION BY AORTAS OF NORMOTENSIVE(N) 
AND GENETICALLY HYPERTENSIVE (GH) RATS. 
COMPARING N TO GH *p < 0,05 **p < 0,02 
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These results are Qualitatively consistent with the findings of 
other authors who have studied spontaneously hypertensive rats: 
Pace-Asciak, Carrara, Rangaraj and Nicolaou (1978) have 
reported that intact rings and homogenates of aorta from 
spontaneously hypertensive rats of the Wistar, Aoki-Okamoto 
strain contained enhanced capacity over normal rats to convert 
arachidonic acid into prostacyc1in and Okuma, Vamori, Ohta and 
Uc hino (1979) have shown that prior to stroke, elevated amounts 
of 'prostacyc1in-1ike' substance were produced by spontaneously 
hypertensive rats (stroke-prone and stroke-resistant) of the 
Wi star-Kyoto colony. 
CHAPTER 5 
AORTIC RELEASE OF PROSTACYCLIN 
IN EXPERIMENTAL RENAL HYPERTENSION 
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5.1. INTRODUCTION. 
The relationship between elevated pressure and aortic release 
of prostacyc 1 in was further invest i gated us i ng a second rat 
mode 1. 
In 1939, Page reported that application of cellophane or 
surgical silk to one kidney, produces hypertension which can be 
intensified and usually stabil ised by extension of the 
procedure to, or removal of, the contralateral kidney. The 
perinephritis caused by the cellophane, results in the 
formation of a fibrocollagenous shell which constricts the 
renal parenchyma. Whether it is compression of the kidney or 
of the pedicle which is important in the production of this 
hypertension is disputed. However as far as is known, it 
behaves in all ways like that due to renal artery constriction 
(Pickering, 1968) which, in turn, is like that found in man 
with respect to a number of features (Pickering, 1974). 
5.2. MATERIALS AND METHODS. 
The systemi c arteri a 1 pressures of a group of rna 1 e, wean 1 i ng 
Wistar rats (University of Natal inbred strain), approximately 
150g in weight, were recorded. The animals were then 
anaesthetised with intraperitoneal pentobarbital 6mg/100g. 
Working aseptically, a left uninephrectomy was performed in 
every animal through a midline abdominal incision. The right 
kidney was mobilised in all animals. While half the animals 
acted as sham controls (N), in the other half (ERH) (randomly 
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selected) the right kidneys were wrapped carefully with sterile 
braided silk suture (Mersilk, Ethnor) and were then returned to 
the abdomi na 1 cav i ties. Wounds were closed wi th interrupted 
sutures. 
Ten weeks elapsed before blood pressures of these animals were 
re-recorded and aortic prostacyclin production was measured. 
5.3. RESULTS. 
The full results for the five experiments in this study can be 
found in Appendix II. Once again, in view of careful age 
matching, weight variations were considered acceptable (Table 
3) • 
Baseline pressures of the whole group, at the time of entry 
into the study, were mean 89 (minimum 84, maximum 96)mm Hg., 
i.e. all normal. As shown in Table 3, binding the kidney and 
removal of the contralateral kidney, produced experimental 
renal hypertension (ERH) in those animals on which the 
procedure was performed. Pressures of the sham group, in which 
uninephrectomies only had been performed although increasing 
with age, remained within normotensive range. 
Aortic prostacyclin production by ERH and N rats is summarised 
in Table 4. At all sampling times, aortas of rats with 
experimentally elevated pressure released more prostacyclin 
than those of their matched controls. Five pairs of data 
cannot be analysed statistically by the Wilcoxon matched-pairs 
signed-ranks test, groups of this size being too small to reach 
a 50,0 level of significance. However, the fact that ERH 
aortas consistently produced more prostacylin than N aortas 
MEAN DIFFERENCE WITHIN PAIRS 
N ERH MINIMUM MAXIMUM 
WEIGHT (9) 287 229 43 77 
B.P.10 WEEKS POST-OP 110 144 10 50 
TABLE 3 WEIGHTS AND BLOOD PRESSURES (B.P.) mmHg OF RATS WITH 
EXPERIMENTAL RENAL HYPERTENSION (ERH) AND THEIR 
MATCHED NORMOTENSIVE CONTROLS (N) IMMEDIATELY 
PRIOR TO ASSAY OF AORTIC PROSTACYCLIN . 
ng PGI2 PRODUCTION/mg WET WT. AORTA 
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INCUBATION MEAN MEAN DIFFERENCE WITHIN PAIRS 
TIME 
(mi n) 
2 
8 
18 
TABLE 4 
(NUMBER OF PAIRS IN BRACKETS) 
N ERH N > ERH 
3,04 4,90 0,03(1) 
5,90 7,56 (0) 
6,19 8,05 (0) 
PROSTACYCLIN PRODUCTION BY AORTAS OF RATS WITH 
EXPERIMENTAL RENAL HYPERTENSION (ERH) AND 
THEIR MATCHED CONTROLS (N). 
ERH > N 
2,34(4) 
1,66(5) 
1, 86(5) 
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in all five experiments, would indicate that the results for 
this small sample are likely to be representative of the true 
situation. 
5.4. CONCLUSION. 
Aortas of rats with experimental renal hypertension, were shown 
to produce more prostacyclin than those of their matched 
controls. This finding, together with that for genetic 
hypertension (Chapter 4) and with the fact that similar results 
have been reported for rats with DOCA-saline hypertension 
(Friedman, Webster, Hensby and Lewis, 1980), indicates that a 
variety of forms of hypertension in rats are associated with 
elevated aortic prostacyclin production. This is in complete 
contrast to the original hypothesis of Moncada, Gryglewski, 
Bunting and Vane (1976a) viz. that the vasodilator and 
ant i-aggregant prostacyc 1 in may be 1 ack ing in certa informs of 
hypertension. 
CHAPTER 6 
EFFECT OF PRESSURE REDUCTION WITH HYPOTENSIVE AGENTS 
ON AORTIC PROSTACYCLIN RELEASE 
IN GENETICALLY HYPERTENSIVE RATS 
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6.1. INTRODUCTION. 
To further elucidate the relationship between elevated arterial 
pressure and elevated aortic production of prostacycl in, the 
effect of pressure reduction (with hypotensive agents) on the 
ability of the aortas of spontaneously hypertensive rats to 
produce prostacyclin, was investigated. 
Freis (1972) has reported that a combination of reserpine, 
hydra 1 az i ne and ch 1 orothi azi de added to dri nk i ng water, 
effectively lowers the blood pressure of spontaneously 
hypertensive rats without apparent toxicity to the animals. In 
this study, the regimen was altered by substitution of suitable 
amounts of furosemide for the chlorothiazide. 
6.2. MATERIALS AND METHODS. 
Eighteen, two month old, male, Wistar rats of the New Zealand 
genetically hypertensive strain were divided randomly into two 
groups. The systemic arteri al pressures of consc ious animal s 
were recorded. Both groups recei ved the same diet and 
unlimited access to drinking water. However, while the control 
group (C) drank tap water only, the treatment group (T) 
received drinking water containing a combination of reserpine 
(Serpas i 1, C i ba Gi egy) , d i hydra 1 az i ne methane su 1 phonate 
(Nepresol, Ciba Giegy) and furosemide (Lasix, Hoechst) in 
concentrations of 1,4mg, lOOmg and 40mg/l respectively. The 
injectable form of each of these agents was added to tap water 
without any precipitation. However, the mixture was prepared 
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freshly each day in an attempt to ensure maximum stabi 1 ity. 
Pressures of both groups of animals were recorded at weekly 
intervals. When the pressures of the treated group had been 
controlled below l20mmHg for one week (this required 
approximately one month of treatment), aortas of paired C and T 
animals were assayed for aortic production of prostacyclin. 
6.3. RESULTS. 
Weights and blood pressures of C and T animals are summarised 
in Table 5. While pressures were similar in the two groups on 
entry into the study, the drug regimen sucessfully lowered 
pressures of the test group to within normotensive range. 
Prostacycl in release by the aortas of the treated and control 
groups can be seen in Table 6. While at all sampling times the 
means indicate a tendency for treated aortas to produce less 
prostacyc 1 i n than their matched controls, there was no 
consistent trend in this direction in the nine experiments. 
Analysis of the data by the Wilcoxon matched-pairs signed-ranks 
test, showed the difference between T and C groups (at all 
sampling times) to be non-significant at the 50,0 level. 
(Full results in Appendix III). 
6.4. CONCLUSION. 
The hypotensive agents employed effectively lowered the 
pressures of the treated group compared to controls. However, 
despite the pressure difference between the two groups there 
MEAN DIFFERENCE WITHIN PAIRS 
T C MINIMUM 
WEIGHT (g) 218 229 
° 
B.P..BEFORE TREATMENT 168 159 3 
B.P. POST TREATMENT 105 172 48 
TABLE 5 WEIGHTS AND BLOOD PRESSURES (B.P.) mmHg OF 
GENETICALLY HYPERTENSIVE CONTROL (C) AND 
TREATED (T) RATS. 
MAXIMUM 
75 
30 
100 
ng PGI2 PRODUCTION/mg WET WT. AORTA 
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INCUBATION MEAN MEAN DIFFERENCE WITHIN PAIRS 
TIME 
(min) 
2 
8 
14 
TABLE 6 
(NUMBER OF PAIRS IN BRACKETS) 
T C T > C 
0,46 0,63 0,10(3) 
1,62 1,96 0,46(2) 
2,12 2,39 0,21(2) 
AORTIC PROSTACYCLIN PRODUCTION BY CONTROL (C) AND 
TREATED (T) GENETICALLY HYPERTENSIVE RATS 
C>T 
0,29(6) 
0,57(7) 
0,42(7) 
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was no consistent, statistically significant difference in 
aortic prostacyclin generation. 
Since completion of this study, it has become clear that at 
1 east two of the drugs admi n i stered to the treated group may 
influence prostaglandin levels, irrespective of their effect on 
arterial pressure. 
There is evidence, (reviewed by Ciabattoni, Pugliese, Cinotti, 
Stirati, Ronci, Castrucci, Pierucci and Patrono, 1979), that 
furosemide causes generalised activation of the renal 
prostagl andin system. The excretion rate of 6-keto-PGF la , 
1 ike other members of the renal prostaglandin system, increases 
during the first fifteen minutes following furosemide 
i nj ect i on. Whether there is any extra-renal effect of 
furosemide, especially after oral administration as would be 
important in this study, is unknown. However, the findings 
reported above do not augur well for this model providing 
information about the direct relationship between arterial 
pressure and prostacyclin production. 
Forster, Taube and Fahr (1980), while reporting that 
dihydralazine (4mg/kg) given intravenously to spontaneously 
hypertensive rats decreased the blood pressure by 12 - 22° 10 
and increased aortic prostacyclin synthesis by 80°/ 0, have 
not indicated what the causeleffect relationship may be between 
these three variables. Haeusler and Gerold (1979) and McGiff 
and Quilley (1980) suggest that the hypotensive effects of the 
vasodilators hydralazine and dihydralazine, may actually be 
mediated through the vasodilator prostaglandins, indomethacin 
having completely reversed within fifteen minutes, the 
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hypotension produced by either of these agents in anaesthetised 
dogs. 
It is therefore clear, that as these 
prostaglandins directly, no conclusions 
drugs 
about 
may 
the 
affect 
direct 
relationship between arterial pressure and prostacyclin release 
can be drawn from this study. Accordingly, despite the results 
obtained, the possibility cannot be excluded, that reduction of 
raised arterial pressure may have some effect on the capacity 
of the aorta to release prostacyclin. 
CHAPTER 7 
EFFECT OF MECHANICAL PRESSURE REDUCTION 
ON AORTIC PROSTACYCLIN RELEASE 
IN GENETICALLY HYPERTENSIVE RATS 
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7.1. INTRODUCTION. 
The unsatisfactory nature of the previous study, stimulated 
consideration of further models of pressure reduction. 
One possibility which was pursued, was that of saline 
hypertension which could be reversed on reduction of the salt 
intake. However, the animals used for this study (University 
of Natal inbred strain) were not salt-sensitive and did not 
develop satisfactorily elevated pressure. In retrospect, it 
was felt that even this model would have involved sodium 
chloride as a further variable besides the two being 
investigated, namely, pressure and prostacyclin. Accordingly, 
a mechanical method of pressure reduction was eventually 
selected. 
Goldblatt and Kahn (1938) have reported that constriction of 
the aorta of dogs immediately above the renal arteries, 
produced hypertension above and immediate hypotension below the 
clamp. Pressure reduction in abdominal aortas of genetically 
hypertensive rats, was achieved by the use of this method. 
7.2. MATERIALS AND METHODS. 
The systemic arterial pressures 
fourteen week old, male, Wi star 
of sixteen, approximately 
rats of the New Zealand 
genetically hypertensive strain were recorded. Pairs of rats 
were then anaesthetised with intraperitoneal pentobarbital 
(6mg/lOOg ) . Working aseptically, the aorta, just below the 
diaphragm, was mobilised in both animals through a mid-line 
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abdominal incision. It was then constricted above the hepatic 
artery and as near to the diaphragm as possible, by a silver 
clip (Scoville Lewis IN 1300 IW). In one animal, which acted 
as a sham control (S), the clip was immediately removed. In 
the other (C) it was left in position thus producing 
hypotension distally. Wounds were closed with interrupted 
sutures. Eighteen hours after the operation, distal aortic 
pressures were measured by the tail cuff method in both 
conscious animals which had been fasted overnight. After their 
weights had been recorded the two animals were sacrificed and 
their aortic prostacyclin production measured. 
7.3. RESULT. 
In both groups post-operative tail pressures were reduced 
compared to pre-operative values, possibly due to a residual 
effect of the barbiturate anaesthetic or constriction of the 
aortas due to handling. However, comparing C to S, while 
pressures were very simi 1 ar pre-operat i ve ly, post-operat i ve ly 
those of the C group were much lower than S controls due to the 
application of the clip (Table 7). 
The aortas from the group in which pressures had been reduced 
mechanically, generated less prostacycl in than those of their 
matched controls. This tendency was consistent at the 8 and 
14 minute sampling times and when anal ysed by the Wilcoxon 
matched-pairs signed-ranks test, reached a level of significance 
of p < 0,02 (Table 8). Full results for the eight experiment s 
appear in Appendix IV. 
MEAN DIFFERENCE WITHIN PAIRS 
C S MINIMUM MAXIMUM 
WEIGHT (g) 291 295 0 50 
PRE OP B.P. (mmHg) 178 180 0 12 
POST OP B.P. (mmHg) 95 160 34 93 
TABLE 7 WEIGHTS AND BLOOD PRESSURES (B.P.) mmHg OF 
CLIPPED (C) AND SHAM (S) RATS. 
ng PGI2 PRODUCTION/mg WET WT. AORTA 
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INCUBATION MEAN MEAN DIFFERENCE WITHIN PAIRS 
TIME (NUMBER OF PAIRS IN BRACKETS) 
(mi n) 
C S C > S S ~ C 
2 1,50 1,57 0,26(4) 0,41(4) 
8* 3,14 3,75 0,14(1) 0,72(7) 
14** 3,54 4,04 (0) 0,50(8) 
TABLE 8 AORTIC PROSTACYCLIN PRODUCTION BY CLIPPED (C) AND 
SHAM (S) RATS. COMPARING C TO S *p < 0,02 **p < 0,01. 
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7.4. CONCLUSION. 
Blood flow, pressure and pulse pressure were consistently 
reduced in C abdominal aortas, as was the subsequent ex vivo 
capacity of aortas to produce prostacyclin. These results 
indicate that local pressure/pulse pressure and the subsequent 
ability of the vessel to generate prostacyclin may be related. 
CHAPTER 8 
RESPONSE OF GENETICALLY HYPERTENSIVE RAT PLATELETS 
TO PROSTACYCLIN AND ADP 
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8.1. INTRODUCTION. 
In an attempt to discover more about the possible signif icance 
of raised aortic generation of prostacyclin in hypertension, 
the sensitivity of platelets of spontaneously hypertensive rats 
to prostacyclin was investigated. 
It would appear obvious that in any pathological condition, 
haemostat i c ba 1 ance must be i nfl uenced not on ly by vascul ar 
prostacyclin production, but also by platelet sensitivity to 
prostacyc 1 in (Burghuber, S i nz i nger, S i 1 berbauer, Wo 1 f and 
Haber, 1981). For example, in diabetes both decreased vascular 
prostacycl i n generation (see Chapter 2.8.2.) and decreased 
sensitivity of platelets to prostacyclin (K lein, Sinzinger, 
Kaliman and Schernthaner, 1980) have been reported. 
When atherosclerosis is induced in rabbits, decreased 
prostacyclin generation occurs together with increased 
sensitivity of platelets to prostacyclin (Chapter 2.8.1). 
Since the sensitivity of human platelets to prostacyclin, has 
been shown to be decreased during long term intra- arterial 
infus ion of the substance in peripheral vascular disease 
(Sinzinger, Silberbauer, Horsch and Gall, 1981), the 
possibility existed that increased aortic generation of 
prostacyc l in in hypertension, might be associated with reduced 
platelet sensitivity to prostacyclin. A comparison of the 
effect of prostacyclin on the in vitro, ADP-induced aggregation 
of platelets, of male Wi star rats of the New Zealand 
genetically hypertensive stra i n (GH) and those of matched 
normotensive Wistar control rats (N) , was used to test this 
hypothesis. 
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8.2. MATERIALS AND METHODS. 
Systemic arterial blood pressures were measured in twenty one, 
three month old, male animals from each group (GH and N). 
In each of seven experiments three animals from each group were 
fasted overnight, weighed and anaesthetised with 
intraperitoneal pentobarbital (6mg/100g). Through a midline 
incision, a plastic cannula was placed in the abdominal aorta 
and blood was co11ected into disposal plastic syringes 
containing heparin (IOU/ml of blood). (Heparin was chosen as 
anti-aggregant because heparinised rat platelet rich plasma is 
much more sensitive to aggregating agents than citrated 
platelet rich plasma (Hwang, 1980).) 
Platelet rich plasma (prp) was prepared by centrifugation of 
blood at 160g for 18 minutes. Further centrifugation of 
remaining blood at 2000g (at 4°C) for 15 minutes, yielded 
platelet poor plasma (ppp). For the aggregation test, prp 
obtained from the three rats in each group was pooled. Ppp for 
each group was obtained by pool ing ppp from the appropriate 
animals. Details of handling and storage of prp and ppp were 
as described in Chapter 3.3.1. Platelet counts were performed 
as described in Chapter 3.3.2. except that prp was diluted 1 in 
40 rather than 1 in 20 with trisodium citrate, to facilitate 
counting of the large number of platelets. 
Aggregat i on of poo 1 ed prp from the three rats in each group, 
was carried out in a dual channel aggro-meter as previously 
described (Chapter 3.3.3.2.). ADP (final concentration l\lM) 
was added to prp, one minute after the addition of tris buffer 
PPP-
y 
t 
TRIS ADP 
or 
TRIS + PGI2 
% AGGREGATION =..!.. x 100 y 
FIG.19: DIAGRAM OF RECORDER TRACING SHOWING AGGREGATION 
OF RAT PRP. 
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or an equal volume of the same buffer containing various 
concentrations of prostacyclin sodium salt (Chapter 3.3 . 5.1). 
Maximum aggregation was measured as a percentage of the 
distance between prp and ppp as shown in Figure 19. 
8.3. RESULTS. 
Weights? blood pressures and platelet counts, which can be seen 
in full in Appendix V, are summarised in Table 9. Platelet 
counts in prp differed by no more than 40,0 in the two groups. 
As illustrated in Figure 20 (full results in Appendix V), the 
response of the platelets to ADP did not differ significantly 
between the two groups, whether ADP followed tris buffer alone 
or buffer conta i n i ng vari ous concentrat ions of prostacyc 1 in. 
(The slightly greater aggregation for GH platelets may have 
been due to the slightly higher platelet count.) 
WEIGHT (g) 
B.P. (mmHg) 
PLATELET COUNT 
x 103 
TABLE 9 
N GH 
MEAN MIN MAX MEAN MIN MAX 
263 220 300 261 230 320 
115 80 125 173 158 190 
1469 996 2134 1532 1156 2226 
WEIGHTS, BLOOD PRESSURES AND PLATELET COUNTS OF 
GENETICALLY HYPERTENSIVE (GH) AND NORMAL (N) RATS. 
75 GH 
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8.4. CONCLUSION. 
Contrary to expectat i on the resu lts i nd icate that plate 1 ets 
from both GH and N rats are equally sensitive, in vitro, to the 
aggregatory action of ADP and the anti-aggregatory effect of 
prostacycl in. 
CHAPTER 9 
DISCUSSION 
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9.1. ELEVATED AORTIC GENERATION OF PROSTACYCLIN IN HYPERTENSION 
This study was originally initiated by an interest in the 
properties of prostacyclin, in relation to the features of 
hypertension. The possibility existed that a lack of this 
vasodilatory, anti-aggregatory prostaglandin might be an 
aetio logical factor in certain forms of hypertension. 
The findings resulting from testing this hypothesi s were 
comp 1 ete ly contrary to expectat i on. In both genet ica lly 
hypertens i ve rats (Chapter 4) and in rats with experimental 
renal hypertension (Chapter 5), the abil ity of the abdominal 
aorta to generate prostacycl in, was found to be consistently 
greater than that of matched controls. 
While these studies were in progress various other authors 
published their investigations on this subject. Though it is 
difficult to make quantitative comparisons between results 
obtained, due to the use of different strains of animals, forms 
of hypertension and methodology, many findings are 
qualitatively cons i stent with those reported in the present 
studies. 
Pace-Asciak, Carrara, Rangaraj and Nicoloau (1978) reported 
that intact rings and homogenates of spontaneously hypertensive 
rats (SHR) of the Wistar, Aoki-Okamoto strain, possessed 
enhanced capacity to convert arachidonic acid to PGI 2. In 
fact, prostacyclin was the major prostaglandin formed by SHR, 
arachidonic acid metabolism being uniquely directed along this 
pathway (Pace-Asciak, Carrara and Nicoloau, 
Pace-Asciak, Carrara, Rangaraj and Nicoloau, 1978). 
1978 and 
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Pace-Asciak and Carrara (1980) were further able to show, that 
a positive correlation exists between rise in blood pressure 
and aortic synthesis of PGI 2 and that the unique specificity 
to PGI 2 production appears to be acquired with age. In 
another study involving SHR, this time from the Wi star Kyoto 
colony, Okuma, Yamori, Ohta and Uchino (1979) showed that 
aortas of both stroke-prone and stroke-resistant animals, 
generate elevated amounts of 'prostacyclin-like' substance. 
Detre, Leithner, Winter, Sinzinger, Silberbauer, Fr6dy and 
Je 11 i nek (1980), who induced mali gnant rena 1 hypertens i on by 
aortic ligature between the origins of the renal arteries 
(Rojo-Ortega method), noted elevated PGI 2 formation by the 
aortic wall both above and below the 1 igature in the first 
phase of hypertension. Elevated PGI 2 has also been reported 
in other forms of hypertension in experimental animals: 
Treatment of rats for 10 oestral cycles with an 
oestrogen-progestogen combination was found by Roncaglioni, di 
Minno, Pangrazzi, Reyers, Mussoni, de Gaetano and Donati (1980) 
to trigger a vascular response, characterised by increased 
prostacyclin activity in arterial walls and increased systolic 
blood pressure. Increased aortic PGI 2 activity has been 
shown by a number of authors to occur in DOCA-saline or saline 
induced hypertension (Friedman, Webster, Hensby and Lewis, 
1980, Yoshimura, Kaimasu, Kitani, Kawamura, Takeda, Sasaki, 
Kajita, Nakagawa and Ijichi, 1980 and Limas, Goldman, Limas and 
Iwai, 1981). 
Despite these reports in support of the findings presented in 
this thesis there are a few interesting conflicting results 
which should be mentioned: 
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Firstly, there are two groups of workers who have actually 
reported results which contrast completely with those reported 
above. Markov (1978) found that biosynthesis of prostacyc1in 
from arachidonic acid was decreased in aortic homogenates of 
SHR, and Inoue, Hayashi, Hara, Watanabe, Enomoto and Nomura 
(1979) reported that i ndomethac i n pretreated aort i c ri ngs from 
Wistar Kyoto rats produced more PGI 2-1ike substance than 
SHR. 
Secondly, there are two groups of workers, who although 
reporting elevated aortic prostacyc1in production early in 
hypertension, found, unlike Pace-Asciak and Carrara (1980) who 
studied SHR, that these elevations were not . sustained 
indef initely, despite continued elevation of blood pressure. 
This phenomenon was noted by Detre, Leithner, Winter, 
Sinzinger, Si1berbauer, Fody and Jellinek (1980) in that, by 
the th irty-fifth day of Rojo-Ortega hypertension, vessel wall 
PGI 2 content had returned to normal or even subnormal 
values. Similar to this was the finding of Yoshimura, Kaimasu, 
Kitani, Kawamura, Takeda, Sasaki, Kajita, Nakagawa and Ijichi 
(1980) that, after eight weeks of salt loading, though pressure 
was significantly raised, elevated prostacyc1in activity was 
not susta i ned and 1 eve 1 s actua lly fe 11 to appprox imate 1y 80 
percent of normal. Als o interesting is the finding of these 
authors that two weeks of salt depletion, which had no effect 
on blood pressure, resulted in significantly elevated PGI 2 
activity. These results would indicate that salt has an effect 
on prostacyc1in generation irrespective of blood pressure, 
possibly mediated by the renin-angiotensin-a1dosterone system. 
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Friedman, Webster, Hensby and Lewis (1980) support this view in 
reporting that in man, salt loading, which lowers renin levels, 
decreases prostacyclin. In the long term Rojo-Ortega model of 
hypertens i on some factor other than pressure, such as ren i n 
levels, may also influence prostacyclin. 
Skidgel and Printz (1980) have shown that the elevated 
prostacyclin producing capacity in SHR arteries, is related to 
enhanced cyclo-oxygenase activi ty and not prostacyc 1 in 
synthetase activity, which is essentially the same as that for 
normal controls. Though these findings do not seem quite 
cons i stent with the report of Pace-Asc iak, Carrara, Rangaraj 
and Nicoloau (1978), that in adult SHR arachidonate metabolism 
is uniquely directed towards one prostaglandin, namely 
6-keto-PGF la , they are in accord with the findings of the 
same authors, that SHR aortas have increased capacity to 
convert arachidonic acid to prostacyclin. They also correlate 
with the findings of authors who have studied production of 
'PG-like' material (rather than prostacyclin specifically) by 
aortic strips of hypertensive rats. Rioux, Quirion and Regoli 
(1977) have reported elevated release of 'PG-like' material 
(analysis of which suggested the presence of PGE2 and El ) 
from aortic strips of SHR, renal hypertensive and DOCA-salt 
hypertensive rats. If cyc 1 o-oxygenase is the important 
variable, then perhaps the methodology of Inoue, Hayashi, Hara, 
Watanabe, Enomoto and Nomura (1979), namely pretreatment with 
indomethacin, may, by inhibition of cyclo-oxygenase, have 
obscured the difference in PGI 2 generation reported by other 
workers for SHR. 
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9.2. STIMULUS TO ELEVATED AORTIC PROSTACYCLIN GENERATION 
It is interesting to note that Rioux, Quirion and Regoli (1977) 
found that production of 'PG-like' material by aortic strips of 
renal and DOCA-salt hypertensive rats, was largely reduced when 
hypertension was interrupted, indicating an association between 
the elevated product i on of 'PG-l ike' materi a 1 and the elevated 
pressure. Limas, Goldman, Limas and Iwai (1981) have 
suggested that the enhanced PGI 2 synthesis, which they found 
in salt loaded, salt sensitive Dahl rats, may be secondary to 
the hypertension and Friedman, Webster, Hensby and Lewis (1980) 
in their similar study, were also of this opinion in view of 
the fact that salt loading, per se, may be expected to decrease 
prostacyc 1 in. 
Various suggestions have been put forward as to the possible 
stimulus to elevated prostacyclin production in hypertension. 
Since they were able to show that norepinephrine stimulated 
6-keto-PGF la formation from arachidonic acid by aortic 
homogenates of both SHR and control rats (probably at the 
cyclo-oxygenase level), Pace-Asciak, Carrara, Rangaraj and 
Nicoloau (1978) have suggested that the enhancement of 
biosynthetic capacity in hypertensive aortas, might represent 
an adaptive response to elevated plasma catecholamine levels 
during hypertension. Proliferation of aortic endothelial cells 
is another proposed explanation (Friedman, Webster, Hensby and 
Lewis, 1980). There is also the possibility, that increased 
mechanical stimulation of the aorta resulting from the pressure 
elevation, may be related to the increased PGI 2 release. 
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The release of many prostaglandins is altered by mechanical 
stress of the secreting cells - to quote Vane: "Now, we know 
that whenever you stretch a tissue or touch it, or cause even 
the sl ightest disturbance, there is an exaggerated PG release" 
(Aiken, Gorman and Shebuski, 1979). There is evidence that 
this may also be the case for prostacyclin release by vascular 
tissue: ten Hoor, de Deckere, Haddeman, Hornsta and 
Vendelmans-Starrenburg (1978) have reported that production of 
PGI Z by pieces of rat aorta, increases after damaging the 
endothelium with sand paper, and Hamilton, Rosza, Hutton, Chow, 
Dandona and Hobbs (1981) have shown that direct trauma of the 
hepatic vein caused a small increase in the PGI 2 activity of 
the vesse 1 measured one week 1 ater. It has also been noted 
(Gryglewski, 1979), that increased ventilation of the lung 
increases prostacyclin release and that in isolated, perfused 
rabbit aorta pulsations stimulate PGI 2 release into the 
perfusate (Voss, Haddeman, Don, and ten Hoor, 1980). 
In hypertension, due to elevated pressure, there is an 
increased mechanical force acting upon the vessel wall. In 
addition, the pulse pressure is often elevated such that there 
is increased excursion of the arterial diameter with associated 
extra transmural stress. It is possible that PGI 2 production 
is stimulated as a direct consequence of these increased 
mechanical stresses on the vessel wall. 
To investigate this possibility, pressures and pulse pressures 
were reduced mechanically in abdominal aortas of genetically 
hypertens i ve rats (Chapter 7). In this model, blood flow 
through the abdominal aorta and thus pressure and pulse 
pressure, are diminished immed iately the clip is applied. After 
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eighteen hours exposure to this reduced pressure and pulse 
pressure, these aortas released consistently less PGI 2 than 
did matched controls which had been subjected to identical 
surgical manipulation. These results indicate, that the 
reduction in mechanical stress, may have removed a stimulus to 
prostacyc 1 in product i on and that there may be a di rect 
relationship between the mechanical effect of elevated pressure 
and the increased ability of the vessel to generate PGI 2. 
Of interest, in relation to this possible mechanical 
explanation, is the finding of Skidgel and Printz (1980), that 
unlike arteries, veins of SHR do not differ from those of 
normal rats in their cyclo-oxygenase activity. Clearly, veins 
of the two groups are not subject to the difference in 
transmural stress that is apparent between the arteries of the 
two groups. Similarly, Detre, Leithner, Winter, Sinzinger, 
Silberbauer, Fody and Jellinek (1980) showed, that except for 
significantly elevated levels at day one, production of PGI 2 
by inferior vena cava, was normal in renovascular hypertension 
induced by the Rojo-Ortega method for a period of thirty-five 
days, during which aortic PGI 2 was elevated. 
There is also an inherent difference in prostacyclin generating 
capacity between arteries and veins in general. Although 
Moncada, Higgs and Vane (1977) reported that more prostacyclin 
was generated by human venous than arterial tissue, two 
independent groups have reported the oppos i te for rat vesse 1 s. 
Villa, Mysliwiec and de Gaetano (1 977) found that rat aorta 
generated more 'prostacyclin-like' activity than vena cava and 
Skidgel and Printz (1978 and 1980) have shown that arteries of 
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rats have a greater capacity than veins to utilise arachidonic 
acid and PGH2 in the formation of prostacyclin. The findings 
of these two groups, if it were not for the contradictory 
results of Moncada, Higgs and Vane (1977), would make it 
tempting to speculate that the different transmural stress 
between arteri es and veins may account, at 1 east in part, for 
their difference in PGI 2 generation. 
It appears that PGI 2 production by veins may be subject to a 
pressure effect, for Hamilton, Rosza, Hutton, Chow, Dandona and 
Hobbs (1981) have shown that rat portal vein, in which portal 
hypertension has been induced by l igature one week previously, 
shows significantly elevated prostacyclin compared with control 
vesse 1 exposed to the same surg ica 1 procedure. Sk i dge 1 and 
Printz (1978) have also found that the thoracic aorta of the 
rat has a greater capacity than the abdominal portion to 
convert PGH2 to 6-keto-PGF la. The thoracic portion is 
clearly under the greater stress, as it is exposed to 
variations in thoracic pressure due to respiration and 
experiences back pressure from the closing of the right atrial 
valves. 
Thus increased direct transmural stress, appears attract i ve as 
an explanation for the elevated release in 
hypertension. However, the studies of Detre, Leithner, Winter, 
Sinzinger, Silberbauer, F6dy and Jellinek (1980) do not support 
th i s idea. These workers induced renovascu 1 ar hypertens i on by 
application of a clip between the renal arteries. Above the 
cl ip they recorded elevated pressure and elevated PGI 2 
formation, results which would be consistent with the findings 
reported in this thesis. However, they report an initial fall 
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in pressure below the clip (as recorded via the femoral 
artery), during which time PGI 2 production was elevated above 
normal values. It is possible that in this model of 
hypertension some other factor also effects prostacyclin 
release, for it is in this same study that by thirty-five days, 
despite a still elevated pressure, PGI 2 production by aorta 
both above and be 1 ow the c 1 i p had returned to norma 1 or be 1 ow 
normal. This study, together with that of Yoshimura, Kaimasu, 
Kitani, Kawamura, Takeda, Sasaki, Kajita, Nakagawa and Ijichi 
(1980), in which after eight weeks of salt loading, pressure 
was elevated but PGI 2 had returned to normal, indicates that 
other factors beyond local mechanical effect are involved in 
the in vivo regulation of vascular PGI 2 generation. 
Synthesis of PGI 2 by pig endothelial cell cultures and rat 
aortic rings, is stimulated in vitro by human plasma and there 
is evidence that plasma stimulation of PGI 2 synthesis may 
occur in vivo (Remuzzi, Misiani, Marchesi, Livio, Mecca, de 
Gaetano and Donati, 1978). These authors have suggested the 
existence of a plasma factor, which stimulates PGI 2 activity 
and which may be lacking in such disorders as haemol ytic 
uraemic syndrome (HUS). If perhaps the increased PGI 2 
release in hypertension were related to an elevation of this 
plasma factor, reduced plasma fl ow resultant on application of 
the clip (in the study in Chapter 7) could remove the stimulus 
to increased PGI 2 generation. This idea however, would not 
correlate with the fact that veins of SHR and normal rats 
(wh ich would, li ke arteries, be exposed to different amounts of 
plasma factor) do not differ in prostacyclin producing 
capac i ty. It would also not be consistent with the proposal 
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of Remuzzi, Misiani, Marchesi, Livio, Mecca, de Gaetano and 
Donati (1978) that the hypertension in HUS may be due to 
defective PGI 2 release, due to lack of the plasma factor. 
Noradrenaline (Horton, Pipili and Poyser, 1980 and Pace-Asciak, 
Carrara, Rangeraj and Nicoloau, 1978), nerve stimulation 
(Horton, Pipili and Poyser, 1980) and angiotensin II 
(Gryglewski, Korbut and Splawinski, 1979) have also been shown 
to stimulate PGI 2 production in various situations. While 
therefore, there are clearly a number of factors wh i ch may 
interact to regulate PGI 2 release, it would appear that 
fluctuations in renin levels and mechanical transmural stress 
may be particularly important. 
9.3. BIOLOGICAL SIGNIFICANCE OF THE ELEVATED VASCULAR RELEASE OF 
PROSTACYCLIN IN HYPERTENSION. 
In experiments in which increased aortic PGI 2 generation in 
experimental hypertension have been reported, results have been 
statisticallY significant. However, what is really important 
is whether or not differences obtained between test and control 
groups are of biological significance, i.e. are they 
quantitatively large enough to exert a noteable effect? 
Unfortunately this is very difficult to assess, for the 
absolute amounts of endogenous PGI 2 required to cause any 
particular response are not known. There are many experiments 
in which the effects of exogenous prostacyclin have been 
quantitated, but obviously extrapolation from these should be 
made with caution. In addition, it is not certain whether the 
amounts of PGI 2 being measured in vitro accurately reflect the 
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in vivo situation. Pace-Asciak, Carrara, Rangaraj and Nicoloau 
(1978) have shown that as 1 ittle as a 5 mm section of SHR 
aorta, can produce enough prostacyclin to cause a 30 mmHg fall 
in blood pressure and they feel that this indicates the great 
capacity for PGI 2 production in vivo. However, there are two 
points which should be considered. Firstly the aortic rings in 
these experiments were incubated with arachidonic acid - a 
false situation as the quantity of substrate may be 
rate-limiting in vivo. Quirion, Rioux and Regoli (1978) have 
shown that SHR aortic strips produce twice as much 
'prostaglandin-like' materi a 1 when pre incubated with 
arachidonic acid. Secondly, the use of aortic rings may not be 
truly representative. Certainly, preparation of the tissue is 
important, for Pace-Asciak, Carrara, Rangaraj and Nicoloau 
(1978) have reported that the products formed from arachidonate 
by aortic homogenates, are slightly different from those formed 
by rings. Further, ten Hoor, de Dec kere, Haddeman, Hornstra 
and Quadt (1980) have reported that when expressed per cm2 
surface area, PGI 2 production by pieces of aorta is about 
five times that of pulsating perfused aorta. This finding 
would indicate, that investigators may be detecting amounts 
greatly in excess of those produced in vivo. On the other 
hand, in terms of detecting quantitative differences between 
two groups, these authors note that while changes in dietary 
linoleic acid did not significantly influence PGI 2 production 
of pieces of aorta, a significant increase was detected in the 
pulsating perfused aorta model. They suggest that the moderate 
activation of the perfused aorta, by simulation of physiologica l 
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pulsati.ons, makes it p.ossible t.o detect m.ore subtle changes in 
PGI 2 pr.oducti.on than in a mare vig.or.ously stimulated system. 
This w.ould indicate that differences in PGI 2 pr.oducti.on 
between hypertensive and c.ontral vessels, may be even greater 
than m.ost w.orkers have detected. It appears that in future 
studies, a truer reflecti.on .of the in viv.o situati.on might be 
.obtained, by use .of the clearly m.ore physi.ol.ogical m.odel .of 
perfused a.orta, rather than by use .of rings .or strips. 
Any c.onclusi.on ab.out the meaning .of the elevated levels .of 
a.ortic PGI 2 pr.oductian in hypertensi.on which have been 
rep.orted t.o date, sh.ould .obvi.ously be drawn bearing in mind the 
sh.ortc.omi ngs .of the meth.od.o I .ogy and the uncertainty ab.out the 
bi.ol.ogical significance .of the differences. 
9.4. MEANING OF THE ELEVATED LEVELS OF AORTIC PROSTACYCLIN IN 
HYPERTENSION 
If the c.onsistent difference in pr.ostacyclin generati.on which 
has been rep.orted between hypertensi ve and cantr.o l vessels, is 
in fact large en.ough t.o exert bi.olagical effect, then it is 
interesting t.o speculate .on the p.ossible functi.on .of the 
elevated levels in hypertensi.on. 
There has been much interest in a p.ossible systemic r.ole f.or 
circulating pr.ostacyclin. N.ow h.owever, evidence is m.ounting 
aga i nst the c.oncept .of PG I2 functi.on i ng as a circulating 
h.orm.one, either with a vas.odepress.or functi.on, .or as a 
regulat.or .of platelet aggregability (Chapter 2.5) • It 
theref.ore appe ars likely, that synthesis and acti.on .of PGI 2 
9.4.1. 
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is most often part of a localised response to a local stimulus, 
e.g regulation of vascular tone or thrombus formation at a 
regional level. For this reason, amounts synthesised by blood 
vessels may be of particular importance. 
Since all the studies that have been done to date on 
prostacyclin in experimental hypertension, have involved 
vessels (e.g. aorta) which are not a major site of vascular 
resistance regulation, the functional implications of the 
results depend on the extent to which they reflect changes of 
PGI 2 production in resistance vessels. Skidgel and Printz 
(1980) have shown that cyclo-oxygenase activity is enhanced in 
homogenates of carotid artery of SHR as well as in aortic 
homogenates, i nd icat i ng that the phenomenon may extend to all 
arteries. However, in the future, this will have to be 
confirmed for resistance vessels. 
POSSIBLE EFFECT ON THE VASCULATURE. 
Though there is ample evidence that prostacyclin generally 
dilates vascular beds and lowers blood pressure (Chapter 
2.6.2), Levy (19BO) has cautioned against ascribing to it a 
general ised vasodilator role, in view of the heterogeneity of 
individual blood vessel responses in a variety of species. Of 
particular relevance to the present study, may be his finding 
that PGI 2 (500-5000 ng /ml) produced a concentration dependent 
increase in contractile tension of isolated thoracic aortic 
strips, from normotensive r ats and SHR. (No significant 
difference in response was noted between aortas from the two 
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groups of animals.) If large enough amounts of PGI 2 are 
generated by rat vessels and Levy's results are extrapolated to 
the in vivo situation, it would appear that for the thoracic 
aorta at least, vaso-constriction could be affected. On the 
basis of these findings, the elevated aortic generation of 
PGI 2 found in hypertension might appear to participate in the 
genesis or maintenance of hypertension. However, Kiprov and 
Somova, who noted in 1975 that the vasodepressor prostaglandins 
E and A paradoxically contracted isolated aortic smooth muscle 
strips of both normotensive rats and SHR, felt that this tissue 
could not be used as an indicator of vascular reactivity 
especially of resistance vessels, because of the paradoxical 
response. 
If endogenous PGI 2 actually exerts a vasodilator role in the 
resistance vessels of the rat, then it may be that the enhanced 
synthes i sin hypertens i on serves as an adapt ive response to 
attenuate elevations in blood pressure, or keep them in 
'control'. This hypothesis has been proposed by Pace-Asciak 
(1979). Release of PGI 2 has been shown to be increased in 
response to such stimuli as noradrenaline (Pace-Asciak, 
Carrara, Rangeraj and Nicoloau, 1978 and Horton, Pipili and 
Poyser, 1980), nerve stimulation (Horton, Pipili and Poyser, 
1980) and angiotensin II (Gryglewski, Korbut and Splawinski, 
1979 and Mullane and Moncada, 1980) and most evidence points to 
the fact that prostacyclin attenuates the vasoconstrictor 
action of the se stimuli (Rascher, Dietz, Schomig, Burkart, 
LUth, Mann and Weber, 1979, Carmignani, Marchetti and Caprino, 
1980, Fischetti, Carmignani, Marchetti, Ranelletti and Caprino, 
114 
1980, Mullane and Moncada, 1980, Okuna, Kondo, Suzuki and 
Saruta, 1980 and Yabek and Avner, 1980). This property, i.e. 
modulation of pressor responses would be consistent with the 
protective role proposed by Pace-Asciak (1979). If the 
elevated PGI 2 were protective in nature, then the effect 
could be ampl ified by the altered sensitivity of the 
vasculature to prostacycl in which has been reported in 
hypertension. Pace-Asciak, Carrara and Nicoloau (1978) have 
shown, using anaesthetised animals, that SHR are much more 
respons ive than normals to the hypotens i ve act i on of injected 
PGI 2. Similar findings have been reported by Casals-Stenzel 
and Morton (1979) for infusions of PGI 2 into conscious renal 
and DOC-salt hypertensive rats. The studies of Sch51kens 
(1978) are also consistent with these findings:- rats with 
spontaneous hypertension and chronic renal hypertension 
appeared more sens it i ve than norma 1 rats to the 
antihypertensive activity of PGI 2 . It is unclear whether 
this increased response to prostacyclin in hypertension is 
actually related to the elevated pressure. Though the fall in 
blood pressure aChieved 24 hours after the removal of the clip 
in 1 clip-2 kidney hypertension in the rat, is accompanied by a 
reduct i on of the hei ghtened hypotens ive response to PGI 2 (ten 
Berg, de Jong and Nijkamp, 1980), the increased response of SHR 
is abolished by feeding a diet containing a-linoleic acid, even 
though the pressure remains elevated (Feinberg, Trachte, 
Curt is and Lefer, 1980). 
In 1 ine with the possible protective role for elevated 
, 
prostacyclin, Pace-Asciak (1979) has suggested that stimulation 
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of PGI 2 production before deviation of vascular resistance in 
hypertension, may be useful. Certainly, Weeks and Sutter 
(1979) were able to demonstrate that continuous LV. infusion 
of prostacyclin into concious rats, inhibited the development 
of one-kidney Goldblatt renal hypertension. Although they 
found no lowering of blood pressure with a comparative dose in 
sham operated rats, the doses used did have potential depressor 
activity which was masked by compensatory mechanisms. To 
exclude the possibility that the vasodilator action of PGI 2 
may have merely provided compensation for the pressor influence 
following clipping of the renal artery, they studied sodium 
nitroprusside similarly (Sutter and Weeks, 1980) and found that 
it did not inhibit the development of .hypertension as 
prostacycl in had done. They therefore concluded that PGI 2 may 
play a specific role in preventing the onset of renal 
hypertension in the rat. 
Another interesting study, which would also support the 
'protective role' theory, is that of Terragno (1980). On 
inducing renovascular hypertension, while he found vascular 
PGI 2 production to be elevated, he found it to be even higher 
in animals which never developed raised pressure, despite 
manipulation aimed at inducing hypertension. He interpreted 
this result as indicating, that elevated prostacyclin levels 
may be protective and in some cases, may actually inhibit the 
development of hypertension. 
Against the possible 'protective role' theory are such resu lts 
as those of Detre, Leithner, Winter, Sinzinger, Silberbauer, 
F6dy and Jellinek (1980 ) and Yoshimura, Kaimasu, Kitani, 
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Kawamura, Takeda, Sasaki, Kaj ita, Nakagawa and Ijichi (1980) in 
which, after a number of weeks of certain forms of experimental 
hypertension, though pressure was still elevated, aortic PGI 2 
elevation had returned to normal or below normal. A 1 so, of 
course, one cannot be impressed by a protective mechanism that 
generally does not work, i.e. animals have an increased ability 
to generate PGI 2 but they are still hypertensive. 
It appears that trying to assign a clear vascular function to 
the elevated aortic generation of PGI 2 found in hypertension, 
may be premature. Further studies will obviously provide 
additional insight. For example, metabolites of PGI 2 may be 
functionally important (Chapter 2 .5 ) e.g. Gimeno, Sterin-Borda, 
Borda, Lazzari and Gimeno (1980) have reported that human 
plasma transforms PGI 2 into a platelet anti -aggregatory 
substance, which actually contracts isolated bovine coronary 
arteries (this may be 6-keto-PGE 1). Also, there are many 
vasoact i ve substances, 1 eve 1 s of wh ich may be important in 
relation to those of prostacyclin in the vasoconstriction of 
hypertension. Of particular interest are levels of TXA2, 
since it is the balance between TXA2 and PGI 2 which is more 
likely to be important in regulation of vascular tone, than are 
absolute amounts of either substance alone (C hapter 2). 
Unfortunately, measurement of thromboxane levels in hyper-
tension have not kept pace with those of prostacycl in. 
Matsumoto, Nukada, Uyama, Yoneda, Imaizumi, Miyamoto and Kayama 
( 1980) found that human platelets collected from control or 
hypertensive subjects, did not differ significantly in their 
ability to generate TXB 2 from arachidonic acid or PGH 2 . 
9.4.Z. 
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However, Inoue, Hayashi, Hara, Watanabe, Enomoto and Nomura 
(1979) have indicated that TXAZ generation in platelets of 
SHR is increased. Should this be so, and if it also applies to 
other forms of experimental hypertension, then the elevated 
PGI Z recorded may be nothing more than a mechanism to 
counterbalance the vasoconstrictor effects of excess TXAZ. 
Evidence reviewed by Ally and Horrobin (1980), indicates that 
in addition to its formation in platelets, TXAZ is produced 
by vessel walls, in amounts which though small, are adequate to 
exert actions on both vascular reactivity and on platelets. 
Levels of vessel and platelet TXAZ and hence the 
TXAZ/PGI Z ratio need further attention and clarification if 
the relevance of the elevated levels of PGI Z in hypertension, 
is to be established. 
POSSIBLE EFFECT ON PLATELETS. 
Another potential role for the elevated prostacycl in reported 
in hypertension, is at the level of platelet function, since 
prostacyclin has the capacity to increase platelet cAMP levels 
and inhibit platelet aggregation (Chapter Z.6.1). Clearly, one 
factor which might influence platelet response to the elevated 
levels of PGI Z' would be the sensitivity of the platelets to 
prostacyc 1 in (Burghuber, Si nz i nger, Si 1 berbauer, Wo If and 
Haber, 1981 ) . The pos sib i 1 ity that the increased 
responsiveness of hypertensive vessels to the hypotensive 
effect of PGI Z' might amplify the proposed protective effect 
of the elevated levels of prostacyclin on the vasculature, has 
already been discussed (Chapter 9.4.1). 
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The sensitivity of genetically hypertensive rat platelets, to 
the ant i-aggregatory effect of prostacyc 1 in was invest i gated 
(Chapter 8). Sinzinger, Silberbauer, Horch and Gall (1981) 
have reported decreased sensitiv ity of human platelets to 
PGI 2, during long-term intra-arterial prostacyclin infusion 
in per iphera l vascular disease. The possibility therefore 
existed, that increased aortic generation of PGI 2 in 
hypertension, might be associated with reduced platelet 
sensitivity. The results of the study however, invalidated 
this hypothesis. In fact, platelets of hypertensive rats 
showed sensitivity almost identical to that of normal 
controls. 
Measurements of vascular PGI 2 in relation to platelet 
prostacyclin sensitivity have been made in other disorders. In 
diabetics, both decreased vascular prostacyclin generation and 
decreased platelet sensitivity, i.e. a 'double defect' have 
been reported and when atherosc 1 eros i sis induced in rabb i ts, 
though decreased vascular PGI 2 generation occurs, platelets 
are more sens it i ve to prostacyc 1 in (Chapter 8.1) . Beari ng in 
mind the disadvantage of making comparisons when studies have 
involved different species, it is still interesting that in 
three disorders which are all associated with a high risk of 
arterial thrombosis, namely hypertension, diabetes and 
atherosclerosis, changes in vessel prostacyclin production and 
platelet sensitivity to prostacyclin do not appear to be 
consistent. In fact, the normal sensitivity of platelets in 
hypertension, would tend to indicate that the elevated vascular 
generation of PGI 2 may exert a protective role at the 
platelet level. 
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However, once again, consideration of prostacyclin in isolation 
obviously gives an incomplete picture. Generation of, and 
platelet sensitivity to TXA2, will be of the utmost 
importance in determination of the TXA2'PGI 2 balance, which 
is more likely to be relevant than levels of either substance 
alone, in the regulation of thrombus formation. In 
atherosclerosis in rabbits there is increased platelet 
production of, and sensitivity to, TXA2 (Chapter 2.8.1) and 
in diabetic patients increased platelet synthesis of TXA2 
(Chapter 2.8.2). Thus in diabetics and in experimental 
atherosc 1 eros i s (most part icul ar ly at three months after 
feeding the atherogenic diet (Gryglewski, Dembinska-Kiec, Zmuda 
and Gryglewska, 1978)), it appears that the TXA2'PGI 2 
balance may be tipped in favour of thrombus formation. 
In hypertension, if it is possible to extrapolate to 
experimental animals, the findings of Matsumoto, Nukada, Uyama, 
Yoneda, Imaizumi, Mijamoto and Kayama (1980) that for human 
subjects platelet thromboxane generation is normal, then the 
increased vascular generation of PGI 2 may continue to appear 
protective at the platelet level. However, it appears on a 
species basis, that the findings of Inoue, Hayashi, Hara, 
Watanabe, Enomoto and Nomura (1979) (that SHR platelets 
generate increased TXA2 ) are more 1 ikely to extend to other 
models of experimental hypertension. If this is so, then any 
effect of the elevated prostacyclin on platelets may be 
balanced or even overshadowed by TXA2 . An elevated 
TXA2'PGI 2 ratio would be in 1 ine with the observation of an 
increased tendency to arterial thrombosis in hypertension and 
1Z0 
would correlate better with the type of balance recorded for 
di abetes and atherosc 1 eros is. C1 ear 1y, thromboxane product i on 
(by both platelet and vessel) and platelet sensitivity to 
TXAZ' need further investigation in the models in which 
elevated prostacyc1in has been reported. 
Even after estab1 ishment of the TXAZ'PGI Z ratio, there will 
be many other factors to be integrated with this knowledge. It 
has been shown, for example, that epinephrine blocks PGI Z 
disaggregation of ADP aggregated platelets (Rao, Reddy and 
White, 1980), i.e. there are other vasoactive compounds (the 
exact involvement of which in hypertension is still to be 
established) which may interact with the arachidonate 
derivatives and platelet function. In addition, not all 
plate 1 et behavi our is dependent on prostag1 and i n pathways and 
of course, in occlusive arteriolar disease events in the lumen 
(thrombosis) invariably co-exist with disease of the wall 
(atheroma) • 
9.5. CONCLUSION 
These studies have revealed, that aortas of rats with various 
forms of experimental hypertension, have an increased capacity 
for generation of the vasodil atory, ant i -aggregatory substance 
prostacyc1 in. The findings are consistent with those of most 
other workers. Further, it has been shown that the elevated 
ability to release PGI Z' may be directly related to the 
mechanical effect of the increased transmural stress associated 
with elevated pressure. 
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Assuming that the establ ished increased capacity of the aorta 
for prostacycl in generation extends to other arteries, various 
suggestions have been put forward as to the possible local 
function and consequent relevance of these elevated levels. 
Pace-Asciak (1979) has proposed that the raised levels may be a 
protect i ve response to elevated pressure, attenuat i ng further 
pressure rises. The results presented in this thesis, that 
hypertens i ve rat plate 1 ets are not 1 ess respons i ve than those 
of normals, to the anti-aggregatory effects of prostacyclin, 
would indicate that the 'protective role' may extend to 
platelet function. 
Despite this proposed explanation, it appears that it will be 
possible to draw more valid conclusions about the findings once 
thromboxane levels and thus ratio in 
hypertension have been established. It is possible, that 
despite elevated generation of PGI 2 by the vessel wall, the 
TXA2' PGI 2 balance may be tipped in favour of the 
vasoconstrictive, proaggregatory substance TXA 2• 
The discovery of the thromboxanes and prostacycl in has 
uncovered a new d imens i on of card i ovascu 1 ar research but many 
Questions remain unanswered. While studies with rats do 
contri bute to our understandi ng, of greater interest wi 11 be 
the situation in humans, where direct measurement of vascular 
prostacyclin producing capacity is obviously more difficult 
than in experimental animals. Though plasma 6-keto-PGF la 
levels have been reported recently to be low in patients with 
essential hypertension (Uehara, Ishi i, Takeda, Ikeda, Atarshi 
and Murao, 1981), one cannot be certain whether difference in 
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species or methodology, is responsible for results which 
conflict with studies in the rat. 
In the future, further studies in this field are likely to 
provi de i nformat ion 1 eadi ng to a better understand i ng of the 
pathophysiology of such disorders as hypertension. 
- REFERENCES -
123 
AIKEN, J.W., GORMAN, R.R. and SHEBUSKI, R.J. (1979). Prostacyclin 
prevents blockage of partially obstructed coronary arteries. In: Vane, 
J.R. and Bergstr6m, S. (eds): Prostacyclin. New York, Raven Press, p311 -
321. 
ALLY, A.I. and HORROBIN, D.F. (1980). Thromboxane A2 in blood vessel 
walls and its physiological significance: relevance to thrombosis and 
hypertension. Prostaglandins Med i, 431 - 438. 
ARMSTRONG, J.M., CHAPPLE, D., DUSTING, G.J., HUGHES, R., MONCADA, S. and 
VANE, J.R. (1977). Cardiovascular actions of prostacyclin (PGI 2) in 
chloralose anaesthetized dogs. Br J Pharmacol Ql, 136P. 
ARMSTRONG, J.M., LATTIMER, N., MONCADA, S. and VANE, J.R. (1978). 
Comparison of the vasodepressor effects of prostacyclin and 
6-oxo-prostaglandin Fla with those of prostaglandin E2 in rats and 
rabbits. Br J Pharmacol g, 125 - 130. 
ASHMAN, B. (1976). An assessment of platelet counting methods. Med Lab 
Sci ~, 201 - 208. 
BENDITT, E.P. (1977). The origin of atherosclerosis. Sci Am 236, 74 - 85. 
BERGSTROM,S., DANIELSSON, H. and SAMUELSSON, B. (1964). The enzymatic 
formation of prostaglandin E2 from arachidonic acid. Prostaglandins and 
related factors 32. Biochim Biophys Acta 90, 207 - 210. 
BERSGTROM, S. and SJOVALL, J. (1960). The isolation of prostaglandin F 
from sheep prostate glands. Acta Chem Scand li, 1693 - 1700. 
BIANCHI, G., FOX, U., DI FRANCESCO, G.F., GIOVANETTI, A.M. and PAGETTI, D. 
(1974). Blood pressure changes produced by kidney cross-transplantation 
between spontaneously hypertensive rats and normotensive rats. Clin Sci 
Mol Med 47, 435 - 448. 
BIGGS, R. (ed) (1976). Human blood coagulation, Haemostasis and 
Thrombosis. Oxford, Blackwell Scientific Publications, p737. 
124 
BLACKWELL, G.J., FLOWER, R.J., RUSSELL-SMITH, N., SALMON, J.A., THOROGOOD, 
P.B. and VANE, J.R. (1978) . Prostacyclin is produced in whole blood. 
Br J Pharmacol 64, 436P. 
BOLGER, P.M., EISNER, G.M., RAMWELL, P.W., SLOTKOFF, L.M. and COREY, E.J. 
(1978). Renal actions of prostacyclin. Nature 271, 467 - 469. 
BOLOGNA, E. (1974). Anti-hypertensive treatment and platelet 
aggregation. ~: Coprina, L. and Ross, E.C. (eds): Platelet aggregation 
and drugs. New York, Academic Press, p213 - 219. 
BORER, J.S. (1980). Unstable angina: a lethal gun with an invisible 
trigger. N Engl J Med 302, 1200 - 1202. 
BORN, G.V.R. (1962). Aggregation of blood platelets by adenosine 
diphosphate and its reversal. Nature 194, 927 - 929. 
BORN, G.V.R. (1970). Observations on the change in shape of blood 
platelets brought about by adenosine diphosphate. J Physiol (Lond) 209, 
487 - 511. 
BORN, G.V.R. and CROSS, M.J. (1963). The aggregation of blood platelets. 
J Physiol (Lond) 168, 178 - 195). 
BOULLIN, D.J., BUNTING,S., BLASO, W.P., HUNT, T.M. and MONCADA, S. 
(1979). Responses of human and baboon arteries to prostaglandin 
endoperoxides and biologically generated and synthetic prostacyclin: 
their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol L, 
139 - 147. 
BRANAN, R.C., POULSEN, R.S., WOLFE, L.S., DILA, C., HODGE, C.P. and 
FEINDEL, W. (1979). Effects of prostacyclin on the epicerebral 
circulation with velocity of interval anaylsis by computer. ~: Vane, 
J.R. and BergstrHm, S. (eds): Prostacyclin. New York, Raven Press, p289 -
297. 
125 
BREDDIN, K., GRUN, H., KRZYWANEK, H.J. and SCHREMMER, W.P. (1976). On the 
measurement of spontaneous platelet aggregation. The platelet aggregation 
test III. Thromb Haemost 1i, 669 - 691. 
BRODY, M.J., HAYWOOD, J.R. and TOUW, K.B. (19BO), Neural mechanisms in 
hypertension. Annu Rev Physiol 42, 441 - 453. 
BUNTING, S., GRYGLEWSKI, R., MONCADA, S. and VANE, J.R. (1976). Arterial 
walls generate from prostaglandin endoperoxides a substance (prostaglandin 
X) which relaxes strips of mesenteric and coeliac arteries and inhibits 
platelet aggregation. Prostaglandins l£, 897 - 913. 
BUNTING,S., MONCADA, S., REED, P., SALMON, J.A. and VANE, J.R. (1978). 
An antiserum to 5,6-dihydro-prostacyclin (PGI 1) which also binds 
prostacyclin. Prostaglandins 12, 565 - 573. 
BUNTING, S., MONCADA, S. and VANE J.R. (1976). The effects of 
prostaglandin endoperoxides and thromboxane A2 on strips of rabbit 
coeliac artery and certain other smooth muscle preparations. Br J 
Pharmacol ~, 462P - 463P. 
BUNTING, S., MONCADA, S. and VANE, J.R. (1977). Antithrombotic properties 
of vascular endothelium. Lancet ii, 1075 - 1076. 
BURGHUBER, 0., SINZINGER, H., SILBERBAUER, K., WOLF, Ch. and HABER, P. 
(1981). Decreased prostacyclin sensitivity of human platelets after 
jogging and squash. Prostaglandins Med~, 127 - 130. 
BUTKUS, A., SKRINSKA, V.A. and SCHUMACHER, D.P. (1980) . Thromboxane 
production and platelet aggregation in diabetic subjects with clinical 
complications. Thromb Res 11, 211 - 223. 
CARMIGNANI, M., MARCHETTI, P. and CAPRINO, L. (1980). Prostacyclin 
effects on the blood pressure responses to norepinephrine in rats treated 
with aspirin or indomethacin. Artery~, 90 - 95. 
126 
CASALS-STENZEL, J. and MORTON, J.J. (1979). The vasodepressor action of 
prostacyclin (PGI 2) and its effects on plasma angiotensin II and 
vasopress i n in unanaesthet i zed normotens ive and hypertens i ve rats. Cl in 
Exp Hypertension 1, 577 - 596. 
CHAPPLE, D.J., DUSTING, G.J., HUGHES, R. and VANE, J . R. (1978). A vagal 
reflex contributes to the hypotensive effect of prostacyclin in 
anaesthetized dogs. J Physiol 281, 43P - 44P. 
CHAPPLE, D.J., DUSTING, G.J., HUGHES, R. and VANE, J.R. (1980). Some 
direct and reflex cardiovascular actions of prostacyclin (PGI 2) and 
prostaglandin E2 in anaesthetized dogs. Br J Pharmacol 68, 437 - 447. 
CHO, M.J. and ALLEN, M.A. (1978). Chemical stabil ity of prostacycl in 
(PGI 2) in aqueous solutions. Prostaglandins ji, 943 - 954. 
CHRIST-HAZELHOF, E. and NUGTEREN, D.H. (1980). Prostacycl in, a 
circulating hormone? In: International Symposium on Prostaglandins and 
the Cardiovascular System. Wilrijk, Belgium, - 3 December, 1980. 
(Abstract of Papers, European Society of Cardiology. Abstract number 53.) 
CIABATTONI, G., PUGLIESE, F., CINOTTI, G.A., STIRATI, G., RONCI, R., 
CASTRUCCI, G., PIERUCCI, A. and PATRONO, C. (1979). Characterization of 
furosemide-induced activation of the renal prostaglandin system . Eur J 
Pharmacol 60, 181 - 187. 
COCCHERI, S. and FIORENTINI, P. (1971 ) . Platelet adhesiveness and 
aggegation in hypertensive patients. Acta Med Scand (Suppl) 525, 273 -
275 . 
COCEANI, F., BISHAI, I., BODACH, E., WHITE, E.P. and OLLEY, P.M. (1979). 
On the evidence implicating PGE2 rather than prostacyclin in the patency 
of the fetal ductus arteriosus. .!!!.: Vane, J.R. and Bergstom, S. (eds): 
Prostacyclin. New York, Raven Press, p247 - 252. 
127 
CRONBERG, S. (1971). A mathematical model for optical platelet 
aggregation test. Acta Med Scand (Suppl) 525, 49 - 53. 
D'ANGELO, V., VILLA, S., MYSLIWIEC, M., DONATI, M.B. and DE GAETANO, G. 
(1978). Defective fibrinolytic and prostacyclin-like activity in human 
atheromatous plaques. Thromb Haemost 39, 535 - 536. 
DE DECKERE, E.A.M., NUGTEREN, D.H. and TEN HOOR, F. (1977). Prostacyclin 
is the major prostaglandin released from the isolated perfused rabbit and 
rat heart. Nature 268, 160 - 163. 
DEMBINSKA-KIEC, A., GRYGLEWSKA, T., ZMUDA, A. and GRYGLEWSKI, R.J. 
(1977). The generation of prostacycl in by arteries and by the coronary 
vascular bed is reduced in experimental atherosclerosis in rabbits. 
Prostaglandins l±, 1025 - 1034. 
DEMBINSKA-KIEC, A., RUCKER, W. and SCHONHOFER, P.S. (1979). 
Prostacyclin-dependent differences in TXA2 formation by platelets from 
normal and atherosclerotic rabbits. Atherosclerosis~, 217 - 226. 
DETRE, Z., LEITHNER, Ch., WINTER, M., SINZINGER, H., SILBERBAUER, K., 
F6DY, L. and JELLINEK, H. (1980). Aortic response to renovascular 
hypertension. Artery~, 398 - 403. 
DUSTING, G.J., CHAPPLE, D.J., HUGHES, R., MONCADA, S. and VANE, J.R. 
(1978). Prostacyclin (PGI 2) induces coronary vasodilatation in 
anaesthetised dogs. Cardiovasc Res }£, 720 - 730. 
DUSTING, G.J., MONCADA, S. and VANE, J.R. (1977a). Prostacyclin (PGI 2) 
is a weak contractor of coronary arteries in the pig. Eur J Pharmacol ~, 
301 - 304. 
DUSTING, G.J., MONCADA, S. and VANE, J.R. (1977b). Prostacycl in (PGX) is 
the endogenous metabolite responsible for relaxation of coronary arteries 
induced by arachidonic acid. Prostaglandins 11, 3 - 15. 
DUSTING, G.J., MONCADA, S. and VANE, J.R. (1978a). Recirculation of 
prostacyc l in (PGI 2) in the dog. Br J Pharmacol 64, 315 - 320. 
128 
DUSTING, G.J., MONCADA, S. and VANE, J.R. (1978b). Disappearance of 
prostacyclin (PGI 2) in the circultion of the dog. Br J Pharmacol 62, 
414P - 415P. 
DUSTING, G.J., MONCADA, S. and VANE, J.R. (1978c). Vascular actions of 
arachidonic acid and its metabolites in perfused mesenteric and femoral 
beds of the dog. Eur J Pharmacol 49, 65 - 72. 
DYERBERG, J. and BANG, H.O. (1978). Dietary fat and thrombosis. Lancet 
i, 152. 
DYERBERG, J., BANG, H.O., STOFFERSEN, E., MONCADA, S. and VANE, J.R. 
(1978). Eicosapentaenoic acid and prevention of thrombosis and 
atherosclerosis? Lancet ii, 117 - 119. 
FASCIOLO, J.C. (1979). El efector vascular en la hipertension arterial. 
Medicina (B Aires) 39, (Suppl 1) 48 - 58. 
FEINBERG, G., TRACHTE, G.J., CURTIS, M. and LEFER, A.M. (1980). Dietary 
modification of the vascular effect of prostacyclin in hypertensive rats. 
Prostaglandins Med 2, 235 - 241. 
FERGUSON, J.C., MACKAY, N., PHILIP, J.A.D. and SUMNER, D.J. (1975). 
Determination of platelet and fibrinogen half-life with [75Se ]seleno -
methionine: studies in normal and diabetic subjects. Clin Sci Mol Med 49, 
115 - 120. 
FISCHETTI, B., CARMIGNANI, M., MARCHETTI, P., RANELLETTI, F.O. and 
CAPRINO, L. (1980). Prostacyclin reversal of aspirin and indomethacin 
effect on blood pressure responses to norepinephrine. Pharmacol Res 
Commun ~, 319 - 328. 
FITZGERALD, G.A., HOSSMANN, V., HUMME RICH, W. and KONRADS, A. (1980). The 
renin-kalli krein-prostaglandin system: Plasma acti ve and inactive renin 
and urinary kall ikrein during prostacyclin infusion inman. 
Prostaglandins Med 2, 445 - 456. 
129 
FITZPATRICK, T.M., ALTER, 1., COREY, E.J., RAMWELL, P.W., ROSE, J.C. and 
KOT, P.A. (1978). Cardiovascular responses to PGI 2 (prostacyclin) in 
the dog. Circ Res 1£, 192 - 194. 
FLETCHER, J.R. and RAMWELL, P.W. (1979). Comparison of the cardiovascular 
effects of prostacyclin with those of prostaglandin E2 in the Rhesus 
monkey. l!!.: Vane, J.R. and Bergstom, S. (eds): Prostacyclin. New York, 
Raven Press, p259 - 267. 
FOLKOW, B., GRIMBY, G. and THULESIUS, o. (1958). Adaptive structural 
changes of the vascular walls in hypertension and their relation to the 
control of the peripheral resistance. Acta Physiol Scand 44, 255- 272. 
FORSTER, W., TAUBE, Ch. and FAHR, A. (1980). Correlation between the 
antihypertensive effects of clonidine (C), dihydralazine (D) and 
propranolol (P) and the ex vivo stimulation of PGI 2 biosynthesis in the 
aorta of SHR. In: International Symposium on Prostaglandins and the 
Cardiovascular System. Wilrijk, Belgium, 1 - 3 December, 1980. (Abstract 
of Papers, European Society of Cardiology. Abstract number 13.) 
FREIS, E.D. (1972). Modification of hypertension by antihypertensive drug 
treatment in spontaneously hypertensive rats. In: Okamoto, K. (ed): 
Spontaneous Hypertension its Pathogenesis and Complications Tokyo, Igaku 
Shoin Ltd., p231 - 237. 
FRIEDMAN, L.A., WEBSTER, J., HENSBY, C.N. and LEWIS P.J. (1981). 
Prostacyclin production in arterial hypertension. l!!.: Lewis, P.J. and 
O'Grady, J. (eds): Clinical Pharmacology of Prostacyclin. New York, Raven 
Press, p97 - 101. 
GAARDER, A., JONSEN, J., LALAND, S., HELLEM, A. AND OWREN, P.A. (1961). 
Adenosine diphosphate in red cells as a factor in the adhesiveness of 
human blood platelets. Nature 192, 531 - 532. 
130 
GERRARD, J.M., STUART, M.J., RAO, G.H.R., STEFFES, M.W., MAUER, S.M., 
BROWN, D.M. and WHITE, J.G. (1980). Alteration in the balance of 
prostaglandin and thrombaxane synthesis in diabetic rats. J Lab Clin Med 
~, 950 - 958. 
GIMENO, M.F., STERIN-BORDA, L., BORDA, LS., LAZZARI, M.A. and GIMENO, 
A.L. (1980). Human plasma transforms prostacyclin (PGI 2) into a 
plate 1 et ant i aggregatory substance wh i ch contracts i so 1 ated bov i ne 
coronary arteries. Prostaglandins li, 907 - 916. 
GLAVIND, J., HARTMAN, S., CLEMMESEN, J., JESSEN, K.E., and DAM, H. 
(1952). Studies on the role of 1 ipoperoxides in human pathology II. The 
presence of peroxidised lip ids in the atherosclerotic aorta. Acta Pathol 
Micorbiol Scand 30, 1 - 6. 
GOLD8LATT, M.W. (1935). Properties of human seminal plasma. J Physiol 
(Lond) 84, 208 - 218. 
GOLDBLATT, H. and KAHN, J.R. (1938). Experimental hypertens ion 
Constriction of the aorta at various levels. JAMA 110, 686. 
GOLDBLATT, H., LYNCH, J., HANZAL, R.F. and SUMMERVILLE, W.W. (1934). 
Studies on experimental hypertension I. The production of persistent 
elevation of systolic blood pressure by means of renal ischaemia. J Exp 
Med ~, 347 - 379. 
GORMAN, R.R., BUNTING, S. and MILLER, O.V. (1977). Modulation of human 
platelet adenyl ate cyclase by prostacyclin (PGX). Prostaglandins ll, 377-
388. 
GROLLMAN, A. (1972). The spontaneously hypertensive rat: an experimental 
analogue of essential hypertension in the human being. In: Okamoto, K. 
(ed): Spontaneous Hypertension its Pathogenesis and Complications. Tokyo, 
Igaku Shoin Ltd., p238 - 242. 
GROLLMAN, A. (1980). Hypertension: a critical survey. Pathobiol Annu .!Q, 
269 - 303. 
131 
GRYGLEWSKI, R.J. (1979). Is the lung an endocrine organ that secretes 
prostacyc1in? l!2.: Vane, J.R. and Bergstom, S. (eds): Prostacyc1in. New 
York, Raven Press, p275 - 288. 
GRYGLEWSKI, R. J. (1980) • Prostacyc 1 in and atherosc1 eros is. Trends 
Pharmaco1 Sci 1, 164 - 166. 
GRYGLEWSKI, R.J., BUNTING,S., MONCADA,S., FLOWER, R.J. and VANE, J.R. 
(1976). Arterial walls are protected against deposition of platelet 
thrombi by a substance (prostaglandin X) which they make from 
prostaglandin endoperoxides. Prostag1andins]£, 685 - 713. 
GRYGLEWSKI, R.J., DEMBINSKA-KIEC, A., ZMUDA, A. and GRYGLEWSKA, T. 
(1978). Prostacyc1in and thromboxane A2 biosynthesis capacities of 
heart, arteri es and plate 1 ets at vari ous stages of experiment a 1 
atherosclerosis in rabbits. Atherosclerosis 11, 385 - 394. 
GRYGLEWSKI, R.J., KORBUT, R. and OCETKIEWICZ, A. (1978). Generation of 
prostacyc1in by lungs in vivo and its release into arterial circulation. 
Nature 273, 765 - 767. 
GRYGLEWSKI, R.J., KORBUT, R. and SPLAWINSKI, J. (1979). Endogenous 
mechanisms which regulate prostacyc1in release. Haemostasis~, 294 - 299. 
GULLNER, H.G., CERLETTI, C., BARTTER, F.C., SMITH, J.B. and GILL, J.R. Jr. 
(1979) • Prostacyc 1 in overproduct i on in Bartter' s syndrome. Lancet ii, 
767 - 769. 
HAEUSLER, G. and GEROLD, M. (1979). Increased levels of prostaglandin-
1 ike material in the canine blood during arterial hypotension produced by 
hydralazine, dihydralazine and minoxidil. Naunyn Schmiedenbergs Arch 
Pharmacol 310, 155 - 167. 
HAMBERG, M. and SAMUELSSON, B. (1973). Detection and isolation of an 
endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad 
Sci USA 70, 899 - 903. 
132 
HAMBERG, M., SVENSSON, J. and SAMUELSSON, B. (1975). Thromboxanes: A new 
group of biologically active compounds derived from prostaglandin 
endoperoxides. Proc Natl Acad Sci USA Z£, 2994 - 2998. 
HAMBERG, M., SVENSSON, J., WAKABAY ASH I, T. and SAMUELSSON, B. ( 1974) • 
Isolation and structure of two prostaglandin endoperoxides that cause 
platelet aggregation. Proc Natl Acad Sci USA Zl, 345 - 349. 
HAMILTON, G., ROSZA, 1., HUTTON, R., CHOW, F.P.R., DANDONA, P. and HOBBS 
K.E.F. (1981). Portal vein prostacyclin activity in experimenta l portal 
hypertension in rats. Clin Sci 60, 327 - 329. 
HAN, P. and ARDLIE, N.G. (1974). The influence of pH, temperature and 
calcium on platelet aggregation : maintenance of environmental pH and 
platelet function for in vitro studies in plasma stored at 37'C. Br J 
Haematol ~, 373 - 389. 
HARRISON, H.E., REECE, A.H. and JOHNSON, M. (1978). Decreased vascular 
prostacyclin in experimental diabetes. Life Sci fl, 35 1 - 356. 
HASLAM, R.J. and McCLENAGHAN, M.D. (1981). Measurement of circulating 
prostacyclin. Nature 292, 364 - 366. 
HEDQVIST, P. (1976). Prostaglandin action on transmitter release at 
adrenergic neuroeffector junctions. Adv Prostaglandin Thromboxane Res 1, 
357 - 363. 
HENSBY, C.N., BARNES, P.J., DOLLERY, C.T. and DARGIE, H. (1979). 
Production of 6-oxo-PGF la by human lung in vivo. Lancet ii, 1162 - 1163. 
HEYNS, A.P., VAN DEN BERG, D.J., POTGIETER, G.M. and RETIEF, F.P. (1974). 
The inhibition of platelet aggregation by an aorta intima extract. Thromb 
Diath Haemorrh l£, 417 - 431. 
HIGGS, G.A., CARDINAL, D. C., MONCADA, S. and VP.NE, J.R. (1979). 
Microcirculatory effects of prostacyclin (PGI 2) in hamster cheek pouch. 
Microvasc Res ~, 245 - 254. 
133 
HIGGS, E.A., HIGGS G.A., MONCADA, S. and VANE, J.R. (1978). Prostacyclin 
(PGI 2) inhibits the formation of platelet thrombi in arterioles and 
venules of the hamster cheek pouch. Br J Pharmacol ~, 535 - 539. 
HIGGS LA., MONCADA, S., VANE, J.R., CAEN, J.P., MICHEL, H. and TOBELEM, 
G. (1978). Effects of prostacyclin (PGI 2) on platelet adhesion to 
rabbit arterial subendothelium. Prostaglandins~, 17 - 22. 
HILL, T.W.K. and MONCADA, S. (1979). The renal haemodynamic and excretory 
actions of prostacyclin and 
Prostaglandins 1I, 87 - 98. 
6-oxo-PGF la in anaesthetized dogs. 
HORNYCH, A. (1978). Prostaglandins and high blood pressure. Contib 
Nephrol 1£, 54 - 68. 
HORTON, E.W., PIPILI, E., and POYSER, N.L. (1980). The effect of nerve 
stimulation on release of prostacyclin (PGI 2) from the rat and rabbit 
mesenteric arteries. Br J Pharmacol 70, 87P - 88P. 
HWANG, D.H. (1980). Aggregation and inhibition of rat platelets, and the 
formation of endoperoxide metabolites. Prostaglandins Med 2, 163 - 173. 
INOUE, K., HAYASHI, H., HARA, K., WATANABE, M., ENOMOTO, H. and NOMURA, T. 
(1979) . Comparative studies on the activities of prostaglandin 
bi osynthes i sin plate 1 ets and aortas of normotens i ve and spontaneous ly 
hypertensive rats. Jpn Heart J gQ, 706. 
ISAKSON, P.C., RAZ, A., DENNY, S.L, PURE, E. and NEEDLEMAN, P. (1977). A 
novel prostaglandin is the major product of arachidonic acid metabolism in 
rabbit heart. Proc Natl Acad Sci USA 74, 101 - 105. 
JOHNSON, M., HARRISON, H.E., RAFTERY, A.T. and ELDER, J.B. (1979). 
Vascular prostacyclin may be reduced in diabetes in man. Lancet i, 325 -
326. 
JOHNSON, R.A., MORTON, D.R., KINNER, J.H., GORMAN, R.R., McGUIRE, J.C., 
SUN, F.F., WHITTAKER, N., BUNTING, S., SALMON, J., MONCADA, S. and VANE, 
J.R. (1976). The chemical structure of prostaglandin X (prostacyclin). 
134 
Prostaglandins 2£, 915 - 928. 
KEEN, H. , (1976). Glucose intolerence diabetes mellitis and 
atherosclerosis; prospects for prevention. Postgrad Med J 52, 445-451. 
KIPROV, D. and SOMOVA, L. (1975). Action of E and A prostaglandins on 
isolated aorta of rats with spontaneous hypertension. Cor Vasa lI, 292 -
30l. 
KLEIN, K., SINZINGER, H., KALlMAN, J. and SHERNTHANER, G. (1980). 
Decreased platelet sensitivity to PGI 2 in maturity onset diabetes. 
Pharm Res Comm (in press). 
KLOEZE, J. (1967). Influence of prostaglandins on platelet adhesiveness 
and platelet aggregation. In: Bergstrom, S. and Samuelsson, B. (eds): 
Prostaglandins, Proceedings of the Second Nobel Symposium. New York, 
Interscience, p241 - 252. 
KURZROK, R. and LIEB, C.C. (1930). Biochemical studies of human semen. 
I I. The act i on of semen on the human uterus. Proc Soc Exp B io 1 Med 28, 
268 - 272. 
LAGARDE, M. and DECHAVANNE, M. (1977). Increase of platelet prostaglandin 
cyclic endoperoxides in thrombosis. Lancet l, 88. 
LEFER, A.M., OGLETREE, M.L., SMITH, J.B., SILVER, M.J., NICOLAOU, K.C., 
BARNETTE, W.E. AND GASIC, G.P. (1978). Prostacyclin: A potentially 
valuable agent for preserving myocardial tissue in acute myocardial 
ischaemia. Science 200, 52 - 54. 
LEFFLER, C.W. and HESSLER, J.R. (1979). Pulmonary and systemic vascular 
effects of exogenous prostaglandin 12 in fetal lambs. Eur J Pharmacol 
54, 37-42. 
LENTINI, S. and BOLOGNA, E. (1974). Hypertension and pl atelet aggregation . 
In: Coprina, L. and Ross, LC. (eds): Platelet aggregation and drugs. 
New York, Academic Press, p 63 - 76. 
LEVY, J.V. (1978). Contractile responses to prostacyclin (PGI Z) of 
135 
isolated human saphenous and rat venous tissue. Prostag1andin~, 93 - 97. 
LEVY, J.V. (1980). Prostacyc1in-induced contraction of isolated aortic 
strips from normal and spontaneously hypertensive rats (SHR). 
Prostaglandins ]2, 517 - 525. 
LIEBERMAN, G.E., LEWIS, G.P. and PETERS, T.J. (1977). A membrane-bound 
enzyme in rabbit aorta capable of inhibiting adenosine-diphosphate-induced 
platelet aggregation. Lancet jl, 330 - 332. 
LIMAS, C., GOLDMAN, P., LIMAS C.J. and IWAI, J. (1981). Effect of salt on 
prostag1 and i n metabo 1 ism in hypertens i on-prone and -res i stant Dah 1 rats. 
Hypertension 1, 219 - 224. 
LOCKETT, C.J., LEARY, W.P. and ASMAL, A.C. (1979). A modified method of 
determining systolic blood pressure in the rat. Lab Prac ~, 257 - 258. 
MAGUIRE, M.H. and MICHAL, F. (1968). Powerful new aggregator of blood 
platelets - 2-ch1oroadenosine-5'-diphosphate. Nature 217, 571 - 573 . 
MARCUS, A.J. (1978). Personal communication. 
MARKOV, C.M. (1978). The role of prostaglandins in the pathogenesis of 
hypertension. C1in Sci Mol Med ~, 207s - 210s. 
MATSUMOTO, M., NUKADA, T., UYAMA, 0., YONEDA, 5., IMAIZUMI, M., 
MIYAMOTO,T. and KAYAMA, N. (1980). Thromboxane generation in patients 
with essential hypertension or cerebrovascular disease and effect of oral 
aspirin. Thromb Haemost 44, 16 - 22. 
McGIFF, J.C. (1979). Prostaglandins in circulatory disorders. Triangle 
~, 101 - 107. 
McGIFF, J.C. and QUILLEY, J. (1980) . Prostaglandins, kinins, and the 
regulation of blood pressure. C1in Exp Hypertension £, 729 - 740. 
McGIFF, J.e. and QUILLEY, C.P. (1981). The rat with spontaneous genetic 
hypertension is not a suitable model of human essential hypertension. 
Circ Res 48, 455 - 463. 
136 
MICHAL, F. and BORN, G.V.R. (1971). Effect of the rapid shape change of 
platelets on the transmission and scattering of 1 ight through plasma. 
Nature (New Biol) 231, 220 - 222. 
MILLER, O.V., AIKEN, J.W., SHEBUSKI, R.J. and GORMAN, R.R. (1980). 
6-keto-prostaglandin El is not equipotent to prostacyclin (PGI 2 ) as an 
antiaggregatory agent. Prostaglandins 20, 391 - 400. 
MILLER, O.V., JOHNSON, R.A. and GORMAN, R.R. (1977). Inhibition of PGE 1-
stimulated cAMP accumulation in human platelets by thromboxane A2 • 
Prostaglandins 11, 599 - 609. 
MITCHELL, J.R. and SHARP, A.A. (1964). Platelet clumping in vitro. Br J 
Haematol lQ, 78 - 93. 
MONCADA, S., FLOWER, R.J. and VANE, J.R. (1980). Prostaglandins, 
prostacyclin, and thromboxane A2• In: Goodman Gilman, A., Goodman, L.S. 
and Gilman,A. (eds): The Pharmacological Basis of Therapeutics. New York, 
Macmillan Publishing Co. Inc., p668 - 681. 
MONCADA, S., GRYGLEWSKI, R., BUNTING, S. and VANE, J.R. (1976a). An 
enzyme isolated from arteries transforms prostaglandin endoperoxides to an 
unstable substance that inhibits platelet aggregation. Nature 263, 663 -
665. 
MONCADA, S., GRYGLEWSKI, R.J., BUNTING, S. and VANE, J.R. (1976b). A lipid 
peroxide inhibits the enzyme in blood vessel microsomes that generates 
from prostaglandin endoperoxides the substance (prostaglandin X) which 
prevents platelet aggregation. Prostaglandins 1£, 715 - 737. 
MONCADA, S., HERMAN, A.G., HIGGS, E.A. and VANE, J.R. (1977). 
Di fferent i a 1 format i on of prostacyc 1 in (PGX or PGI 2) by 1 ayers of the 
arterial wall. An explanation for the anti-thrombotic properties of 
vascular endothelium. Thromb Res ll, 323 - 344. 
137 
MONCADA, S., HIGGS, E.A. and VANE, J.R. (1977). Human arterial and venous 
tissues generate prostacyclin (prostaglandin X), a potent inhibitor of 
platelet aggregation. Lancet l, 18 - 20. 
MONCADA, S., KORBUT, R., BUNTING, S. and VANE, J.R. (1978). Prostacyclin 
is a circulating hormone. Nature 273, 767 - 768. 
MONCADA, S. and VANE, J. (1977). Discovery of prostacyclin (PGI 2) 
brings fresh insight into prostaglandin roles in cardiovascular function 
and disease. Prostaglandins Ther l, 1 and 4. 
MONCADA, S. and VANE, J.R. (1979a). Pharmacology and endogenous roles of 
prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol 
Rev 30, 293 - 331. 
MONCADA, S. and VANE, J.R. (1979b). Prostacyclin in perspective. In: 
Vane, J.R. and Bergstr6m, S. (eds): Prostacyclin. New York, Raven Press, 
p5 - 16. 
MONCADA, S. and VANE, J.R. (1980a). The pharmacology and clinical 
potential of prostacyclin. In: Turner, P. (ed): Clinical Pharmacology and 
Therapeutics. London, Macmillan Publishers Ltd., p15 - 32. 
MONCADA, S. and VANE, J.R. (1980b). Biological significance and 
therapeutic potential of prostacyclin. J Med Chern 23, 591 - 593. 
MULLANE, K.M. and MONCADA, S. (1980). Prostacyclin release and the 
modulation of some vasoactive hormones. Prostaglandins 20, 25-49. 
MULLANE, K.M., MONCADA, S. and VANE, J.R. (1979). Format i on and 
disappearance of prostacyclin in the circulation. In: Vane, J.R. and 
Bergstrom, S. (eds): Prostacyclin. New York, Raven Press, p221 - 246. 
NEEDLEMAN, P., BRONSON, S.D., WYCHE, A., SIVAKOFF, M. and NICOLAOU, K.C. 
(1978). Cardiac and renal prostaglandin 12, J Clin Invest £1., 839 -
849. 
138 
NEEDLEMAN, P., MONCADA, S., BUNTING, S. , VANE, J.R., HAMBERG, M. and 
SAMUELSSON, B. (1976). Identification of an enzyme in platelet microsomes 
wh i ch generates thromboxane A2 from prostagl andi n endoperox ides. Nature 
261, 558 - 560. 
NEEDLEMAN, P., WHITAKER, M.O., WYCHE, A., WATTERS, K., SPRECHER, H. and 
RAZ, A. (1980). Manipulation of platelet aggregation by prostaglandins 
and their fatty acid precursors: Pharmacological basis for a therapeutic 
approach. Prostaglandins~, 165 - 181. 
NIJKAMP, F.P., MONCAOA, S., WHITE, H.L. and VANE, J.R. (1977). Diversion 
of prostaglandin endoperoxide metabolism by selective inhibition of 
thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J 
Pharmacol 44, 179 - 186. 
NISHIZAWA, E.E., MILLER, W.L., GORMAN, R.R., BUNDY, G.L., SVENSSON, J. and 
HAMBERG, M. (1975). Prostaglandin D2 as a potential antithrombotic 
agent. Prostaglandins 1, 109 - 121. 
NOMENCLATURE ANNOUNCEMENT. (1977). Prostacyclin (PGI 2). Prostaglandins 
ll, 375. 
NORD0'Y, A., SVENSSON, B., WIEBE, D. and HOAK, J.C. (1978). Lipoproteins 
and the inhibitory effect of human endothelial cells on platelet 
function. Circ Res 43, 527 - 534. 
NOWAK, J. (1979). Prostaglandins in the cardiovascular system in man. A 
biochemical and physiological study. Acta Physiol Scand (suppl 467) 7 -
49. 
NUGTEREN, D.H. and HAZELHOF, E. (1973). Isolation and properties of 
intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326, 
448 - 461. 
O'BRIEN, J.R. (1962). Platelet aggregation II: Some results from a new 
method of study. J Clin Path 12, 452-455. 
139 
O'GRADY, J. (1980). Prostacyclin. l.!:!.: Turner, P. and Shand, D.G. (eds): 
Recent Advances in Clinical Pharmacology. 
Livingstone, pl13 - 128. 
Edinburgh, Churchill 
O'GRADY, J., WARRINGTON, S., MOTI, M.J., BUNTING, S., FLOWER, R., FOWLE, 
A.S.E., HIGGS, E.A. and MONCADA, S. (1979). Effects of intravenous 
prostacyclin infusions in healthy volunteers some preliminary 
observations. In: Vane, J.R. and Bergstrom, S. (eds): Prostacyclin. New 
York, Raven Press, p409 - 417. 
OGLETREE, M.L., SMITH,J.B. and LEFER, A.M. (1978). Actions of 
prostaglandins on isolated perfused cat coronary arteries. Am J Physiol 
235, H400 - H406. 
OKUMA, M., YAMORI, Y., OHTA, K. and UCHINO, H. (1979). Production of 
prostacyclin-like substance in stroke-prone and stroke-resistant 
spontaneously hypertensive rats. Prostaglandins 1I, 1 - 7. 
OKUNO, T., KONDO, K., SUZUKI, H. and SARUTA, T. (1980). Effects of 
prostaglandins E2, 12 and F2a , arachidonic acid and indomethacin on 
pressor responses to norepinephrine in concious rats . Prostaglandins~, 
855 - 864. 
PACE-ASCIAK, C. (1976). Isolation, structure and biosynthesis of 
6-ketoprostaglandin Fla in the rat stomach. J Am Chern Soc 98, 2348 -
2349. 
PACE-ASCIAK, C. (1979). PGs and hypertension: Developmental aspects. 
Prostaglandins Ther ~, 3 - 4. 
PACE-ASCIAK, C.R. and CARRARA, M.C. (1978). Evidence suggesting a 
systemic antihypertensive role for PGI 2. Prostaglandins~, 704. 
PACE-ASCIAK, C. and CARRARA, M.C. (1980). Ontogeny of aortic PGI 2 
formation in the developing spontaneously hypertensive rat - correlation 
with elevations in blood pressure. Adv Prostaglandin Thromboxane Res I, 
797 - 801. 
140 
PACE-ASCIAK, C.R., CARRARA, M.C., LEVINE, L. and NICOLAOU, K.C. (1980). 
PGI 2-specific antibodies administered in vivo suggest against a role for 
endogenous PGI 2 as a circulating vasodepressor hormone in the 
normotensive and spontaneously hypertensive rat. Prostaglandins 20, 1053 -
1060. 
PACE-ASCIAK, 
Prostaglandin 
C. R. , CARRARA, M. C. , and NICOLAOU, K.C. 
has more potent hypotensive properties 
(1978). 
than 
prostaglandin E2 in the normal and spontaneously hypertensive rat. 
Prostaglandins 12, 999 - 1003. 
PACE-ASCIAK, C.R., CARRARA, M.C., RANGARAJ, G. and NICOLAOU, K.C. (1978). 
Enhanced formation of PGI 2, a potent hypotensive substance, by aortic 
rings and homogenates of the spontaneously hypertensive rat. 
Prostaglandins 12, 1005 - 1012. 
PACE-ASCIAK, C.R. and NASHAT, M. (1977). Mechanistic studies on the 
biosynthesis of 6-keto-prostaglandin Fla' Biochim Biophys Acta 487, 495-
507. 
PACE-ASCIAK, C.R. and RANGARAJ, G. (1977). The 6-ketoprostaglandin Fla 
pathway in the lamb ductus arteriosus. Biochim Biophys Acta 486, 583 -
585. 
PACE-ASCIAK, C.R., ROSENTHAL, A. and DOMAZET, Z. (1979). Comparison 
between the in vivo rate of metabolism of prostaglandin 12 and its 
blood-pressure-lowering response after intravenous administration in the 
rat. Biochim Biophys Acta 574, 182 - 186. 
PACE-ASCIAK, C. and WOLFE, L.S. (1971). A novel prostaglandin derivative 
formed from arachidonic acid by rat stomach homogenates. Biochemistry lQ, 
3657 - 3664. 
PAGE, I.H. (1939). The production of persistent arterial hypertensi on by 
cellophane perinephritis. JAMA 113, 2046 - 2048. 
141 
PAGE, I.H. (1980). Angiotensin and hypertension. JAMA 243, 1631. 
PANGANAMALA, R.V., HANUMAIAH, B. and MEROLA, A.J. (1981). Age-related 
increase in prostacyc1in production in the rat aorta. Prostaglandins Med 
~, 233 - 235. 
PICKERING, G. (1968). High Blood Pressure. London, J.A. Churchill Ltd. 
PICKERING, G.W. (1974). Hypertension, Causes, Consequences and 
Management. Edinburgh, Churchill Livingstone. 
PIPER, P.J. and VANE, J.R. (1969). Release of additional factors in 
anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223, 29-
35. 
POMERANTZ, K., SINTETOS, A. and RAMWELL, P. (1978). The effect of 
prostacyc1in on the human umbilical artery. Prostag1andins.12, 1035 -
1044. 
PONTECORVO, E.G., MYERS, C.B., l!PPTON, H.L. and KADOWITZ, P.J. (1981). 
Inhibition of platelet aggregation by 6-keto-PGE 1: Lack of an effect on 
cyclic GMP levels. Prostaglandins Med ~, 473 - 483. 
POWELL, W.S. and SOLOMON, S. (1977). Formation of 6-oxo-prostag1andin 
Flu by arteries of fetal calf. Biochem Biophys Res Commun 12, 815 - 822. 
PRESTON, F.E., WHIPPS, S., JACKSON, C.A., FRENCH, A.J., WYLD, P.J. and 
STODDARD, C. J. (1981). Inhibition of prostacyc1in and platelet 
thromboxane A2 after low-dose aspirin. 
QUILLEY, C. P., McGIFF, J.C., LEE, 
N Eng1 J Med 304, 76 - 79. 
W.H., SUN, F.F. and WONG, P.Y.K. 
(1980) • 6-keto PGE 1: A possible metabolite of ' prostacyc1in having 
platelet antiaggregatory effects. Hypertension £, 524 - 528. 
QUIRION, R., RIOUX, F. and REGOl!, D. (1978). Effects of arachidonic acid 
and indomethacin on the in vitro release of prostaglandins by aortic 
strips of spontaneously hypertensive rats. Can J Physio1 Pharmaco1 ~, 
509 - 511. 
142 
RAO, G.H.R., REDDY, K.R. and WHITE, J.G. (1980). The influence of 
epinephrine on prostacyc1in (PGI 2) induced dissociation of ADP 
aggregated platelets. Prostaglandins Med~, 385 - 397. 
RASCHER, W., DIETZ, R., SCH~MIG, A., BURKART, G., LOTH, J.B., MANN, J.F. 
and WEBER, J. (1979). Modulation of sympathetic vascular tone by 
prostaglandins in corticosterone-induced hypertension in rats. C1in Sci 
~, 235s - 237s. 
RAZ, A., ISAKSON, P.C., MINKES, M.S. and NEEDLEMAN, P. (1977). 
Characterization of a novel metabolic pathway of arachidonate in coronary 
arteries which generates a potent endogenous coronary vasodilator. J Bio1 
Chem 252, 1123 - 1125. 
REID, J.L., JONES, D.H. and HAMILTON, C.A. (1978). Adrenoceptors and 
essential hypertension. In : Szabadi, E., Bradshaw, C.M. and Bevan, P. 
(eds): Recent Advances in Pharmacology of Adrenoceptors. Amsterdam, 
Elsevier/North-Holland Biomedical Press, p251 - 258. 
REMUZZI, G., CAVENAGHI, A.E., MECCA, G., DONATI, M.B. and DE GAETANO, G. 
(1977). Prostacyc1in-1ike activity and bleeding in renal failure. Lancet 
ii, 1195 - 1197. 
REMUZZI, G., MISIANI, R., MARCHESI, D., LIVIO, M., MECCA, G., DE GAETANO, 
G. and DONATI, M.B. (1978). Haemolytic - uraemic syndrome: Deficiency of 
plasma factor(s) regulating prostacyc1in activity. Lancet ii, 871 - 872. 
RIOUX, F., QUIRION, R. and REGOl!, D. (1977). The role of prostaglandins 
in hypertension . I. The release of prostaglandins by aorta strips of 
renal, DOCA-sa1t and spontaneously hypertensive rats. Can J Physio1 
Pharmaco1 55, 1330 - 1338. 
RONCAGl!ONI, M.C., 01 MINNO, G., PANGRAZZI, J., REYERS, I., MUSSONI, L., 
DE GAETANO, G. and DONATTI, M.B. (1980). Plasmatic and vascular factors 
of the hemostatic system in rats receiving an estrogen - progestogen 
combination. Contraception~, 249 - 257. 
143 
ROSSI, E.C. and LOUIS, G. (1977). Kinetic parameters of platelet 
aggregat i on as an express i on of plate let res pons i veness. Thromb Haemost 
E, 283 - 290. 
ROTH, G.J. and MAJERUS, P.W. (1975). The mechanism of the effect of 
aspirin on human platelets I. Acetylation of a particulate fraction 
protein. J Clin Invest 56, 624 - 632. 
RUBIN, M.H., WESTON, M.J., BULLOCK, G., ROBERTS, J., LANGLEY, P.G., WHITE, 
Y.S. and WILLIAMS, R. (1977). Abnormal platelet function and 
ultrastructure in fulminant hepatic failure. 0 J Med New Series XLVI, 339-
352. 
SABA, S.R. and MASON, R.G. (1974). Studies of an activity from 
endothelial cells that inhibits platelet aggregation, serotonin release 
and clot retraction. Thromb Res 2, 747 - 757. 
SAGEL, J., COLWELL, J.A., CROOK, L. and LAIMINS, M. (1975). Increased 
platelet aggregation in early diabetes mellitus. Ann Intern Med 82, 733 -
738. 
SALMON, J.A., SMITH, D.R., FLOWER, R.J., MONCADA, S. and VANE, J.R. 
(1978). Further studies on the enzymatic conversion of prostaglandin 
endoperoxides into prostacyclin by porcine aorta microsomes. Biochim 
Biophys Acta 523, 250 - 262. 
SAMUELSSON, B. (1963). Prostaglandins and related factors. 17. The 
structure of prostaglandin E3. J Am Chem Soc 85, 1878 - 1879. 
SAMUELSSON, 8. (1965). On the incorporation of oxygen in the conversion 
of 8, 11, 14-eicosatrienoic acid to prostagl andin El • J Am Chem Soc 87 , 
3011 - 3013. 
SANO, T., BOXER, M.G.J., BOXER, L.A. and YOKOYAMA, M. (1971). Platelet 
sensitivity to aggregation in normal and diseased groups. A method for 
assessment of platelet aggregability. Thromb Diath Haemorr h fi, 524 - 531. 
144 
SCHOLKENS, B.A. (1978). Antihypertensive effect of prostacyclin (PGI 2) 
in experimental hypertension and its influence on plasma renin activity in 
rats. Prostaglandins Med 1, 359 - 372. 
SCHROR, K., MONCADA, S., UBATUBA, F.B. and VANE, J.R. (1978). 
Transformation of arachidonic acid and prostaglandin endoperoxides by the 
guinea pig heart. Formation of RCS and prostacyclin. Eur J Pharmacal iL, 
103 - 114. 
SILBERBAUER, K., SCHERNTHANER, G., SINZINGER, H., PIZA-KATZER, H. and 
WINTER, M. (1979). Decreased vascular prostacyclin in juvenile-onset 
diabetes. N Engl J Med 300, 366 - 367. 
SINTETOS, A.L., BOLGER, P.M. and RAMWELL, P.W. (1979). Effects of 
prostacyclin on isolated canine renal artery and vein. ~: Vane, J.R. and 
Bergstrom, S. (eds): Prostacyclin. New York, Raven Press p269 - 274. 
SINZINGER, H., SILBERBAUER, K., HORSCH, A.K. and GALL, ' A. (1981). 
Decreased sensitivity of human platelets to PGI 2 during long-term 
intraarterial prostacyclin infusion in patients with peripheral vascular 
disease - a rebound phenomenon? Prostaglandins fl, 49 - 51. 
SINZINGER, H., SILBERBAUER, K., WINTER, M. and CLOPATH, P. (1979). 
Effects of experimental atherosclerosis on prostacyclin 
generation in arteries of miniature swine. Artery 2, 448 - 462 
SKIDGEL, R.A. and PRINTZ, M.P. (1978). PGI 2 production by rat blood 
vessels: Diminished prostacyclin formation in veins compared to arteries. 
Prostaglandins ~, 1 - 16. 
SKIDGEL, R.A. and PRINTZ, M.P. (1980). Vascular PG synthesis in 
hypertens ive and normotens ive rats. Adv Prostagl andi n Thromboxane Res 7.., 
803 - 805. 
SLATER, T.F. (1972). Free Radical Mechanisms in Tissue Injury. London, 
Pion Ltd. 
145 
SLEIGHT, P. (1978). Hypertension . .!!::: Bodley Scott, R. (ed): Price 's 
Textbook of the Pract i ce of Medi cine. Oxford, Oxford Un i vers ity Press, 
p808 - 829. 
SMITH, J.B., OGLETREE, M.L., LEFER, A.M. and NICOLAOU, K.C. (1978). 
Antibodies which antagonise the effects of prostacyclin. Nature 274, 64 -
65. 
SMITH, J.B., SILVER, M.J., INGERMAN, C.M. and KOCSIS, J.J. (1974). 
Prostaglandin D2 inhibits the aggregation of human platelets. Thromb 
Res ~, 291 - 299. 
STEER, M.L., MACINTYRE, D.E., LEVINE, L. and SALZMAN, E.W . (1980). Is 
prostacyclin a physiologically important circulating anti-platelet agent? 
Nature 283, 194 - 195. 
STONE, K.J., WILLIS, A.L., HART, M., KIRTLAND, S.J., KERNOFF , P.B .A. and 
McNICOL, G.P. (1979). The metabolism of dihomo-gamma-linolenic acid in 
man. Lipids li, 174 - 180. 
SUTTER, D.M. and WEEKS, J.R. (1980). An antihypertensive effect of 
prostacyclin. Adv Prostaglandin Thromboxane Res 7, 789 - 790. 
SZCZEKLIK, A. and GRYGLEWSKI, R.J. (1979). Actions of prostacyclin in 
man. In: Vane, J.R. and Bergstrom, S. (eds) : Prostacyclin. New York, 
Raven Press, p393 - 407. 
SZCZEKLIK, A., GRYGL£WSKI, R.J., MUSIAL, J., GRODZINSKA, L., SERWONSKA, M. 
and MARCINKIEWICZ, E. (1978). Thromboxane generation and platelet 
aggregation in survivals of myocardial infarction. Thromb Haemost 40, 66 -
74. 
SZCZEKLIK, A., GRYGLEWSKI, R.J., NIZANKOWSKI, R., MUSIAL, J . , PIETON, R. 
and MRUK, J. (1978). Circulatory and anti-platelet effects of intravenous 
prostacyclin in healthy man. Pharmacal Res Commun lQ, 545 - 556. 
146 
SZCZEKLIK, A., GRYGLEWSKI, R.J., NIZANKOWSKI, R., SKAWINSKI, S., Gr USZKO, 
P. and KORBUT, R. (1980). Prostacyclin therapy in peripheral arterial 
disease. Thromb Res ]2, 191 - 199. 
SZCZEKLI K, A., NIZANKOWSKI, R., SKAWINSKI, S., SZCZEKLIK, J. GtUSZKO, P. 
and GRYGLEWSKI, R.J. (1979). Successful therapy of advanced arterio-
sclerosis obliterans with prostacyclin. Lancet l, 1111 - 1114. 
TATESON, J.E., MONCADA, S. and VANE, J.R. (1977). Effects of prostacyclin 
(PGX) on cyclic AMP concentrations in human platelets. Prostaglandins ll, 
389 - 397. 
TEN BERG, R.G.M., DE JDNG, W. and NIJKAMP, F.P. (1980). Attenuated 
depressor response to arachidonic acid and prostaglandins in unclipped 
renal hypertensive rats. Br J Pharmacol 68, 519 - 524. 
TEN HOOR, F., DE DECKERE, E.A.M., HADDEMAN, E., HORNSTRA, G. and QUADT, 
J.F.A. (1980). Dietary manipulation of prostaglandin and thromboxane 
synthes i sin heart, aorta and blood plate 1 ets of the rat. Adv 
Prostaglandin Thromboxane Res ~, 1771 - 1781. 
TEN HOOR, F., DE DECKERE, E.A.M., HADDEMAN, E., HDRNSTRA, G. and 
VENDELMANS-STARRENBURG, A. (1978). The production of prostaglandin 12 
in heart and blood vessels and its physiological role in heart function 
and thromboregulation. Acta Biol Med Ger 37, 729 - 730. 
TERRAGNO, N.A. (1980). Personal Communication to Professor Leary. 
TERRAGNO, N.A., TERRAGNO, A., McGIFF, J.C. and RODRIGUEZ, D.J. (1977). 
Synthesis of prostaglandins by the ductus arteriosus of the bovine fetus. 
Prostaglandins ~, 721 - 727. 
TIMPERLEY, W.R., WARD, J.D., PRESTON, F.E., DUCKWORTH, T. and O'MALLEY, 
B.C. (1976). Clinical and histological studies in diabetic neuropathy. A 
reassessment of vascular factors in relation to intravascular coagulat ion. 
Diabetologia 1£, 237 - 243. 
147 
UBATUBA, F.B., MONCADA, S. and VANE, J.R. (1979). The effect of 
prostacyclin (PGI 2) on platelet behaviour. Thrombus formation in vivo 
and bleeding time. Thromb Haemost il, 425 - 435. 
UEHARA, Y., ISHII, M., TAKEDA, T., IKEDA, 1., ATARSHI, K. and MURAO, S. 
(1981). Plasma 6-keto-PGF la in normotensive subjects and patients with 
essential hypertension. In: International Congress of Pharmacology. 
Eighth, Tokyo, 19 - 24 July, 1981. (Abstract of Papers, IUPHAR, p737.) 
ULUTIN, O.N. (1976). The Platelets. Fundamentals and Clinical 
Applications. Istanbul, Kagit ve Basim Isleri A.S., pl12. 
VAN DORP, D.A., BEERTHUIS, R.K., NUGTEREN, D.H. and VONKEMAN, H. (1964). 
The biosynthesis of prostaglandins. Biochim Biophys Acta 90, 204 - 207. 
VANE, J.R. (1981). The pharmacology and clinical potential of 
prostacyclin. In: International Congress of Pharmacology. Eighth, Tokyo, 
19 - 24 July, 1981. (Abstract of Papers, IUPHAR, p69.) 
VILLA, S., MYSLIWIEC, M. and DE GAETANO, G. (1977). Prostacyclin and 
atherosclerosis in rats. Lancet 1, 1216 - 1217. 
VON EULER, U.S. (1936). On the specific vaso-dilating and plain muscle 
stimulating substances from accessory genital glands in man and certain 
animals (prostaglandin and vesiglandin). J Physiol (Lond) 88, 213 - 234. 
VOSS, R., HADDEMAN, E., DON, J.A. and TEN HOOR, F. (1980). The isolated 
pulsating perfused rabbit aorta. In: International Symposium on 
Prostaglandins and the Cardiovascular System. Wilrijk, Belgium, 1 - 3 
Dec ember, 1980. (Abstract of Papers, European SOCiety of Cardiology. 
Abstract number 49.) 
WALDMAN, H.M., ALTER, 1., KOT, P.A., ROSE, J.C. and RAMWELL, P.W. (1978). 
Effect of 1 ung trans i t on systemi c depressor responses to arach i don i c 
acid and prostacyclin in dogs. J Pharmacol Exp Ther 204, 289 - 293. 
148 
WEBER, P.C., SIESS, W. and SCHERER, B. (1980). Possible significance of 
renal prostaglandins in essential hypertension. Clin Exp Hypertension £, 
741 - 760. 
WEEKS, J.R. and SUTTER, D.M. (1979) . An antihypertensive effect of 
prostacyclin. In : Vane, J.R. and BergstrHm, S. (eds): Prostacyclin. New 
York, Raven Press, p253 - 257. 
WEKSLER, B.B., LEY, C.W. and JAFFE, E.A. (1978). Stimulation of 
endothelial cell prostacyclin production by thrombin, trypsin and the 
Ionophore A23187. J Clin Invest 62, 923 - 930. 
WILNER, G.D., NOSSEL, H.L. and LE ROY, E.C. (1968). Aggregation of 
platelets by collagen. J Clin Invest 47, 2616 - 2621. 
YABEK, S.M. AND AVNER, B.P. (1980). Effects of prostacyclin (PGI 2) and 
i ndomethac i n on neonata 1 1 amb mesenteri c and rena 1 artery responses to 
electrical stimulation and norepinephrine. Prostaglandins}2, 23 - 30. 
YOSHIMURA, M., KAIMASU, 1., KITANI, T., KAWAMURA, T., TAKEDA, K., SASAKI, 
S., KAJITA, Y., NAKAGAWA, M. and IJICHI, H., (1980). Effect of sodium 
loading and depletion on vascular reactivity and prostacyclin generation. 
Jpn Circ J 44, 388 - 393. 
ZANCHETI, A. (1979). Overview of cardiovascular reflexes in 
hypertension. Am J Cardiol 44, 912 - 918. 
ZMUDA, A., DEMBINSKA-KIEC, A., CHYTKOWSKI, A. and GRYGLEWSKI, R.J. 
(1977). Experimental atherosclerosis in rabbits: platelet aggregation, 
thromboxane A2 generat i on and ant i-aggregatory potency of prostacyc 1 in. 
Prostaglandins Ii, 1035 - 1042. 
ZUCKER, M.B. and BORRELLI, J. (1954). Reversible alterations in platelet 
morphology produced by anticoagulants and by cold. Blood 2, 602 - 608. 
149 
PAPERS PUBLISHED DURING THE COURSE OF THESE STUDIES. 
BOTHA, J.H. and LEARY, W.P. (1981). Mechanical reduction in pressure and 
pulse pressure decreases the ability of hypertensive rat aortas to produce 
'PGI 2-1ike' activity. Prostaglandins Med ~, 267 - 268. 
BOTHA, J.H. and LEARY, W.P. (1981). Platelets of spontaneously 
hypertensive rats are not abnormally sens it ive to PGI 2. Prostag1 andins 
Med (in press). 
BOTHA, J.H., LEARY, W.P. and ASMAL, A.C. (1979). Enhanced release of 
'PGI2-1ike' substance in experimental hypertension. Prostaglandins Med 
1, 251 - 252. 
BOTHA, J.H., LEARY, W.P. and ASMAL, A.C. (1980). Enhanced release of 
'prostacyc1in-1ike' substance from aortic strips of spontaneously 
hypertensive rats. Prostag1andins]1, 285 - 289. 
- APPENDIX I -
N GH 
EXPT. WEIGHT BLOOD WEIGHT BLOOD 
NO. (g) PRESSURE (g) PR ESSURE 
(mmHg) (mmHg) 
1 322 135 300 200 
2 330 120 290 195 
3 360 112 300 200 
4 360 130 320 210 
5 370 110 310 210 
6 340 118 300 210 
7 360 135 310 190 
8 360 110 300 175 
WEIGHTS AND BLOOD PRESSURES OF GENETICALLY HYPERTENSIVE 
RATS (GH) AND MATCHED NORMOTENSIVE CONTROLS (N). 
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
8 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
N GH 
INCUBATION TIME (MIN) INCUBATION TIME 
2 8 14 2 8 
1,77 3,41 3,77 2,43 3,99 
2,24 2,35 3,36 2,02 4,68 
0,69 2,80 3,68 2,36 3,57 
0,57 3,14 3,52 1,30 3,69 
1,66 3,00 4,05 2,77 4,43 
2,41 4,27 4,36 3,40 4,39 
0,99 2,37 3,29 1,62 2,93 
2,93 4,02 4,39 2,55 3,82 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
OF GENETICALLY HYPERTENSIVE RATS (GH) 
AND MATCHED NORMOTENSIVE CONTROLS (N) 
AT VARIOUS SAMPLING TIMES. 
(MIN) 
14 
4,22 
4,81 
4,03 
4,35 
4,81 
4,62 
3,79 
4,36 
- APPEND! X II -
EXPT. 
NO. 
1 
2 
3 
4 
5 
N ERH 
WEIGHT B. P. 10 WEEKS WEIGHT B. P. 10 WEEKS 
(g) POST-OP (g) 
(mmHg) 
295 106 236 
325 115 282 
275 110 227 
275 110 215 
265 108 188 
WEIGHTS AND BLOOD PRESSURES (B.P.) OF RATS 
WITH EXPERIMENTAL RENAL HYPERTENSION (ERH) 
AND MATCHED NORMOTENSIVE CONTROLS (N). 
POST-OP 
(mmHg) 
130 
125 
160 
160 
.145 
EXPT. 
NO. 
1 
2 
3 
4 
5 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
N ERH 
INCUBATION TIME (min. ) INCUBATION TIME 
2 8 18 2 8 
2,28 4,70 4,86 2,41 6,13 
3,85 6,17 6,32 7,18 8,14 
2,90 6,80 6,35 5,47 7,84 
2,20 5,96 6,45 5,51 8,63 
3,98 5,85 6,97 3,95 7,05 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
OF RATS WITH EXPERIMENTAL RENAL HYPERTENSION (ERH) 
AND MATCHED NORMOTENSIVE CONTROLS (N) 
AT VARIOUS SAMPLING TIMES. 
(m i n. ) 
1B 
7,48 
8,61 
8,06 
8,77 
7,32 
- APPENDIX III -
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
T C 
WEIGHT B. P. B .P. WEIGHT B.P. 
(g) BEFORE AFTER (g) BEFORE 
TREATING TREATING TREATMENT 
(mmHg) (mmHg) PERIOD 
I (mmHg) 
200 155 105 205 145 
210 170 105 225 150 
202 150 110 235 138 
210 175 100 285 165 
220 190 110 230 160 
220 162 120 220 180 
I 
220 ! 165 95 220 157 
260 I 172 90 220 175 
I 
220 175 106 220 164 
WEIGHTS AND BLOOD PRESSURES (B .P.) OF TREATED (T) 
AND UNTREATED CONTROL (C) RATS . 
B. P. 
AFT ER 
TREATMENT 
PERIOD 
(mmHg) 
160 
190 
170 
200 
160 
168 
168 
165 
165 
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
T C 
INCUBATION TIME (MIN) INCUBATION TIME 
2 8 14 2 8 
0,28 1,80 2,38 0,23 1, 87 
0,45 0,83 1,47 0,33 1,06 
0,00 1,42 2,07 0,17 1,95 
0,90 2,08 2,20 0,78 1,80 
0,80 1,94 1,94 0,92 2,06 
0,59 2,57 2,66 1 ,14 2,93 
0,53 0,66 0,91 0,60 1,00 
0,29 2,59 2,93 0,56 1,96 
0,34 0,68 2,49 0,90 3,02 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
OF TREATED (T) AND UNTREATED CONTROL (C) RATS 
AT VARIOUS SAMPLING TIMES. 
(MIN) 
14 
2,39 
1,57 
2,30 
1,98 
2,24 
3,17 
1,75 
2,73 
3,41 
- APPENDIX IV -
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
8 
C S 
WEIGHT PRE-OP. POST-OP. WEIGHT PRE-OP. 
(g) B.P. B. P. (g) B. P. 
(mmHg) (mmHg) (mmHg) 
, 
320 218 116 320 212 
300 182 107 290 194 
305 172 95 300 172 
I 
I 
I 
308 170 95 310 170 
240 168 90 290 I 172 
I 
270 158 90 260 161 
295 189 75 290 182 
292 166 90 300 174 
WEIGHTS AND BLOOD PRESSURES (B.P.) OF CLIPPED (C) 
AND SHAM (S) RATS. 
I I 
: POST -OP. I 
i 
I B.P. 
I (mmHg) I 
I 
I 
150 
I 
I 165 
I 
159 
I 
I 
I 
I 
I 162 I 
152 
147 
168 
178 
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
8 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
C S 
INCUBATION TIME (MI N) INCUBATION TIME 
2 8 14 2 8 
1 ,61 2,68 3,08 1,20 2,90 
0,97 2,86 2,90 1, 27 2,72 
1 ,51 3,47 3,76 1,26 4,12 
2,00 4,06 4,47 1,63 4,40 
1,67 3,09 3,96 2,40 3,76 
0,76 2,11 2,81 0,74 3,86 
2,02 3,31 3,50 2,09 4,15 
1,47 3,54 3,83 1,99 4,11 
ng PROSTACYCLIN RELEASED I mg WET WEIGHT AORTA 
OF CLIPPED (C) AND SHAM (S) RATS 
AT VARIOUS SAMPLING TIMES. 
(MIN) 
14 
3,28 
2,90 
4,29 
4,9 1 
4,24 
3,96 
4,38 
4,36 
- APPENDIX V -
• 
EXPT. 
NO 
1 
I 
I 
2 
3 
4 
5 
5 
7 
N GH 
WEIGHT I BL OOD POOLED WEIGHT BLOOD POOLED , 
(g) PRESSURE PLATELET (g) PRESSURE PLATELET I 
(mmHg) NO. X103 (mmHg) NO.X103 
240 80 320 170 
230 95 996 250 158 
270 111 260 160 
290 106 290 180 
250 120 1334 240 180 
260 125 240 180 
280 118 240 175 
270 115 1296 240 170 
300 125 240 188 
260 115 230 170 
280 119 1540 260 156 
230 122 265 179 
270 116 265 169 
300 124 1302 270 183 
265 125 240 175 
280 96 280 150 
250 115 1682 250 150 
240 11 8 310 I 190 , ! 
I , 
260 115 240 I 172 I 
270 120 2134 280 I 168 , 
220 125 270 180 
WEIGHTS, BLOOD PRESSURES AND PLATELET COUNTS OF 
GENETICALLY HYPERTENSIVE (GH) AND NORMAL (N) RATS. 
1176 
1322 
1156 
1420 
1482 
1942 
2226 
EXPT. 
NO. 
1 
2 
3 
4 
5 
6 
7 
MAXIMUM AGGREGATION MEASURED AS • I' OF DISTANCE PRP TO PPP 
N GH 
CONC. ADDED PGI2 (ng/ml) CONC. ADDED PGI2 (ng/ml) 
0 20 33,33 50 0 20 33,33 50 
68,12 48,33 26,72 19,05 65,33 44,10 19,06 13,79 
47,02 18,07 9,73 0,00 63,59 29,94 33,06 13,85 
64,49 49,04 31,96 5,68 49,75 41,24 21,74 3,32 
63,46 40,97 33,71 24,04 68,48 45,88 45,64 27,67 
59,45 40,00 19,51 8,17 73,04 53,73 27,51 , 15,39 
69,61 - 25,24 0,00 70,82 - 36,72 4,41 
74,88 56,73 15,07 9,71 80,39 50,52 15,71 5,05 
'I'AGGREGATION ACHIEVED WITH l~M ADP 
IN NORMAL (N) AND GENETICALLY HYPERTENSIVE (GH) RAT PLATELETS 
IN THE PRESENCE OF VARYING CONCENTRATIONS OF PGI2 . 
